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 The mitochondrial folate transport protein (MFT) functions to transport folates into 
the mitochondrial matrix. The MFT is a member of a mitochondrial carrier family (MCF) 
of proteins that have a high degree of sequence and structural similarities, yet they 
transport vastly different substrates at high specificities. In this dissertation research, the 
folate-specific transport mechanism of the MFT was explored using experimental and 
computational techniques.  MFT residues that differed from MCF consensus residues in 
conserved PxD/ExxK/R motifs and at a predicted substrate-binding site common to all 
MCF proteins were investigated.  Site-directed mutagenesis of these anomalous residues in 
   
 xix 
the MFT revealed that these residues were adapted for optimal folate transport, and that the 
MCF consensus residues at these positions were incompatible with folate transport.   
 The structure of the MFT was predicted by homology modeling using the solved 
crystallographic structure of the ADP/ATP carrier as a template and this model was 
subjected to ~75 ns of molecular dynamics simulations. These simulations predicted a 
stepwise descent for the folate substrate into the MFT transport cavity and implicated 
several aromatic and basic residues in folate recognition and orientation. A predicted set of 
interactions at the base of the transport cavity between the MCF PxD/ExxK/R conserved 
motif residues did not appear static as previously hypothesized; these interactions appeared 
to be induced in the presence of the folate substrate.  Therefore, we believe it is unlikely 
that these interactions form a barrier at the base of the transport cavity.    
 We also investigated the role of the MFT in the compartmentalization of folate 
metabolism. Cell lines were created that could be induced with doxycycline to express 
either the cytosolic or mitochondrial isoform of the enzyme folylpoly-γ-glutamate 
synthetase (FPGS).  The constructed cell lines were used to study the flux of 
folylpolyglutamates across the mitochondrial membrane.  It appeared that cellular 
folylpolyglutamates are not transported across the mitochondrial membrane in either 
direction. We also demonstrated that many antifolates, including methotrexate and 
pemetrexed, impaired mitochondrial folate uptake.  We believe that these folate analogs 
competitively inhibit the MFT and have purified the MFT protein for future analysis in 
reconstituted transport systems.   
 1 
 
 
 
CHAPTER 1 Introduction 
 
 
 Folate molecules are water-soluble B-vitamins that are required for cell growth and 
survival. Unlike bacteria, mammals are unable to synthesize folates and thus, must obtain 
folates from their diet. The United States Food and Drug Administration recommends a 
daily intake of 400 µg/day of folate for males and females over the age of 19 and 600 
µg/day for pregnant women (66). Dietary folates can be separated into two groups: those 
that are naturally contained in food and those that are made synthetically. Dietary folates, 
or folates that are contained in food, are present in dark, leafy green vegetables, fruits, and 
beans.  However, cooking destroys most of the naturally occurring folate in foods.  More 
recently, synthetic folate, termed folic acid, has been added to many grain products in the 
United States and has also become available in pill-form supplements. Fortification of 
foods and the availability of supplements are responsible for increasing the folate status in 
the United States population (34). Despite this effort, folate deficiency, predominantly 
caused by insufficient intake and less commonly attributable to malabsorption, aberrant 
folate metabolism, or alcoholism, is still linked to diseases such as neural tube defects in 
pregnancy (135), anemia, and cancer.  
 
 
   
 2 
Folate structure 
 Folate molecules are low molecular weight, anionic compounds that exist in a 
number of modified and conjugated forms within organisms.  The basic folate chemical 
structure consists of a pteridine ring linked to a p-amino benzoate ring that has a glutamate 
residue attached via an amide bond (Figure 1-1).  The structure of folic acid differs from 
the structure of tetrahydrofolate in that double bonds link the 5- and 6- and the 7- and 8- 
positions in the pteridine ring of folic acid.  While this significantly enhances the stability 
of folic acid, in order for this compound to be biologically utilized the 6- and 7- positions 
in the structure of folic acid need to be reduced.  In biological reactions 5,6,7,8-
tetrahydrofolate derivatives serve to accept and donate 1-carbon units; the 5- and 10- 
position nitrogen atoms in the folate structure are the typical acceptors and donors of 
carbon groups. The vast majority of endogenous folates are modified on the glutamate end 
of the folate structure where 4-5 additional glutamate moieties are added.  Folate molecules 
that contain multiple additions of glutamic acid are collectively referred to as folate 
polyglutamates. The purposes for and the function of these modifications will be discussed 
later in this chapter.  In this thesis, use of term “folates” refers to all modified folate 
molecules unless otherwise stated. 
  
Absorption and intracellular transport of folates 
 An understanding of folate structure and folate modification is important in 
understanding how ingested folates are utilized in the body. Folates that are naturally 
present in foods are folate polyglutamates and contain additional glutamate moieties linked  
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Figure 1-1 Structure of tetrahydrofolate, folic acid, and tetrahydrofolate 
polyglutamate.
 4 
γ-carboxyl group of the glutamate side chain of folate.  Folate polyglutamates cannot be 
absorbed and depend on local enzymes, γ-glutamate carboxypeptidases (55, 146), to 
remove these additional glutamate moieties, leaving a single glutamate moiety on the 
folate molecule.  Monoglutamyl tetrahydrofolate analogs do not contain any additional 
glutamate moieties and are absorbed into enterocytes without regard to carboxypeptidase 
activity. Folates are predominantly absorbed by the enterocytes in the small intestine by a 
proton-coupled folate transporter (PCFT) on the apical surface of the duodenum and 
proximal jejunum (115, 138).  This transporter has a high affinity for folates (Km (6S)-5-
methyl-tetrahydrofolate = 0.53 µM) and synthetic folate (Km folic acid = 0.83 µM) at a pH 
of 5.5 (138). A homozygous mutation has been identified in the PCFT and is linked to 
hereditary folate malabsorption (50, 138).  The reduced folate carrier (RFC), another folate 
transport protein, is also present in the intestine, however, the RFC is pH-dependent and 
does not retain significant function at a pH below 6 (168), which is the pH at the apical 
surface in this area of the small intestine (94, 95). The mechanism of folate exit from 
enterocytes is less clear although it does appear evident that this process is carrier-
mediated (144).  Folate exit from enterocytes appears to be mediated by a multidrug-
resistance protein, possibly MRP3 (78).  Once transported across the basolateral 
membrane, folates enter the hepatic portal vein and travel to the liver, where they are 
stored or proceed to enter the systemic circulation as 5-methyl-tetrahydrofolate.  
 Folates, predominantly in the form of 5-methyl-tetrahydrofolate, circulating in the 
blood are transported into cells by either the reduced folate carrier (RFC) (51) or by a 
folate receptor (FR). The RFC and FR are both widely expressed in humans.  The majority 
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of FR expression is localized to kidney and lung (126) with very low levels of expression 
elsewhere.  The RFC appears ubiquitously expressed at moderate levels with increased 
expression in the liver  (172). The PCFT also appears to be expressed on the cell surface, 
but is minimally active at a pH of 7.0 or above (138). The RFC and FR possess no 
homology to one another and exhibit different transport characteristics.  The FR is 
suggested to be a high affinity, low capacity folate transporter (Km 5-methyl-
tetrahydrofolate = 3 nM) (21, 69, 167), that uses endocytosis-mediated receptor cycling to 
deliver folates into the cell (70). The RFC is a lower affinity folate transporter (Km 5-
methyl-tetrahydrofolate = 1 µM) that is dependent on an electrochemical potential 
produced by the cellular export of anions, particularly organic phosphates, to transport 
folates into the cell (52). However, as the folate concentration increases, the RFC was 
shown to transport the majority of folate into the cell (151).  Therefore, the RFC is 
currently thought to be the primary protein responsible for the transport of folates into 
cells.  The role of the folate receptor in folate transport is less clear, although the 
expression of this receptor appears to be increased in a number of solid tumors and is 
currently being explored in targeted therapeutic approaches (93). 
 
Intracellular folate metabolism 
 At the cellular level, an initial step in folate metabolism is the intracellular retention 
of folate molecules. A majority of the folates found in tissues contain multiple additions of 
glutamate molecules to the glutamate end of the folate (11).  Polyglutamation of folates is 
attributed to the enzyme folylpoly-γ-glutamate synthetase (FPGS) (110, 111), which 
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enables cellular retention of folates (106). Two isoforms of FPGS have been identified in 
humans and these isoforms are transcribed from a single gene (45, 156); one in the cytosol 
and the other in mitochondria (90). Like FPGS, folates are found in the mitochondrial and 
cytosolic subcellular compartments (28, 155) and appear to be equally distributed between 
these two compartments (60). Chinese hamster ovary (CHO) cells that lack functional 
FPGS, known as AuxB1 cells, are unable to accumulate any cellular folates and therefore 
require an exogenous supply of purines, thymidine and glycine to the growth culture 
medium (106, 154).  These studies suggested that the purpose of mammalian folate 
metabolism is to produce purines, thymidine and glycine. 
 Folate metabolism in mammalian cells is separated into reaction sequences that 
occur in the cytosolic and mitochondrial compartments and these reactions permit the 
recycling of folate molecules.  Despite having all of the enzymes present in the cytosol to 
synthesize purines, thymidine, methionine and glycine, the cellular contributions of 
cytosolic folate metabolism are limited to purine, thymidine, and methionine synthesis.  
This was evidenced when the cytosolic isoform of FPGS was transfected into AuxB1 cells 
and relieved the purine and thymidine auxotrophy of these cells, but was unable to 
eliminate their requirement for exogenous glycine (45, 90). Furthermore, the glycine 
auxotrophy of AuxB1 cells was complemented only when the cells were transfected with a 
mitochondrially-targeted FPGS protein (45, 91).  It would appear that mitochondrial folate 
metabolism serves to supply the cell with sufficient glycine and cytosolic folate 
metabolism is involved in purine and thymidine synthesis.  
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 Cytosolic folate metabolism uses folate molecules as cofactors in reactions that 
contribute to the synthesis of purines, thymidine, and methionine (Figure 1-2).  Cytosolic 
folate metabolism begins with the conversion of 5-methyl-tetrahydrofolate and 
homocysteine to tetrahydrofolate and methionine.  Tetrahydrofolate can be converted to 
either 10-formyl-tetrahydrofolate or 5,10-methylene-tetrahydrofolate.  The formyl carbon 
of 10-formyl-tetrahydrofolate is used by two folate-dependent enzymes of purine 
synthesis, glycinamide ribonucleotide formyltransferase (GART) and aminoimidazole 
carboxamide ribonucleotide formyltransferase (AICARFT). 5,10-methylene-
tetrahydrofolate can be converted either to 5-methyl-tetrahydrofolate or to dihydrofolate. 
Dihydrofolate and thymidylate are produced by thymidylate synthase (TS) from 5,10-
methylene-tetrahydrofolate and deoxyuridylate.  The dihydrofolate produced during 
thymidylate synthesis is then converted to tetrahydrofolate by dihydrofolate reductase 
(DHFR).   
 Mitochondrial folates also participate in single carbon transfer reactions (Figure 1-
3).   The folate pools that participate in mitochondrial reactions are thought to be separated 
from those used in the cytosolic reactions (3).  Of the molecules involved in folate 
metabolism, glycine, serine and formate appear to be exchanged between the 
mitochondrial and cytosolic compartments (127). Folates are cofactors in mitochondrial 
reactions that metabolize glycine.  Specifically, the mitochondrial isoform of serine 
hydroxymethyltransferase (mSHMT) converts serine and tetrahydrofolate into glycine and 
5,10-methylene-tetrahydrofolate. GlyA cells are CHO-derived cells that lack activity of the 
mSHMT isoform, but have an active cytosolic isoform (71).  However, as a result of the  
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Figure 1-2 Schematic of folate metabolism and folate-dependent reactions that occur 
in the cytosolic subcellular compartment. Enzyme abbreviations are AICARFT – 
aminoimidazole carboxamide ribonucleotide formyltransferase ; cSHMT – cytosolic serine 
hydroxymethyltransferase isoform ; DHFR – dihydrofolate reductase ; GART – 
glycinamide ribonucleotide formyltransferase ; TS – thymidylate synthase.  Single arrows 
represent the direction of irreversible reactions and double arrows represent reversible 
reactions. 
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Figure 1-3 Schematic of folate metabolism and folate-dependent reactions that occur 
in the mitochondrial subcellular compartment. Enzyme abbreviations are GCS – 
glycine cleavage system ; mSHMT – mitochondrial serine hydroxymethyltransferase 
isoform.  Single arrows represent the direction of irreversible reactions and double arrows 
represent reversible reactions.  The two reversible reactions shown converting 
tetrahydrofolate to 5,10-methylene-tetrahydrofolate do not occur simultaneously; they are 
separate reactions that use the same molecules in different reactions with different 
enzymes. 
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mSHMT deficiency, glyA cells are auxotrophic for glycine.  GlyA cells were later shown 
to have increased amounts of intracellular serine and decreased amounts of glycine when 
compared to wild-type CHO cells (116). Mitochondria also contain a unique glycine 
cleavage system (GCS) that uses tetrahydrofolate and NAD to catabolize glycine into 
formate, ammonia, 5,10-methylene-tetrahydrofolate and NADH+ (76).  Both the mSHMT 
and GCS reactions are reversible, but are predicted to run in the direction of 
tetrahydrofolate to 5,10-methylene-tetrahydrofolate (towards generation of 10-formyl-
tetrahydrofolate) in mathematical models generated to simulate hepatic folate metabolism 
(120). Interestingly, these reactions oppose each other in terms of glycine regulation, but 
both reactions appear to eventually generate formate.  The GCS directly generates formate 
from the catabolism of glycine.  Additionally, 5,10-methylene-tetrahydrofolate can be 
converted to 10-formyl-tetrahydrofolate in two steps, and 10-formyl-tetrahydrofolate can 
be metabolized into formate and tetrahydrofolate. The importance of mitochondrial 
formate was shown in yeast, where ~25% of the carbon units used in purine synthesis were 
from mitochondrially-derived formate (127).  Furthermore, a computational model of 
hepatic folate metabolism studied the effects of removing mitochondrial folate metabolism 
from the in silico system and found that thymidine and purine synthesis were reduced by 
~40% and 60% respectively, and that other cytosolic folate-dependent processes were 
relatively unaffected (120). Thus, the role of mitochondrial folate metabolism may be to 
produce glycine that can be metabolized into formate for use in the cytosolic synthesis of 
purines and thymidine. 
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Mitochondrial uptake of folates 
 The importance of mitochondrial folate metabolism had been established, but prior 
to 1981, the mechanism of mitochondrial folate transport had not been studied. The 
importance of the metabolic events that occurred after mitochondrial folate transport was 
established in two mutant cell lines.  AuxB1 cells, which harbored an inactivating mutation 
in the fpgs gene, were transfected with cytosolic FPGS, yet were still auxotrophic for 
glycine (45, 90).  Likewise, glyA cells were deficient in mSHMT activity and were also 
auxotrophic for glycine (71). Cybulski and Fisher published a report in 1981 stating that 
mitochondria folate uptake could be saturated by increasing substrate, inhibited by 
structurally related folate molecules, and uptake was dependent on folate structure, as only 
non-reduced pteridine ring folates, i.e., folic acid and dihydrofolate, were shown to 
accumulate in isolated rat liver mitochondria (30). Eleven years later, the process of 
mitochondrial folate uptake was revisited.  Studies were similarly carried out in isolated rat 
liver mitochondria and, in agreement with the earlier work of Cybulski and Fisher, these 
studies demonstrated that mitochondrial folate uptake exhibited characteristics of 
saturation and inhibition (61).  The work by both groups suggested that mitochondrial 
folate accumulation was a carrier-mediated process.  Horne et al. also demonstrated that 
mitochondrial folate uptake was pH-dependent, with a pH optimum of 5.5 at 37° C and 5-
fold less activity at pH 7.4. Cybulski and Fisher examined folate uptake at pH 7.4 at 4° C 
and this may explain why these studies had discrepancies regarding the substrates for the 
carrier protein. Horne et al. showed that the carrier-mediated transport of mitochondrial 
folates was specific to pteridine ring-reduced folates, such as 5-formyl-tetrahydrofolate and 
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5-methyl-tetrahydrofolate.  In addition, they reported that mitochondrial transport of 
reduced folates was hardly inhibited by competition with non-reduced folates.  It was 
thought that the studies by Horne et al. were technically superior to those by Cybulski and 
Fisher and therefore, the prevailing concept is that reduced folates are optimal substrates 
for carrier mediated mitochondrial transport. 
 
Discovery of the protein responsible for mitochondrial folate transport 
 The discovery of a protein responsible for mitochondrial folate transport was 
greatly facilitated by previous studies that created a somatic cell genetic mutant chinese 
hamster ovary (CHO) cell line, the glyB cell (71).  The glyB cell line was generated when 
CHO cells were treated with mutagens to intentionally produce mutant cell lines that 
required glycine for survival (71).  Four classes of mutants were identified: glyA, glyB, 
glyC, and glyD, each of which required an exogenous supply of glycine for cell growth 
and survival.  One group, the glyA cell, was immediately identified to have only 5% of 
wild-type mSHMT activity.  The other three groups were shown to maintain wild-type 
activity of mSHMT, and were suspected to have some other defect in mitochondrial folate 
metabolism.  The cellular defects in the three other cell types, glyB, glyC, and glyD, 
remained unidentified for over 30 years.  The mutations that are responsible for the 
observed glycine auxotrophy in glyC and glyD cell types are still unidentified.  
 GlyB cells were shown to be deficient in mitochondrial folate accumulation, 
despite having normal cytosolic folate metabolism (155).  This suggested the possibility 
that glyB cells were deficient either in mitochondrial folate transport or in mitochondrial 
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folate retention. GlyB cells were characterized in this laboratory 31 years after they were 
first created (108, 160).  Upon transduction with a human cDNA library in a retroviral 
vector, a colony of glyB cells was isolated that was able to sustain growth in the absence of 
glycine (160).  The transduced cDNA sequence from this cell population was isolated and 
cloned into a mammalian expression vector that also encoded resistance to the selective 
agent, G418.  GlyB cells were transfected with this mammalian expression vector and 
~30% of the cells that were resistant to G418, were able to survive in the absence of 
glycine (160). Thus, the protein encoded by the transfected cDNA, which was later named 
the mitochondrial folate transport protein (MFT), complemented the defect in glyB cells 
that induced glycine auxotrophy. The isolated human mft cDNA sequence consisted of a 
945 base pair sequence that encoded a 315 amino acid protein. Analysis of the MFT 
protein sequence demonstrated homology to a previously identified family of proteins that 
were embedded in the inner mitochondrial membrane and functioned to transport small, 
charged molecules into the mitochondrial matrix. The MFT contained three conserved 
motifs that were common to this family of transporters.  In addition, a hydropathy plot 
analysis suggested that the MFT and this family of proteins had structural similarities 
(160).   
 The MFT was suggested to be an integral inner mitochondrial membrane protein 
that transported folates into mitochondria. MFT homologues from hamster, mouse, and 
zebrafish were identified based on sequence homology.  These cDNAs were subsequently 
cloned into a mammalian expression vector and transfected into glyB cells (108). The 
predicted MFT proteins from hamster, mouse, and zebrafish all permitted glyB cell 
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survival in the absence of glycine, suggesting that the transfected putative MFT proteins 
restored mitochondrial folate accumulation in glyB cells. The concept of the transfected, 
wild-type MFT proteins restoring mitochondrial folate accumulation in glyB cells was 
studied using radiolabeled folic acid incubated with glyB and wild-type CHO cells 
followed by analysis of folate uptake into subcellular compartments.  Untransfected glyB 
cells contained mitochondrial folates at levels that were 1-5% of that observed in the wild-
type parental CHO cell line (108, 160).  However, upon transfection of with either human 
or CHO mft cDNA, mitochondrial folate levels in these transfected glyB cells increased to 
43% and 90% of wild-type CHO cells, respectively (108, 160).  Thus, the MFT protein 
was able to restore mitochondrial folate accumulation in glyB cells.   
 It had been established that glyB cells were not capable of accumulating 
mitochondrial folates, but the mechanism of this defect was unknown.  Northern blot 
analysis of glyB and CHO cells showed that the mft mRNA was present in both cells lines 
(108).  Determination of MFT protein expression was not attempted, as there was no 
antibody available at that time to detect the endogenous MFT protein by western blotting.  
Fluorescence in situ hybridization analysis revealed that glyB cells only contained one 
copy of the mft gene in comparison to the two copies contained in wild-type CHO cells 
(108).  This finding was complemented when the genomic DNA from glyB cells was 
sequenced and revealed a single in frame G to A point mutation in the only copy of the mft 
gene in glyB cells (108).  This mutation in glyB DNA translated into a protein mutation 
that changed a glycine codon to a glutamate codon at position 192 in the glyB MFT 
protein.  Hence, glyB cells were auxotrophic for glycine because their only copy of the mft 
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gene had a point mutation that mutated glyB MFT 192 from a glycine residue to a 
glutamate residue, a mutation that was incompatible with mitochondrial folate transport. 
 Understanding the defects in glyB cells enabled this cell line to become a valuable 
reagent in studying the function of the MFT. Since glyB cells are unable to accumulate any 
mitochondrial folates they are auxotrophic for glycine. This phenotype was utilized in 
discovery of the MFT where a functional MFT protein was shown to complement the glyB 
cellular requirement for glycine. Newly constructed MFT mutants could be studied in the 
same way: a mutation in the wild-type CHO mft cDNA could be constructed, transfected 
into glyB cells and the ability of these transfected cells to survive in the absence of glycine 
could be observed.  If cells transfected with this mutated mft cDNA could survive without 
glycine supplementation, the encoded MFT mutant protein was assumed to have retained 
its function as a mitochondrial folate transport protein.  Conversely, if the transfected glyB 
cells still required glycine for survival, the encoded MFT protein was assumed to be unable 
to restore mitochondrial folate uptake in glyB cells; the MFT mutant protein was devoid of 
folate transport activity. In addition to the utility of the glyB cell line in this glyB glycine 
complementation assay, glyB cells were also used as a negative control in folate transport 
studies.  GlyB cells have proven to be an extremely useful and powerful cell line in 
studying the folate transport function of the MFT. 
 
Focus of dissertation 
 The objectives of this research were to understand the folate-specific transport 
mechanism of the MFT and to explore the contributions of the MFT to cellular folate 
   
 16 
metabolism.  While the MFT belonged to a large family of structurally similar 
mitochondrial transport proteins, we were interested in how the MFT was able to 
specifically recognize and transport folate molecules.  We wanted to understand why no 
other protein in this family was capable of folate transport and how the MFT evolved to 
serve this function.  Because of the structural homology in this family of mitochondrial 
transporters, we believed that discrete residue differences within the transport cavity of the 
MFT shaped its substrate-specificity.  In Chapter Two, we highlight some striking residue 
differences in the MFT and the impact of these residue differences on the MFT mechanism 
of folate transport.  We were also interested in the molecular interactions that were 
required for folate recognition and folate transport by the MFT.  We used molecular 
dynamics simulations, also presented in Chapter Two, to gain insight into these events.  
Finally, we wanted to further elucidate the role of the MFT in cellular folate metabolism.  
We knew that the MFT was responsible for mitochondrial folate transport, but we did not 
know what folates, folate conjugates or antifolates were transported by the MFT.  
Specifically, we investigated whether folate polyglutamates were as substrates for the 
MFT, as well as the effects of various antifolates on MFT function; these findings are 
presented and discussed in Chapter Three. 
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CHAPTER 2 The Mechanism of Folate Transport by the Mitochondrial 
Folate Transport Protein 
 
 
 The mitochondrial folate transporter (MFT) was discovered in 2000 and it was 
subsequently determined that this protein was responsible for folate transport into 
mitochondria (108, 160). Its discovery revived questions regarding the substrate specificity 
of mitochondrial folate transport and the molecular mechanisms involved in this process. 
The MFT was highly homologous to an established family of mitochondrial inner 
membrane proteins, the mitochondrial carrier family (MCF), which has been extensively 
investigated over the past 40 years. We used this growing body of literature to aid in the 
design of experiments to better understand the MFT mechanism of folate transport and 
gain insight into the substrate specificity of the MFT. In this chapter, the mitochondrial 
carrier family (MCF) is introduced and compared to the MFT.  The differences between 
the MCF consensus sequence and the MFT were the foundation for our experimental 
designs.  During the course of this dissertation, we have gained an enormous appreciation 
for the synergy achievable when combining experimental and computational approaches.  
Using these approaches, we studied the MFT and analyzed several evolutionary changes 
that have occurred apparently to create a folate-specific transport mechanism for folate 
uptake into mitochondria.  
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The mitochondrial carrier family (MCF) 
 The mitochondrial carrier family (MCF) is a subfamily of a larger solute carrier 
family, which consists of ~365 proteins organized into 48 subfamilies (56, 62).  The 
mitochondrial carrier family, or SLC25, contains ~35 yeast and ~52 human nuclear 
encoded integral membrane proteins that are embedded in the inner membrane of 
mitochondria (62, 124).  The number of human MCF members can increase dramatically 
to ~79, if one includes different isoforms of these transporters (173).   All MCF proteins 
facilitate the transport of small, charged molecules from the mitochondrial inter-membrane 
space into the mitochondrial matrix; the mitochondrial outer membrane is freely permeable 
to molecules under 5000 daltons (121, 173).  Substrates for MCF members include 
nucleotides, amino acids, keto acids and other co-factors such as NAD+, FAD+, and folate 
(Table 2-1). Of the ~52 human MCF proteins, substrates have been identified for ~33 of 
these (125, 173). Since almost all of the known substrates are involved in reaction 
sequences that ultimately produce energy for the cell, efficient transport by MCF proteins 
is required for mitochondrial function and cellular survival.  Furthermore, amino acid 
mutations caused by single nucleotide polymorphisms in MCF proteins have been 
documented in humans and are linked to clinical diseases for eight of these transporters 
(reviewed in (125)). These diseases include AAC1 deficiency (ADP/ATP carrier in heart  
and muscle), Senger’s syndrome (transcription of ADP/ATP carrier), PiC deficiency 
(phosphate carrier in heart and muscle), autosomal dominant progressive external 
ophthalmoplegia (ADP/ATP carrier in heart, muscle, and brain), CAC deficiency 
(carnitine/acylcarnitine carrier), HHH syndrome (ornithine carrier), AGC2 deficiency  
   
 19 
Gene Name Protein Name Substrate(s)
SLC25A1 Tricarboxylate carrier citrate, malate
SLC25A2 Ornithine carrier-2 ornithine, citrulline
SLC25A3 Phosphate carrier phosphate
SLC25A4 ADP/ATP carrier-1 ADP, ATP
SLC25A5 ADP/ATP carrier-2 ADP, ATP
SLC25A6 ADP/ATP carrier-3 ADP, ATP
SLC25A7 Uncoupling protein-1 H+ 
SLC25A8 Uncoupling protein-2 H+ 
SLC25A9 Uncoupling protein-3 H+ 
SLC25A10 Dicarboxylate carrier malate, succinate
SLC25A11 Oxoglutarate carrier 2-oxoglutarate
SLC25A12 Aspartate/glutamate carrier-1 aspartate, glutamate
SLC25A13 Aspartate/glutamate carrier-2 aspartate, glutamate
SLC25A14 Uncoupling protein-5 unknown
SLC25A15 Ornithine carrier-1
ornithine, citrulline, lysine, 
arginine
SLC25A16 Graves disease carrier CoA
SLC25A17 PMP34 ATP
SLC25A18 Glutamate carrier-2 glutamate
SLC25A19 Deoxynucleotide carrier thiamine pyrophosphate
SLC25A20 Carnitine/acylcarnitine carrier carnitine, acylcarnitine
SLC25A21 Oxoadipate carrier oxoadipate, oxoglutarate
SLC25A22 Glutamate carrier-1 glutamate
SLC25A23 Phosphate carrier-2 ATP, ADP, AMP, Pi
SLC25A24 Phosphate carrier-1 ATP, ADP, AMP, Pi
SLC25A25 Phosphate carrier-3 unknown
SLC25A26 S-adenosyl methionine carrier
S-adenosyl methionine, S-
adenosyl homocysteine, S-
adenosyl cysteine, S-adenosyl 
ornithine
SLC25A27 Uncoupling protein-4 unknown
SLC25A28 Mitoferrin-2 Fe2+ 
SLC25A29 Ornithine carrier-3 ornithine, acylcarnitine
SLC25A30 Kidney mitochondrial carrier-1 unknown
SLC25A31 ADP/ATP carrier-4 unknown (ATP, ADP?)
SLC25A32 Mitochondrial folate transporter folate
SLC25A33 Bone marrow stromal cell derived carrier unknown
SLC25A34 No name unknown
SLC25A35 No name unknown
SLC25A36 No name unknown
SLC25A37 Mitoferrin-1 Fe2+ 
SLC25A38 Erythroid specific carrier? glycine?
SLC25A39 No name unknown
SLC25A40 No name unknown
SLC25A41 SCaMC-3L ATP-Mg, Pi
SLC25A42 No name CoA, ADP
SLC25A43 No name unknown
SLC25A44 No name unknown
SLC25A45 No name unknown
SLC25A46 No name unknown
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Table 2-1 Members of the mitochondrial carrier family.  Identified human 
mitochondrial carrier family proteins are listed by the gene names given to them by the 
HUGO Gene Nomenclature Committee (62).  The protein names and substrates are listed 
as identified. 
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(aspartate/glutamate carrier in liver), Amish microcephaly (thiamine pyrophosphate 
carrier), and neonatal myoclonic epilepsy (glutamate carrier). Most of these heritable 
diseases are autosomal recessive and, therefore, cases with severe deficiencies resulting 
from homozygous defects are rare.  Nonetheless, the existence of diseases related to the 
deficiency of MCF transporters reinforces the essential metabolic requirement of these 
carrier proteins. 
 Mitochondrial carrier family proteins can be identified by similarities in their 
primary sequence.  The first primary sequence discovered for a MCF protein was that of 
the ADP/ATP carrier in 1982 (5, 7) followed by the discovery of the phosphate carrier 
sequence in 1987 (6).  Upon the discovery of the phosphate carrier sequence, it was 
suggested that these inner mitochondrial membrane transporters were part of a larger and 
homologous protein family (6). Hydropathy plot analysis of numerous MCF proteins 
predicted these proteins to have six transmembrane spanning regions (6, 65, 72, 165). In 
addition, studies on the tricarboxylate carrier indicated that the N- and C- termini extended 
into the inter-membrane space (24). The sequences of MCF proteins consist of three 100 
amino acid repeats with each repeat predicted to contain two transmembrane domains 
(TMD).  These repeats are sequentially connected to form a protein that consists of ~300-
350 amino acids in total. The hallmark of MCF transporters is the conserved motif, 
Px(D/E)xx(K/R)x(K/R) - (20 to 30 amino acids) - (D/E)Gxxxx(Y/F/W)(K/R)G, commonly 
shortened to PxD/ExxK/R.  This motif appears once every 100 amino acids for a total of 
three times per MCF protein.  Each motif was initially thought to be located immediately 
after the 1st, 3rd, and 5th TMDs in MCF proteins. No other non-MCF protein has been 
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discovered to carry this repeated motif in its primary sequence.  Therefore, proteins that 
contain this PxD/ExxK/R motif repeated thrice throughout their sequence are identified as 
MCF proteins.  Functional identification and substrate analysis of MCF proteins is more 
difficult, explaining why there are ~20 MCF proteins with unknown functions and/or 
substrates at this time. 
 
The structure and proposed transport mechanism of the MCF 
 The study of some MCF members dates back more than 40 years.  Perhaps the 
most studied member of this family is the ADP/ATP carrier (AAC). Early studies on this 
protein were greatly facilitated by its prevalence in heart and liver and the discovery of two 
known classes of inhibitors, atractylosides and bongrekic acids (14, 15, 19, 79-81). The 
availability of radiolabeled forms of these two inhibitors further facilitated the isolation 
and purification of the AAC from mammalian tissues, as it enabled protein-inhibitor 
complex tracking throughout the purification process (4, 82).  Even before the primary 
sequence of the AAC was known, it had been purified and reconstituted into liposomes and 
the kinetics and mechanism of this protein has been investigated (18, 147, 148).  The 
biggest advancement in the MCF field to date was in 2003, when the three-dimensional 
coordinates of the bovine ADP/ATP carrier (bAAC) in complex with carboxyatractyloside  
(CATR) were solved by X-ray crystallography with a resolution of 2.2 Å (128). The 
structure showed that the N- and C- termini were present on the inter-membrane space side 
of the inner mitochondrial membrane.  The protein did, in fact, contain six transmembrane 
spanning α-helices that were connected by hydrophilic loops: two loops that extended into 
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the inter-membrane space and three loops that protruded into the matrix (Figure 2-1) (128). 
The six TMDs were oriented such that the overall bAAC structure was conical and ~30 Å 
in length, with an apparent cavity that extended 20 Å deep into the protein (Figure 2-2).  
This transport cavity progressively narrowed from an initial opening diameter of ~20 Å 
down to ~8 Å at the bottom of the transport cavity where an apparent floor was formed.  
 The solved coordinates of the bAAC not only provided visualization of the 
structure of the bAAC, but also contained valuable insights that pertained to the transport 
mechanism. The exposed loops on both sides of the inner membrane were largely 
hydrophilic.  Within the transport cavity, there was an asymmetric scattering of 
hydrophilic and aromatic residues.  Aromatic residues were predominantly localized to the 
fourth TMD and formed what was formerly known as a tyrosine ladder (128), and more 
recently identified as an aromatic ladder (32). Hydrophilic residues were also found within 
the channel and the hydrophilic residues located at the floor of the cavity were probably 
the most intriguing characteristic in the bAAC structure. Interestingly, the PxD/ExxK/R 
conserved motifs were not located immediately after the 1st, 3rd, and 5th TMDs as 
previously thought, but rather were contained within the 1st, 3rd, and 5th TMDs about 2/3 of 
the distance through the lipid bilayer. The AAC crystal structure identified three basic and 
three acidic amino acids that corresponded to the D/E and K/R residues in the 
PxD/ExxK/R motifs; these residues were located at the base of the transport cavity. Prior 
to the crystallization of the AAC, mutagenesis of the charged, conserved motif residues in 
the AAC eliminated the ADP transport function of this protein (57, 58, 114, 117, 118).  
Thus, these charged, conserved motif residues had been previously shown to be an  
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Figure 2-1 Orientation of the transmembrane domains of the ADP/ATP carrier. The 
structure of the bovine ADP/ATP carrier was solved by X-ray crystallography (128). The 
arrangement of the six transmembrane domains (TMD), N-and C-termini, inter-membrane 
space loops (IML), and matrix loops (M) are shown. Kinks were observed in the first 
(TMD 1), third (TMD 3), and fifth (TMD 5) transmembrane domains and were attributed 
to proline residues in a PxD/ExxK/R conserved motif. 
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Figure 2-2 Depiction of the ADP/ATP carrier protein and transport cavity structure.  
This depiction is based on the solved crystal structure of the bovine AAC (128), a structure 
that is thought to be common to all MCF proteins.  The cylindrical outline of the protein is 
in green.  The cone-shaped transport cavity is shown in red and the positive charge at the 
base of the channel marked by +++ in blue.  Distances are marked by arrows and are in 
angstroms (Å).   
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essential component in the transport function of the AAC, but the exact purpose of these 
residues was unknown before the crystallization of the AAC; they were speculated to 
constitute a charged-pair network that was essential for transport (119). The crystal 
structure showed that the residues in the PxD/ExxK/R motifs formed three symmetrical 
and interhelical bonds between the D/E in the conserved motifs on the 1st, 3rd, and 5th 
TMDs and the K/R within the conserved motifs on the 3rd, 5th, and 1st TMDs, respectively 
(128). Specifically in the AAC, three salt bridge interactions were formed between bAAC 
E29 and R137, D134 and R234, and D231 and K32 (Figure 2-3). Kinks  were observed in 
the TMDs that contained the PxD/ExxK/R motifs and these kinks appeared to be induced 
by the proline residues in the PxD/ExxK/R motifs (Figure 2-1 and 2-3). It appeared that the 
function of the charged residues in the PxD/ExxK/R motifs was for the proline residues to 
provide helical flexibility and for the charged residues to form interhelical salt bridge 
interactions.   
 The static view of the crystallized AAC showed that the transport cavity floor, 
formed by the conserved motif interactions, was impenetrable.  This suggested that a 
conformational change was necessary to remove the transport floor and to provide an 
opening within the transport cavity that would permit substrate passage into matrix.  The 
crystal structure showed, and later molecular dynamics simulations with the AAC 
suggested, that bAAC conserved sequence residues E29, R137, D231 and R234 contacted 
the CATR inhibitor (68, 128). The same residues were predicted to contact ADP within the 
AAC transport cavity when ADP binding was simulated in two other molecular dynamics 
simulations (33, 169). Substrate contact with the residues in the PxD/ExxK/R motifs was  
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Figure 2-3 Orientation of the PxD/ExxK/R conserved motifs in the crystallized 
ADP/ATP carrier. The crystal structure of the bovine ADP/ATP carrier (128) (pdb 
accession 1okc) revealed the orientation of the conserved motif residues. The first, third 
and fifth transmembrane domains (TMD) are shown in transparent blue, red and yellow, 
respectively.  The conserved motif residues are identified by their single letter amino acid 
abbreviation and numbered by their location in the amino acid sequence of the bovine 
ADP/ATP carrier.  Salt bridge interactions were predicted between E29 and R137, D134 
and R234, and D231 and K32. 
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proposed to disrupt the interactions that formed the transport cavity floor (128). The TMDs 
containing the PxD/ExxK/R motifs were then predicted to move about the conserved 
proline residues because the interactions between the charged PxD/ExxK/R residues, 
which held the TMDs in place, were disrupted.  This movement about α-helical proline 
residues is not uncommon as this amino acid is often found in transmembrane helices of 
proteins and can destabilize α helices through steric hindrance and backbone bonding 
disruptions (29, 159). The role of the proline residues in the PxD/ExxK/R motifs was more 
recently examined in molecular dynamics simulations with the AAC. These simulations 
showed that the conformational change in the AAC was not mediated by proline 
isomerization or helical bending, but rather through deviations in swivel angles of the 
proline residues (40, 68). The movement about these conserved proline residues was 
proposed to remove the transport floor, leading to a momentary opening of a transport 
channel and substrate passage into the mitochondrial matrix. 
 In addition to the interactions that were anticipated to form at the base of the 
channel, residues that were positioned above the transport floor were also predicted to 
contact substrates within the AAC transport cavity.  As shown in the AAC crystal 
structure, bAAC residues K22, N87, K91, R79, Y186, Y190, Y194 and R279 contacted the 
CATR inhibitor (128).  These residues have also been suggested to contact either CATR or 
ADP within the AAC transport cavity in molecular dynamics simulations (33, 68, 169). 
The aromatic residues that were shown to be required for ADP transport by mutagenesis, 
bAAC Y186 and F191 (32), were speculated to participate in the coordination of the 
adenine ring of ADP based on the results of two molecular dynamics simulations using the 
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AAC (33, 169). Hydrophilic residues were also located above the cavity floor.  Residues 
bAAC K22, R79, and R279 have all been shown to be required for AAC transport function 
in several mutagenesis studies (57, 58, 113, 117, 118).  As shown in two separate 
molecular dynamics simulations, these residues are thought to coordinate the phosphate 
groups of ADP as it descends into the transport cavity (33, 169).  
 The sequence similarities between MCF proteins were thought to translate into 
structural and mechanistic similarities. Similar to the AAC, mutagenesis of the charged 
residues in the PxD/ExxK/R motifs resulted in other MCF proteins that lost their transport 
function (26, 96, 98, 132, 133).  Because mutagenesis of the charged residues in the 
PxD/ExxK/R motifs resulted in severely impaired transport rates in nearly all MCF 
proteins, the function of the PxD/ExxK/R motifs in all MCF proteins was thought to be the 
same. The solved crystal structure of the AAC provided a structural scaffold that was used 
to predict the structures of other MCF proteins (112, 142, 166). Based on the AAC crystal 
structure, the predicted structures for nine MCF proteins were generated by homology 
modeling and the predicted substrate for each of these transporters was computationally 
docked into the transport cavity (142).  The docking of these substrates led to the 
conclusion that all MCF proteins contain three common “substrate-binding sites” that 
corresponded to the residues in the AAC aromatic ladder for one contact point, K22 and 
R79 for another, and R279 as the third contact point (142).  The residues contained in the 
proposed common substrate-binding sites had been previously mutated in the AAC (see 
above) and in the oxoglutarate (25), carnitine (64), and citrate (98) carrier proteins, and 
were shown to be required for transport function in all of these transporters.  Thus, the 
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residues that constituted the proposed common substrate-binding sites were implicated in 
the transport function of various MCF proteins. It was then proposed that the role of these 
binding sites was to properly orient the substrate for interaction with the charged residues 
in the PxD/ExxK/R conserved motifs at the transport cavity floor and that the amino acids 
present at these common binding sites conferred the substrate specificity of the protein 
(142).  The mechanism of MCF protein transport was proposed to involve substrate 
discrimination and positioning by residues at three locations within the transport cavities of 
these proteins (128, 142). The location of the substrate, held within the transport cavity, 
could disrupt the interactions between the charged residues of the PxD/ExxK/R motifs that 
formed the cavity floor (128).  The disruption of the interaction network at the base of 
cavity would enable flexibility of the conserved proline residues in the PxD/ExxK/R 
motifs, which could induce the formation of different interactions with the transport cavity 
and permit substrate passage into the mitochondrial matrix (119). 
 The MFT possessed a striking deviation from the MCF consensus sequence in its 
second PxD/ExxK/R motif: the MFT had substituted a tryptophan residue for the typical 
D/E residue, changing the second motif in the MFT to PxWxxK.  Even more interestingly, 
there were only four other MCF proteins that contained this same substitution.  Because 
the residues in these PxD/ExxK/R motifs appeared to be intimately involved in the 
transport mechanism of MCF proteins, it was fascinating that the MFT and four other MCF 
proteins deviated from this highly conserved sequence.  The function of this substitution 
had not been investigated.  In fact, only once before the discovery of the MFT had this 
PI/LW motif even been acknowledged (119). This substitution was proposed to influence 
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both the mechanism of transport and the substrate specificity of the transporters that 
carried this tryptophan residue (119). 
 In this chapter, we examine the folate-specific transport mechanism of the MFT. 
We probed residues thought to be involved in the MFT mechanism of transport by site-
directed mutagenesis.  A CHO MFT homology model complemented and later directed 
mutagenesis experiments.  Furthermore, a CHO MFT homology model was subjected to 
molecular dynamics simulations to predict interactions between a tetrahydrofolate 
molecule and the residues that line the MFT transport cavity. These studies aim to 
accomplish multiple goals. We want to better understand the transport mechanism of the 
MFT.  Understanding this mechanism would also provide insight to the substrate 
specificity of the MFT.  We aim to appreciate how and why folates were specifically 
recognized and transported by this MFT protein and not other molecules. We found it 
remarkable that MCF proteins were able to transport such a wide variety of substrates with 
high specificity.  Most of the work in the MCF field had focused on the similarities 
between these proteins and how these commonalities translated into shared mechanisms in 
MCF proteins.  We felt it was possible to contribute to the knowledge of these MCF 
proteins, their substrate specificities and their mechanisms by understanding the roles of 
the anomalous residues in the transport mechanism of the MFT.    
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MATERIALS AND METHODS 
 
Alignment of MCF proteins 
 Sequences for MCF proteins were loaded into the MegAlign program (version 6.1) 
(27) and aligned by ClustalW (158) using the following NCBI protein accession numbers:  
NP_001142 - human ADP/ATP carrier, isoform 1 (HsAAC1); NP_110407 – human 
mitochondrial folate transporter (HsMFT); NP_012132 – yeast FAD+ transporter 
(ScFlx1p); NP_009751 – yeast pyrimidine transporter (ScRim2p); NP_010910 – yeast 
NAD+ transporter (ScYEL006W); NP_014316 – yeast Mg-ATP/Pi transporter (ScSal1p); 
NP_005975 – human citrate transporter (HsCTP); NP_003553 – human oxoglutarate 
carrier (HsOGC); NP_055067 – human ornithine transporter (HsORNT1).  
 
Site-directed mutagenesis of the CHO MFT by overlap extension PCR 
  The CHO and glyB mft cDNA (~1,100 base pairs) had been previously cloned into 
the pcDNA 3.1(-) vector and contained a EQKLISEEDL c-myc tag directly downstream of 
the mft cDNA start codon (129).  Within the pcDNA 3.1(-) vector, XhoI and HindIII 
recognition sites flanked the 5’ and 3’ full-length myc-mft cDNA, respectively, and were 
contained in the multiple cloning site (MCS) of the vector.  Site-directed mutagenesis was 
accomplished by overlap extension polymerase chain reaction (PCR) (59, 145) using the 
myc-tagged CHO mft in pcDNA 3.1 (-).  Overlap extension PCR consisted of two rounds 
of PCR (Figure 2-4).  In the first round, the CHO mft template was placed in two separate 
reactions.  One reaction involved a vector-specific primer that was upstream of the 5’ mft  
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Figure 2-4 Generation of CHO mft mutant cDNAs by overlap extension polymerase 
chain reaction. A. Two fragments of a N-terminal myc tagged CHO mft cDNA (1.1 
kilobases (kb)) that had been cloned into pcDNA 3.1(-) (100 ng) were amplified using two 
sets of primers.  Each set of primers contained a vector-specific primer (vector forward and 
vector reverse) and a mft-specific primer (MFT forward or MFT reverse) that introduced a 
mutation into the CHO mft cDNA.  The mft-specific primers used in separate reactions 
each introduced the same mutation and contained 15 base pairs of DNA sequence overlap.  
The fragments were amplified by polymerase chain reaction (PCR) and were visualized on 
a 1% agarose gel.  B.  The fragments produced and purified from the first PCR reaction 
were added (50 ng of each product) to a second PCR reaction.  This reaction contained the 
same vector-specific primers as in the first PCR reaction.  The 15 base pairs of overlap 
created by the mft-specific primers in the first round PCR hybridized to one another in the 
first cycle of PCR and the vector-specific primers inserted the missing base pairs to 
produce a full-length CHO mft cDNA (1.1 kb) that contained the introduced mutation.  
This full-length CHO mft cDNA was amplified by successive cycles of PCR and visualized 
on a 1% agarose gel.  The “–” signs denotes lanes loaded with PCR reactions that did not 
receive any starting cDNA template. 
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start site that ran 5’ to 3’ and the other primer was located within the mft sequence, 
introduced the mutation and ran 3’ to 5’.  The other reaction used a similar mft-specific 
primer as in the first reaction; it contained ~15 base pairs of overlap with the first reaction 
primer, introduced the mutation, but ran 5’ to 3’.  The second primer in the other first 
round reaction was specific to the vector, was located downstream of the 3’ stop and ran 3’ 
to 5’.  Following first round PCR, products were electrophoresed on a 1% agarose gel with 
ethidium bromide added and the fragment with the expected molecular mass was extracted, 
purified using the Promega Wizard SV gel and PCR clean up system kit, and the 
concentration of the purified PCR products was determined by sample absorbance at 260 
nm. An aliquot containing 50 ng of product from each of the two first round reactions was 
added as template into the second round reaction.  Due to the overlap designed into the 
mft-specific primers that introduced the mutation, these two products hybridized using the 
15 base pair overlap site and were extended during the first PCR extension cycle to form a 
single double stranded DNA product.  The primers used in the second round reaction were 
the 5’ and 3’ vector-specific primers from the first round reactions that flanked the mft 
cDNA.  The second round PCR products were electrophoresed, extracted, purified and the 
concentrations of products were spectrophotometrically determined.  Each PCR reaction 
had a total volume of 50 µL and contained 20 mM Tris-HCl, 50 mM KCl (pH 8.4 ; MgCl2-
free Taq polymerase buffer), 1.5 mM MgCl2, 200 µM deoxynucleotides, 0.3 µM of each 
primer, 2 U Taq DNA polymerase, and 0.5 U PFU turbo polymerase (Stratagene).  PCR 
reactions were initiated at 95° C for two minutes, followed by 20 cycles of 95° C for one 
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minute, 53° C for 1 minute, and 72° C for two minutes, and finished with a ten minute 
incubation at 72° C.  The sequences of all of the primers used are shown in Table 2-2. 
 
Cloning of mutant mft cDNA constructs into a mammalian expression vector 
 Mutant mft cDNA PCR fragments were cloned into a mammalian expression 
vector, pcDNA 3.1(-), for transfection into glyB cells.  The PCR amplification of these 
cDNAs had been carried out so that the 5’ XhoI and 3’ HindIII recognition sites were 
preserved in the fragments.  The pcDNA 3.1(-) vector also contained these restriction sites 
in its MCS.  The vector and the mutant PCR-amplified mft cDNAs were digested with both 
XhoI and HindIII at 37° C for one hour. The total volume of each digest reaction was 20 
µL and each reaction contained 10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, 1 mM 
dithiothreitol (pH 7.9; NEB2), 0.1 µg/µL BSA, 20 U XhoI, and 20 U HindIII.  Following 
digestion, these products were electrophoresed, extracted, purified, and the concentrations 
of purified products were determined as above. Ligation of the vector and mutant mft 
cDNA was carried out at 16° C for 16 hours.  Each ligation reaction had a total volume of 
10 µL that contained a 3:1 molar ratio of mft cDNA to vector pcDNA 3.1(-) (~5.4 
kilobases ; 25 ng vector/reaction), 66 mM Tris-HCl, 5 mM MgCl2, 1 mM dithiothreitol, 1 
mM ATP (pH 7.5 ; Ligase Buffer), and 1 U T4 DNA ligase. 
 
 
 
 
   
 37 
 
 
 
 
Vector Specific Primers
Name Sequence Mutant Direction
T7for taatacgactcactatagggagaccc - Forward
pcDNA 3.1(-) rev. gacagtgggagtggcaccttc - Reverse
MFT Specific Primers
Name Sequence Mutant Direction
CHOMFTW142A-FM acaaacccactggcggtgacgaaaact W142A Forward
CHOMFTW142A-RM agttttcgtcaccgccagtgggtttg W142A Reverse
CHO MFT W142D FM ccactggacgtgacgaaaactcg W142D Forward
CHO MFT W142D RM cgtcacgtccagtgggtttgtg W142D Reverse
CHO MFT W142F FM ccactgttcgtgacgaaaactcgccttatg W142F Forward
CHO MFT W142F RM cgtcacgaacagtgggtttgtgatg W142F Reverse
CHO MFT W142R FM ccactgagggtgacgaaaactcg
W142R                    
W142R / R249W
Forward
CHO MFT W142R RM cgtcaccctcagtgggtttgtgatgcag
W142R                  
W142R / R249W
Reverse
CHO MFT R249W FM tatcaagttgtgtgggcccgtcttcaggac
R249W                      
W142R / R249W
Forward
CHO MFT R249W RM gcccacacaccttgatacgg
R249W                  
W142R / R249W
Reverse
CHO MFT G91R FM gtatggagggcgggtttatcctg G91R Forward
CHO MFT G91R RM acccgccctccatacatttgg G91R Reverse
CHO MFT G91L FM gtatggcttgcgggtttatcctggggactc G91L Forward
CHO MFT G91L RM acccgcaagccatacatttggggttac G91L Reverse
CHO MFT Q246E fp tacccgtatgaggttgtgcgagcccg Q246E Forward
CHO MFT Q246E rp tcgcacaacctcatacgggtatgttgc Q246E Reverse  
 
 
Table 2-2 List of primers used for PCR reactions. All primers are listed from 5’ to 3’ 
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Transformation of E. coli with mutant mft cDNA ligated into pcDNA 3.1(-) for plasmid 
purification 
 Chemically competent TOP10 E. coli cells were stored at -80° C and thawed on ice 
for ~5 minutes.  After thawing, 5 µL of each ligation reaction was added to ~50 µL TOP10 
cells and this mixture incubated on ice for 30 minutes, after which it was placed at 42° C 
for 45 seconds.  Following this heat-shock, the mixture was placed back on ice for 10 
minutes to allow the TOP10 cells to recovery from the heat-shock. S.O.C. Media (2% 
tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 
and 20 mM glucose) (250 µL), warmed to 25° C, was added to the mixture and the 
reaction tube was placed horizontally in a shaking incubator for one hour at 225 rpm and 
37° C.  The transformed TOP10 cells were plated on Luria-Bertani (LB) agar plates with 
100 µg/mL of carbenicillin added and were incubated at 37° C overnight.  The pcDNA 
3.1(-) vector provided an ampicillin resistance cassette that permitted growth in the 
presence of carbenicillin to TOP10 bacteria that were transformed with this vector.  
Approximately five colonies were picked for further expansion, inoculated into 5 mL LB 
media containing carbenicillin and placed in a shaking incubator at 37° C and 225 rpm for 
~16 hours.  Bacterial cells were centrifuged at 4,000 x g to pellet the cells and the plasmid 
DNA was isolated using a Promega Wizard Plus SV Miniprep kit. A XhoI and HindIII 
restriction digest (as above) was used to check for the appropriate insert size and three 
clones containing the correct insert size were sequenced.  Frozen stocks of these clones 
were made in LB broth with 10% DMSO and stored at -80° C. The same procedure was 
followed for large-scale plasmid isolations, only clones were initially inoculated in 5 mL 
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of LB agar with 100 µg/mL carbenicillin for ~4 hours at 37° C and then expanded into a 
total of 50 mL of the same media and grown for an additional 16 hours at 225 rpm and 37° 
C.  Plasmid DNA was isolated using a Promega PureYield Plasmid MidiPrep kit. 
 
Transfection of glyB cells with mutant mft cDNA in pcDNA 3.1(-) 
 Mft cDNAs cloned into pcDNA 3.1(-) that were confirmed by sequencing to 
contain only the intended mutations were transfected into glyB cells to test the function of 
the encoded mutant MFT protein.  The normal growth media of glyB cells was MEM α 
media with deoxynucleosides and ribonucleosides, supplemented with 10% fetal bovine 
serum (FBS).  GlyB cells were routinely grown at 37° C with 5% CO2.  GlyB cells were 
plated at 100,000 cells per 100 mm dish 48 hours prior to transfection with mutant mft 
cDNA in pcDNA 3.1(-). Plasmid DNA was diluted to 100 ng/µL over 1/10 the volume of 
chloroform, mixed well and placed at 4° C 24 hours before transfection.  Transfection was 
carried out using a calcium phosphate-based method (53).  For transfection of a single 100 
mm dish, 700 µL of HEBES buffer (10 g/L HEPES, 16 g/L NaCl, 0.74 g/L KCl, 0.25 g/L, 
Na2HPO4(7H20), 2 g/L glucose, pH 7.04) was added drop-wise into an air-bubbled solution 
containing the pcDNA 3.1(-) vector that encoded a mutated CHO mft cDNA and CaCl2 for 
a final volume of 1 mL/100 mm dish with 5 µg plasmid DNA per 100 mm dish and 135 
mM CaCl2. For transfection of multiple dishes with the same mutant MFT construct, the 
amounts of HEBES, DNA and CaCl2 were proportionally increased, combined into a 
single solution and 1 mL portions were taken from this master solution for each plate. 
After HEBES was added, this solution was incubated at room temperature for 30 minutes.  
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Media was aspirated from the glyB cells and the transfection mix was placed directly on 
the cells for 30 minutes at room temperature with agitation every 10 minutes.  After this 
incubation, 9 mL of fresh non-selective media (MEM α with deoxynucleosides and 
ribonucleosides supplemented with 10% FBS and 1% Penicillin and Streptomycin 
(Pen/Strep)) was added to each transfection dish and the plates were placed in an incubator 
at 37° C and 5% CO2.  The non-selective media containing the transfection mix was 
aspirated from the transfected dishes 24 hours later, 10 mL of fresh, non-selective media 
was added, and the dishes were placed at 37° C in a 5% CO2 incubator for 24 hours.  After 
a total of 48 hours after transfection, selective media was placed on the cells.  Two 
different types of selective media were used in the glyB complementation assay, single 
selection media and double selection media.  Both media types contained glycine-free 
MEM α media that was supplemented with 10% dialyzed FBS, 1% Pen/Strep, and 1 
mg/mL G418.  The difference between the two media types was that single selection media 
was also supplemented with 50 mg/L glycine, while double selection media did not contain 
any glycine. Selective media was replaced every other day for 8-10 days, after which the 
media was removed and the dishes were washed twice with phosphate buffered saline 
(PBS).  Methanol was placed on the dishes for 15 minutes to fix any colonies.  The 
methanol was removed from the plates and colonies were stained in 5% Wright-Giemsa 
stain for 15 minutes.  The stain was removed, the dishes were washed with distilled water, 
the plates were allowed to air-dry and the colonies on each dish were manually counted. 
Every colony that was easily visible to the eye was counted. The data shown represents the 
average from three to six experiments with standard deviation bars.  In each experiment, 
   
 41 
three replicate dishes were used per selection condition. Statistical significance (p < 0.001) 
was determined for all data using a one-way ANOVA analysis followed by a 
Tukey/Kramer analysis.  Selected stained plates are shown in Figure 2-5. 
 
Generation of glyB cells stably transfected with mutant mft cDNA 
 GlyB cells were transfected as described above and colonies of transfected glyB 
cells were grown in single selection media.  After 8-10 days of growth in single selection 
media, colonies were visualized under a microscope and their location was marked on the 
underside of their growth dish with a permanent marker.  In a sterile environment, selective 
growth medium was removed from the 100 mm dishes and colonies were removed from 
dishes by touching sterile cotton swabs to the location of the dish that corresponded to the 
marked areas.  Twelve colonies were randomly selected for each mutation without 
preference for colony size or morphology.  These clones were grown in single selection 
media at all times. 
 
Isolation of mitochondria and mitochondrial protein 
 Stably transfected cells lines were scraped from tissue culture dishes in phosphate 
buffered saline (PBS) with a commercial mixture of EDTA-free protease inhibitors (PI) 
(Roche, cat. #11873580001).  The protease inhibitors in this mixture are a proprietary 
mixture of serine, cysteine, and metalloprotease inhibitors.  All samples were kept on ice 
from herein.  Cells were centrifuged and resuspended in 7.5 mL of homogenization 
solution (250 mM sucrose, 1 mM EDTA, pH 6.8) with protease inhibitors.  Following a  
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Figure 2-5 Stained transfection plates from glyB complementation assay.  GlyB cells 
were plated on 100 mm dishes and transfected with CHO mft cDNA constructs in pcDNA 
3.1(-) by a calcium phosphate-based method.  Transfected cells were grown in media 
containing 1 mg/mL G418 in the presence (single selection) or absence (double selection) 
of glycine.  After 8-10 days of growth in selective media dishes, cells were washed with 
phosphate buffered saline, the colonies that formed were fixed to the dishes with methanol 
and stained in 5% Wright-Giemsa.  The dishes were then air-dried and colonies were 
manually counted. Data was expressed as a ratio of the number of colonies formed in the 
absence of glycine versus in the presence of glycine.  The plates that are shown represent 
glyB cells transfected with either CHO or glyB mft cDNA. 
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five minute incubation in homogenization solution, cells were gently broken open using 15 
strokes in a 7.5 mL dounce homogenizer using a “B” pestle.  This homogenate was 
centrifuged at 2,000 x g at 4° C for 5 minutes to remove cell debris and unbroken cells.  
The post-nuclear supernatant was centrifuged at 11,000 x g at 4° C for 15 minutes and the 
pellet contained the mitochondria.  For further mitochondrial protein analysis, the 
mitochondrial pellet was dissolved in lysis buffer (62.5 mM Tris, pH 6.8; 5% glycerol; 2% 
SDS; 5% 2-mercaptoethanol) formulated with protease inhibitors. Mitochondrial protein 
concentrations were determined by the Bradford reagent (Bio-Rad, cat. #5000006) as 
specified by the manufacturer against a standard of bovine serum albumin. 
 
Western blot analysis of myc-MFT expression 
 Twenty micrograms of isolated mitochondrial protein was loaded into a freshly 
prepared 12% SDS-PAGE gel, subjected to electrophoresis, and the fractionated proteins 
were transferred to a PVDF membrane at 100 V over one hour in a buffer containing 192 
mM glycine, 25 mM Tris, pH 8.3.  Non-specific membrane binding was minimized by a 
one hour incubation with Starting Block T20 (Thermo Fisher Scientific, cat. #37543), 
followed by three vigorous washes in Tris buffered saline containing 0.05% Tween (TBS-
T) for 5 minutes each.  The membrane was incubated with rabbit anti-myc antibody 
(Sigma, cat. #C3956) in Starting Block T20 (1:2000 dilution) at 4° C for 16 hours.  The 
membrane was washed three times for 15 minutes each in 0.05% TBS-T and placed in 
Starting Block T20 with peroxidase conjugated goat anti-rabbit IgG antibody (1:10,000 
dilution, Thermo Fisher Scientific, cat. #31462) for one hour at 25° C, followed by three 
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washes for 15 minutes in 0.05% TBS-T.  Protein IgG complexes were detected using a 
West-Dura chemiluminescent substrate kit (Pierce SuperSignal) that was incubated with 
the membrane in the dark and the membrane was then exposed to X-ray film so that the 
positions of and abundance of myc-tagged proteins could be visualized and documented on 
film. The abundance of MFT that was expressed in cultures expanded from individual 
colonies for each MFT mutation was compared, and clones of each mutant that expressed 
similar levels of myc-tagged MFT were selected for use in radiolabeled folate uptake 
experiments.  The detection of myc-MFT expression in various MFT mutant clones is 
shown in Figure 2-6. 
 
Mitochondrial uptake of 3H-6S-5-formyltetrahydrofolate 
 GlyB cells stably expressing the transfected mutant MFTs were detached from 150 
mm dishes using trypsin/EDTA and resuspended in MEM α media supplemented with 
10% FBS, placed in a 37° C shaking incubator in suspension culture and allowed to 
recover from trypsin exposure for one hour.  Cells were pelleted by centrifugation, 
resuspended in 0.25 mL RPMI 1640 media without folic acid or serum at 10-20 x 106 
cells/mL and placed in a 37° C shaking water bath for 5 minutes.  An equal volume of 
RPMI 1640 media was added without folic acid, but containing 1 µM [3’,5’, 7, 9-3H]-(6S)-
5-formyl-tetrahydrofolate at  a final specific activity of 2.5 µCi/mL.  Uptake was stopped 
by the timed addition of 10 mL of ice cold PBS and samples were kept at 4° C thereafter.  
Cells were pelleted at 2000 x g at 4° C for 5 minutes, washed three times with 10 mL of 
PBS, and mitochondria were isolated by dounce homogenization and differential  
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Figure 2-6 Probing MFT mutant clones for myc-MFT expression by western blotting.  
Ten colonies from glyB cells stably transfected with each mutant myc-MFT cDNA were 
randomly selected, isolated and expanded into ten mass cultures.  Mitochondrial protein 
was isolated from mass cultures of up to ten clones per MFT mutation. In A. and B., 
mitochondrial protein from glyB cells was included as a negative control on these blots.  
The black arrows mark the expected size of the MFT, ~33 kDa.  A. Ten micrograms of 
mitochondrial protein from the indicated MFT mutant clones was loaded onto a gel, 
electrophoresed, and the proteins in the gel were transferred to a PVDF membrane.  This 
membrane was probed for myc-MFT expression using an antibody raised against myc.  
Mitochondrial protein from MFT mutant W142R, clone 7 was determined by western 
blotting (not shown) to contain a high amount of myc-MFT expression.  Other MFT mutant 
clones were probed for myc-MFT expression similar to MFT mutant W142R, clone 7. It 
was later determined that myc-MFT expression in MFT mutant W142R, clone 7 was 
higher than was observed in most other MFT mutant clones and therefore, this clone was 
not used for further experimentation.  B. Twenty micrograms of mitochondrial protein 
from clones of every constructed MFT mutant were loaded onto the same gel, the gel 
electrophoresed, and the proteins in the gel were transferred to a PVDF membrane. This 
membrane was probed for myc-MFT expression using an antibody raised against myc.  All 
of the MFT mutant clones probed on this blot were expanded and used in the transport 
assays presented in the Results section of this chapter.  
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centrifugation, as described above.  Isolated mitochondrial pellets were dissolved in 0.5 
mL of 75 mM NaOH.  The dissolved mitochondria were neutralized with a 0.5 mL 
addition of 100 mM HCl and a 1 mL addition of homogenization solution (250 mM 
sucrose, 1 mM EDTA, pH 6.8). Safety Solve scintillation cocktail (18 mL) was added into 
the 20 mL glass scintillation vials and the vials were placed in a Beckman Coulter LS 6500 
multi-purpose scintillation counter for the determination of 3H content.  The counts per 
minute in each sample were analyzed for two cycles of counting for a total of 10 minutes 
each with no background input. The data shown represents the average of 3-4 experimental 
samples from two different experiments with standard deviation bars.  Statistical 
significance (p < 0.001) was determined for all data using a one-way ANOVA analysis 
followed by a Tukey/Kramer analysis.   
  
Generation of the CHO MFT homology models 
 Throughout the course of these studies, two CHO MFT homology models were 
created.   Both models were generated using the CHO MFT primary sequence and the 
solved crystal structure of the bovine ADP/ATP carrier (128) (bAAC ; pdb accession: 
1okc) as the structural template. The CHO MFT sequence was sent to the PSIPRED server 
(13, 22) to predict the secondary structure of the CHO MFT protein. The primary 
sequences of the CHO MFT and the bAAC were arranged so the predicted membrane-
spanning domains and the PxD/ExxK/R motifs in the MFT were aligned with those in the 
bAAC crystal structure.   The MFT and bAAC primary sequences were also aligned so the 
sequences of the predicted transmembrane domain regions did not contain any gaps in 
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sequence alignment. These regions were considered to be structurally conserved regions 
for MFT homology model generation.  In the structurally conserved regions, the crystal 
structure of the AAC was used as the template to generate the MFT structure. We did not 
consider predicted random coil regions to be structurally conserved between the MFT and 
AAC.  Therefore, gaps in the sequence alignment were permitted in the predicted loop 
regions of the MFT.  Loop regions were modeled using an independent database that was 
contained within the Sybyl 7.1 COMPOSER program (161), in which the sequences of 
these MFT loop regions were paired to similar sequences in other proteins in which the 
structure was known.  The first homology model was created in the COMPOSER module 
of Tripos Sybyl 7.1 (161).  Following the generation of this model, the locations and 
orientations of all amino acid side chains were optimized using the SQWRL program (17).  
 A second model was created in the ORCHESTRAR module in Tripos Sybyl 8.0  
(164) to improve the modeling of MFT loop regions using the enhanced libraries of loop 
structures and advanced prediction methods of that version.  As in the generation of the 
first MFT homology model, the transmembrane domain regions were selected as the 
structurally conserved regions. The structure of these regions was created using the AAC 
crystal structure as the template. Predicted loop regions in the MFT were modeled 
independent of the AAC structure using an enhanced library of protein loop regions 
contained in the ORCHESTRAR program.  Loops regions were searched using a 
combination of ab initio, fragment database (FREAD), and homolog comparison methods.  
Following the generation of the CHO MFT model, the model was inspected and contained 
no peptide bond breaks or distances > 1.60 Å between bonded atoms, no torsion angles that 
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were clearly outside of their allowable Ramachadran plot placement, and steric interactions 
of amino acid side chains were minimized. 
 
Tetrahydrofolate docking into the CHO MFT homology model 
 A molecule of tetrahydrofolate was built in Sybyl 7.1, atom and bond types were 
checked, and the structure equilibrated to an energy minimum.  The COMPOSER-
generated CHO MFT homology model and the crystallography-derived structure of the 
bovine AAC (bAAC) (pdb accession: 1okc) were loaded into the Sybyl 7.1 program.  The 
CHO MFT homology model and bAAC were aligned so that the common structural 
elements of these two proteins overlapped.  Specifically, these proteins were aligned so 
that their transmembrane domains were superimposable. Initially two structure files 
existed, one contained the bAAC structure in complex with a carboxyatractyloside 
(CATR) inhibitor molecule in its transport cavity, and the other contained the CHO MFT 
homology model.  The CATR inhibitor was then extracted in silico from the bAAC 
structure file.  Three separate files now existed, one containing the bAAC, one containing 
the CHO MFT homology model, and one containing the CATR inhibitor, but the spatial 
locations and coordinates of all three structures did not change.  The CATR inhibitor was 
then merged into the MFT homology model structure.  The MFT homology model now 
contained the CATR molecule in the exact location and orientation as it was in the bAAC.  
Atoms in the MFT that were within 9.9 Å of the merged CATR were used as the active 
docking site for tetrahydrofolate using the FlexX program (161). Total Score and CSCORE 
were used to sort the resulting docked conformations of tetrahydrofolate. 
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Molecular dynamics simulation of tetrahydrofolate transport in the MFT homology model   
 A molecular dynamics simulation of the CHO MFT was run using the Ohio 
Supercomputer Center in collaboration with Dr. John C. Hackett of the department of 
Medicinal Chemistry at VCU. Dr. Hackett provided the following description of the 
molecular dynamics simulations methods.  
 A square 100 Å2 palmitoyl oleylphosphatidylcholine (POPC) bilayer membrane 
slab was constructed using the Visual Molecular Dynamics (VMD) program (63) and an 
additional 30 Å and 20 Å of TIP3P water molecules were added to inter-membrane space 
and matrix sides, respectively. All molecular dynamics simulations were performed with 
the NAMD 2.6 suite of programs (134) and the CHARMM27 (99)  force field for 
biomolecular simulations. The hydrated membrane was minimized for 5000 steps, 
followed by equilibration of the aliphatic lipid tails for 500 ps at constant volume and 
temperature (NVT; 300 K). After melting of the lipid tails, the entire membrane system 
was equilibrated in the NVT ensemble for an additional 500 ps.  
 The propKa module of the PDB2PQR suite of programs (10, 37, 74) was used to 
calculate estimates of pKa values for ionizable residues in the MFT homology model that 
were generated in the ORCHESTRAR module. These values were subsequently used to 
assign their protonation states at pH 7.4. After the appropriate adjustments in the 
protonation states, the homology model was oriented in the center of the pre-equilibrated 
POPC membrane. Overlapping lipid and water molecules, as well as those within 0.8 Å 
were removed from the simulation system. Nineteen chloride ions were added to neutralize 
the simulation cell resulting in a system containing ~100,000 atoms for molecular 
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dynamics simulation. The complete system was minimized for 5000 steps followed by 
equilibration of the lipid tails for 200 ps with the remainder of the system frozen. Melting 
of the lipid tails was followed by an additional 1000 steps of minimization and 
equilibration for 200 ps at constant temperature and pressure (NPT) using the Langevin 
piston method with a target pressure of 1.01325 bar, decay period of 100 fs, and piston 
temperature of 300 K. The area of the membrane was maintained constant during NPT 
simulations.  The aforementioned minimization and equilibration protocol was then 
repeated, albeit with a harmonic restraint (5 kcal/mol/Å) applied to the protein backbone 
atoms. Moreover, in these preparative NPT MD simulations harmonic forces (0.1 
kcal/mol/ Å) were applied between select water molecule oxygen atoms and the C21 atoms 
of the POPC lipids to prevent water molecules from entering the hydrophobic phase of the 
membrane during equilibration.  Prior to production simulations, an additional 2 ns of NPT 
simulation was performed with these restraints applied between the water and lipid 
molecules to ensure appropriate equilibration and packing of the POPC membrane around 
the MFT protein. After completion of the preparative simulations, the MFT model was 
equilibrated for an additional 30 ns. 
 CHARMM parameters for tetrahydrofolate (THF) were derived from dihydrofolate 
parameters described by Garcia-Viloca and coworkers (48).  Electrostatic potential charges 
were derived using the CHELPG scheme (20) from a geometry fully-optimized geometry 
at the B3LYP/6-31G* level of theory using the Gaussian03 suite of programs (46).  To 
simulate capture of tetrahydrofolate by the MFT model, this ligand was merged with a 
trajectory snapshot corresponding to t = 5 ns with the carboxylates oriented toward the 
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base of the channel. The molecule of tetrahydrofolate was manually placed above the MFT 
homology model transport cavity.  Overlapping water molecules as well those within of 
THF 0.8 Å were removed from the simulation system. Furthermore, to compensate for the 
dianionic tetrahydrofolate and maintain electrical neutrality, two chloride ions were 
removed from the simulation cell.  
 
RESULTS 
 
 A former graduate student in this laboratory who had worked on the mitochondrial 
folate transporter (MFT) project, Dr. Erin Perchiniak, submitted a manuscript for 
publication before she left the lab.  In her work, she used insertion of a c-myc tag 
(EQKLISEEDL) to study the function of the N- and C- termini and the predicted inter-
membrane space loop regions of the chinese hamster ovary (CHO) MFT.  She also 
designed ten site-specific residue mutations in the MFT protein to study the roles of these 
residues in the transport function of the MFT.  She was able to track these mutant proteins 
within the cell using the c-myc tag that was attached to the N-terminus of the constructed 
MFT mutant proteins. Dr. Perchiniak set up a survival assay to study the effects of regional 
myc-insertion in the MFT and of the site-specific mutations on MFT transport function in a 
MFT functionally-null, CHO-derived cell line, the glyB cell. The manuscript was returned 
from review and requested a more direct transport analysis of the site-directed mutants.  
With Dr. Perchiniak no longer in the lab, Dr. Moran and I devised an assay that more 
directly assessed the effects of mutations on MFT transport function by measuring 
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mitochondrial folate uptake in glyB cells transfected with mutant MFT constructs. 
Additionally, during the review and revision period, we generated a homology model of 
the CHO MFT, based on the solved three-dimensional coordinates of a related MCF 
protein, the ADP/ATP carrier (AAC).  This homology model complemented the 
manuscript, helped explain the experimental data and aided in the design of future 
experiments. 
  
Exploiting the glyB glycine auxotrophy phenotype to study MFT function 
 CHO-derived glyB cells have a single point mutation in their only allele that 
encodes for the MFT, which results in a G192E mutation and eliminates the transport 
function of the MFT (108).  Thus, glyB cells are unable to accumulate any mitochondrial 
folates and, therefore, require an exogenous supply of glycine for survival.   However, 
glyB cells could be relieved of this glycine auxotrophy phenotype by transfection with mft 
cDNA from human, hamster, mouse, zebrafish, even Arabidopsis because these cDNA 
constructs encoded a functional MFT protein that restored mitochondrial folate 
accumulation in the transfected cells (108, 160).  MFT site-specific mutants could be 
studied in the same way; a mutation in wild-type CHO mft cDNA could be constructed, 
transfected into glyB cells and the ability of these transfected cells to survive in the 
absence of glycine could be observed.  If cells transfected with this mutated cDNA could 
survive without glycine supplementation, the encoded MFT mutant protein retained 
function.  Conversely, if the transfected glyB cells still required glycine for survival, it 
would be evident that the encoded MFT protein was unable to restore mitochondrial folate 
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uptake in glyB cells and the mutated MFT protein was considered to be devoid of folate 
transport activity.   
 
Studying ten MFT residues conserved amongst MFT orthologs by mutagenesis 
 MFT site-specific mutations were designed during Erin Perchiniak’s thesis work, 
and at that time, the crystal structure of the AAC was not available.  Hence, there were no 
clues to the structure of the MFT protein in the literature.  However, in the process of 
completing these studies, a crystal structure did become available and the MFT mutants 
that were initially designed are discussed with respect to their predicted locations in a CHO 
MFT homology model later in this section. Charged residues were hypothesized to contact 
and position the folate substrate within the channel.  In addition, residues that were highly 
conserved in MFT orthologs but were altered in other MCF proteins suggested the 
potential involvement of these MFT residues in a folate-specific transport mechanism. The 
function of these residues was studied in a glyB complementation assay using the survival 
of glyB cells in the absence of glycine as an endpoint.   The glyB complementation assay 
data is expressed as the number of colonies that are formed in the presence of G418 with 
and without glycine to control for transfection efficiency in each experiment. GlyB cells 
transfected with wild type CHO mft cDNA were able to form half of the colonies in the 
absence of glycine versus in the presence of glycine (Figure 2-7A).  In contrast, glyB cells 
transfected with glyB mft cDNA (CHO MFT G192E) were unable to form colonies in the 
absence of glycine. Despite the conservation of these residues across MFT orthologs, eight 
of the ten site-directed mutations were capable of some level of folate transport, as  
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Figure 2-7 GlyB complementation and western blotting of MFT mutants.  These 
studies are published in Perchiniak et al. (2007). A. Mutant mft cDNA constructs in 
pcDNA 3.1(-) were transfected into glyB cells and the ability of the transfectants to grow 
in the presence and absence of glycine was observed.  B. Mitochondrial protein was 
isolated from stably transfected and pooled cell lines.  Forty micrograms of protein from 
each cell line was probed for myc-MFT expression using an antibody raised against the 
myc epitope.  Untransfected CHO cells and glyB cells transfected with a N-terminal myc 
tagged CHO mft cDNA were included as negative and positive controls, respectively. 
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suggested by the ability of the mutant transfectants to form colonies in the absence of 
glycine. Only two MFT mutations, CHO MFT R249A and G192E (mimicking the 
mutation in the glyB MFT) resulted in MFT proteins that were unable to restore 
mitochondrial folate accumulation in glyB cells (Figure 2-7A). All of the transfected MFT 
mutant proteins carried an N-terminal myc tag and western blot analysis of mitochondrial 
protein, probed for myc expression, confirmed that the MFT mutant proteins were 
expressed and localized to mitochondria (Figure 2-7B).  This indicated that the glyB 
complementation data could be interpreted on the basis of MFT function without 
complications resulting from significant variance in MFT expression or an inability of the 
MFT to be properly targeted to mitochondria.   
 The endpoint in the glyB complementation assay was glyB cell survival in the 
absence of glycine, which was an indirect measure of the MFT transport.  We did not 
know what level of mitochondrial folate accumulation was compatible with cell survival 
and how this level compared to wild type accumulation.  For instance, it was possible that 
a MFT mutant protein could retain ~50% of its wild-type function, but this level of 
function would still permit enough mitochondrial folate accumulation to permit glyB cell 
survival in the absence of glycine. An assay was designed to more directly measure 
mitochondrial folate uptake and study the effects of these mutations on MFT transport 
function.  This assay was not a direct measure of mitochondrial folate transport, but rather 
measured uptake of radiolabel into mitochondria when intact cells were exposed to 3H-6S-
5-formyl-tetrahydrofolate (5f-thf).  To generate the cell lines used in this uptake assay, ten 
colonies of glyB cells that were transfected with the same mutant mft cDNA construct and 
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that survived G418 selection were expanded.  Equal amounts of cells from each of the 
colonies were pooled together and the cells were used in this transport assay within three 
passages.  In this assay, whole cells were incubated with 5f-thf.  After 5f-thf uptake, cells 
were dounce homogenized and the mitochondrial and cytosolic compartments were 
isolated by differential centrifugation.  The radioactivity in the mitochondrial fraction was 
determined and converted into units that represented mitochondrial folate uptake.  CHO 
and glyB cells were incubated with 5f-thf for varying lengths of time up to one hour 
(Figure 2-8A).  CHO cells actively and near linearly accumulated mitochondrial folates for 
20 minutes, followed by a slower rate of accumulation for the remainder of the 60 minute 
incubation period.  Mitochondrial folate uptake was observed in glyB cells, but was 
minimal when compared to CHO mitochondrial uptake. Based on this data, a 20 minute 
incubation with labeled 5f-thf was chosen for future experimentation; it appeared that 
mitochondrial folate accumulation was relatively linear up to this point and the uptake in 
CHO and glyB mitochondria was sufficiently separated to allow the interpretation of 
various levels of mitochondrial folate uptake in stably transfected MFT mutant cell lines. 
As was observed in the glyB complementation assay, CHO MFT R249A and G192E 
showed a distinct inability to uptake any mitochondrial folates (Figure 2-8B).  Besides the 
R249A and G192 mutations, it appeared that all other MFT mutations studied were able to 
accumulate significant amounts of mitochondrial metabolites of 5f-thf. 
 Somewhat disappointingly, we had constructed ten MFT site-directed mutations 
and only two of these mutations appeared to affect the transport function of the MFT.  
Furthermore, of the two residues that were required for MFT transport, one residue  
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Figure 2-8 Mitochondrial folate uptake in CHO, glyB and MFT mutant cell lines. 
These studies are published in Perchiniak et al. (2007).  A. CHO and glyB cells were 
incubated with 1 µM 3H-6S-5-formyl-tetrahydrofolate for the indicated periods of time.  
Mitochondrial fractions were isolated from the cells and counted for radioactivity. B. GlyB 
cells were stably transfected with MFT mutant cDNAs and ten clones were randomly 
selected, expanded and equal amounts of cells were pooled together. These pooled lines 
were used in mitochondrial uptake experiments within three passages.  Whole cells were 
incubated with 1 µM 3H-6S-5-formyl-tetrahydrofolate for 20 minutes. Mitochondrial 
fractions were isolated from the cells and counted for radioactivity. 
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(G192) was previously established to be mutated in glyB cells and eliminated MFT 
function, and the other residue (R249) was located in a PxD/ExxK/R motif, common to all 
MCF proteins. Using residue conservation in MFT orthologs was an inefficient approach 
to design site-specific MFT mutant proteins to investigate the folate-specific transport 
mechanism in the MFT.  We believed that a structural model of the CHO MFT would 
guide the hypothesis-driven design of future MFT mutations and also provide insight as to 
why the previously examined mutants were relatively uninformative.  In the time it took to 
conduct studies on these ten MFT mutants, a high resolution (2.2 Å) crystal structure had 
become available for the ADP/ATP carrier, a MCF protein similar to the MFT.  Using this 
structure, it was now possible to generate a structural model of the MFT. 
 
Generation and application of a CHO MFT homology model  
 Upon its discovery in 2000, the MFT had both sequence and structural similarities 
with an identified mitochondrial carrier family (MCF) of integral membrane proteins 
(160).  The solved crystal structure of one MCF member, the bovine ADP/ATP carrier 
(bAAC) (pdb accession: 1okc) (128), provided a template for the structural prediction of 
other MCF proteins. Furthermore, the technologies available for the prediction of 
membrane embedded helices are sufficiently advanced for accurate and reliable structural 
predictions (137).  Structural predictions are even further enhanced when the structure of a 
related protein is available and the proteins contain functionally conserved residues or 
motifs, for example, the MCF PxD/ExxK/R conserved motif (137). The primary sequences 
of the CHO MFT and the bAAC were sent to the PSIPRED server (13, 22) for alignment 
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and prediction of secondary structure.  While the CHO MFT and bAAC have only 26% 
sequence identity, there was a high degree of secondary structure homology predicted 
between the two proteins (Figure 2-9).  To generate a predicted structure for the CHO 
MFT, the sequence of the CHO MFT and the protein database file containing the sequence 
and three-dimensional coordinates of the bAAC (pdb accession: 1okc) were loaded into the 
Composer module of Sybyl v7.1 (161).  The bAAC and CHO MFT sequences were 
aligned similarly, but not identically, to the alignment shown in Figure 2-9. The conserved 
PxD/ExxK/R motifs of the CHO MFT and bAAC were aligned and the transmembrane 
spanning regions of the MFT, as predicted by the PSIPRED server, were arranged to have 
minimal sequence gaps and were selected as structurally conserved regions.  These 
structurally conserved regions were specifically modeled using the AAC structure as a 
template, while loop regions were modeled using an independent loop search database 
within the Composer module.  The resulting CHO MFT homology model structure 
superimposed with the crystallized AAC in most of the transmembrane domain (TMD) 
regions (Figure 2-10A-B).  However, there was a noticeable break in the α-helical 
structure of the fourth TMD in the CHO MFT homology model.  Variability between the 
bAAC structure and the CHO MFT homology model was most evident in the loop regions.  
This variability was expected because the loop regions of the CHO MFT were modeled 
using an independent loop search to build these regions of the CHO MFT homology 
model.  The CHO MFT homology model is also shown with surface representation to 
visualize the local charges from the residue side chains throughout the protein (Figure 2-
10C-D).  The aqueous exposed edges contained a large number of polar (green) and  
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Figure 2-9 Alignment and secondary structure prediction of the CHO MFT and the 
ADP/ATP carrier by the PSIPRED server. The sequences of the CHO MFT (Query) 
and the bAAC (1okcA0) were aligned by the PSIPRED server (13, 22).  Amino acids are 
shown in their single letter abbreviations.  In this alignment, residues in green are identical 
in the CHO MFT and AAC, residues in red are conservative substitutions, and the residues 
in blue are unrelated.  The PSIPRED server also made secondary structure predictions, 
which are shown above (AAC ; 1okc0) or below (MFT ; Query) the respective protein 
sequences.  Amino acids predicted to be located in helical structures are marked by “H” 
and “C” marks random coil structures.  Numbers outside of the secondary structure 
predictions, above for the AAC and below for the MFT, correspond to the amino acid 
sequence.  Conserved motifs are located at MFT (Query) amino acid positions 42, 140, and 
244. 
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Figure 2-10 Predicted structure of the CHO MFT by homology modeling.  A 
homology model for the CHO MFT was generated based on the solved crystal structure of 
the bovine ADP/ATP carrier (AAC). A. Cross sectional membrane view of the CHO MFT 
homology model (red) structurally aligned with the AAC (transparent blue). B. View from 
the inter-membrane space looking into the transport cavity of the CHO MFT homology 
model (red) with the AAC overlaid (transparent blue). The black arrow denotes a break in 
the α-helical structure of the fourth transmembrane domain in the MFT homology model.  
C. Cross sectional membrane view of the CHO homology model with a surface 
representation.  Aromatic and aliphatic residues are shown in white, polar residues are in 
green, basic residues are shown in blue and acidic residues are in red. D. View from the 
inter-membrane space looking into the transport cavity of the CHO MFT homology model 
with a surface representation.  Amino acids are color coded as indicated in C. 
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charged (red – acidic/negative and blue – basic/positive) residues.  In addition, the base of 
the MFT transport cavity was highly charged, with basic amino acids predominating in this 
location.  The charges associated with residues that lined the transport cavity above the 
cavity floor were mixed, with polar and neutral (white) side chain residues making up the 
majority of these residues.  The middle portion on the outer surface of the CHO MFT 
homology model protein was largely neutral (white) and contained very few polar or 
charged amino acids, which would be predicted for a membrane embedded protein. 
 The CHO MFT homology model was then used to identify the locations of the ten 
mutations that were previously investigated in the glyB complementation assay (Figure 2-
7A) and the mitochondrial uptake assay (Figure 2-8B). In these studies, CHO MFT R249A 
and G192E were shown to have a significant effect on MFT function.  Observing the 
predicted locations of these residues in the CHO MFT homology model, provided an 
explanation for the mutagenesis data.  CHO MFT R249 was located in the third conserved 
sequence of the MFT. The charged conserved sequence residues were shown in the crystal 
structure of the AAC to form interhelical interactions with one another (Figure 2-3).  The 
orientations of CHO MFT R249 and the other residues in the PxD/ExxK/R motifs 
suggested that a similar network of interactions were occurring in the MFT as was 
observed in the AAC (Figure 2-11A).  Specifically, the homology model predicted 
interactions between CHO MFT D44 and K145, W142 and R249, and Q246 and K47.  
Interestingly, the D/E residue (bAAC D134) in the PxD/ExxK/R motif of the AAC and in 
the vast majority of MCF proteins was a tryptophan in the MFT.  While the ionic 
interaction that was found in the majority of MCF proteins did not appear likely in the  
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Figure 2-11 Orientation of R249 and G192E in the CHO MFT homology model.  The 
CHO MFT homology model was used to aid in understanding the effects of CHO MFT 
R249A and G192E (glyB) mutations.  A. The predicted orientation of conserved motif 
residues in the CHO MFT homology model. The first, third and fifth predicted 
transmembrane domains (TMD) in the CHO MFT are shown in transparent blue, red and 
green ribbon tube display, respectively.  CHO MFT conserved motif residues are shown in 
CPK.  CHO MFT R249 is suggested to interact with W142. B. The CHO MFT homology 
model is shown in transparent red ribbon tube display.  The G192E mutation was created 
in the MacPyMOL program (157) and the side chain location of G192E was one of several 
predicted rotamers within the program.   
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MFT, we proposed that CHO MFT R249 and W142 participated in a cation-π interaction. 
If these two residues were to interact with one another, this would restore an important 
conserved motif interaction at the bottom of the MFT transport cavity that was present in 
the majority of other MCF proteins. This potential interaction was the subject of another 
set of studies that will be presented later in this section.   
 The mechanism by which CHO MFT G192E, or the glyB MFT mutation, 
eliminated the transport function of the MFT was unknown.  To better understand the 
effects of the G192E mutation on MFT transport, the G192E mutation was created in silico 
in the MFT homology model.  In one possible mutant rotamer, the G192E side chain 
projected down and into the transport cavity (Figure 2-11B).  The negatively charged end 
of this glutamate side chain extended within 3 Å of the positively charged side chain of 
CHO MFT R249.  We proposed that the G192E and R249 formed an ionic interaction.  In 
forming this interaction, CHO MFT R249 was surrounded by W142 on one side and 
G192E on the other.  We proposed that multiple interactions with CHO MFT W142 and 
G192E locked CHO MFT R249 in place. Thus, this stabilization appeared to eliminate any 
movement of CHO MFT R249, which inhibited the ability of the adjacent proline residue 
to induce a conformational change that was required for transport.   
 The CHO MFT homology model was also used to understand why most of the 
mutations previously studied did not affect the transport function of the MFT (Figures 2-
7A and 2-8B).  The predicted locations of these mutations were visualized in the CHO 
MFT homology model.  Few residues were located within the MFT transport cavity in the 
CHO MFT homology model (Figure 2-12). One residue, CHO MFT S95, was located  
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Figure 2-12 Predicted locations of mutated MFT residues in the CHO MFT homology 
model. A. Cross-sectional membrane view of the CHO MFT homology model in 
transparent red ribbon tube display with the residues that were mutated in the MFT shown 
in van der Waals representation.  B. View from the inter-membrane space looking into the 
transport cavity of the CHO MFT homology model.  Representations are the same as 
indicated in A. 
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within the MFT transport cavity just above the base of the cavity that was formed, in part, 
by R249.  Residues K184 and H256 also appeared to be centrally located, but on the 
matrix side of the transport floor.  While little is known about the roles of the matrix-
associated regions of MCF proteins, these residues still could have had roles in assisting 
substrate passage into the mitochondrial matrix.  Nevertheless, there was no evidence to 
suggest that these residues impaired the transport function of the MFT. 
 
Computational docking of tetrahydrofolate into the transport cavity of the CHO MFT 
homology model 
 In addition to visually inspecting the residues that lined the transport cavity, 
computationally docking a folate molecule into the transport cavity was another way to 
gain insight into the folate-specific transport mechanism of the MFT. To accomplish this, 
the CHO MFT homology model and the crystallized AAC structure (pdb accession: 1okc) 
were structurally aligned as shown in Figure 2-10A-B.  In addition to the structure of the 
AAC, the protein data bank file also contained the three dimensional coordinates of the 
carboxyatractyloside (CATR) inhibitor that co-crystallized within the transport cavity of 
the AAC.  With the MFT and AAC structurally aligned, the CATR molecule was extracted 
from its location in the AAC with its orientation and three-dimensional coordinates 
retained.  This CATR molecule was then merged into the MFT homology model so that 
the MFT now contained the CATR inhibitor within its transport cavity in the exact 
orientation as in the AAC.  The MFT homology model containing CATR was loaded into 
the FlexX docking suite in Sybyl 7.1 as was a molecule of THF.  The space occupied by 
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CATR and the surrounding 9.9 Å within the MFT transport cavity was selected as the 
docking site for the molecule of THF.  The positions of the glutamate tail of THF in each 
of the two highest scoring conformations were nearly super imposable (Figure 2-13).  In 
each of the two conformations, the glutamate tail of THF was equidistant (< 2 Å) from 
CHO MFT PxD/ExxK/R motif residues K47 and K145 (Figure 2-13B).  The glutamate tail 
of THF was also the portion of the THF molecule that was located the deepest within the 
MFT transport cavity, suggesting that the monoglutamate tail of folate substrates enters the 
transport cavity first. Interestingly, the benzyl ring of THF in the two highest scoring 
conformations differed in their placement relative to the tryptophan residue (W142) 
proposed in the cation-π interaction (Figure 2-13C).  The benzyl ring of the highest scoring 
THF conformation, THF1, was oriented such that further descent of the THF molecule in 
this conformation would place the benzyl ring of THF directly between CHO MFT W142 
and R249.  The benzyl ring of THF in the second highest scoring conformation was 
located on the opposite side of W142.  Either of these THF orientations would likely be 
able to disrupt the conserved motif interactions in the MFT that formed the transport cavity 
floor; the glutamate group of THF would disrupt any interactions with K47 and K145, 
while the benzyl ring would disrupt any interaction with W142.  This docking study 
suggested that the proposed cation-π interaction between CHO MFT W142 and R249 was 
implicated in an opening mechanism used for transport as well as substrate recognition 
through interaction with the benzyl ring of THF.   
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Figure 2-13 Docking of tetrahydrofolate into the CHO MFT homology model. 
Tetrahydrofolate was computationally docked into the CHO MFT homology model using 
the FlexX program and the two highest scoring tetrahydrofolate conformations are shown. 
A. The CHO MFT is shown in transparent red ribbon tube display and the orientations of 
the two highest scoring conformations of tetrahydrofolate, THF1 and THF2, respectively, 
are shown in ball and stick representation. B. Orientations of the two highest scoring 
tetrahydrofolate conformations as shown in A. with CHO MFT R288 and conserved motif 
residues K47 and K145 shown in CPK. C. Orientations of the two highest scoring 
tetrahydrofolate conformations as shown in A. with CHO MFT R249 and W142 shown in 
CPK. 
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MFT mutagenesis guided by sequence alignment and homology modeling 
 The generation of the CHO MFT homology model and the predicted conformations 
of tetrahydrofolate within the MFT transport cavity highlighted a tryptophan substitution in 
a PxD/ExxK/R motif in the MFT that was strikingly different from the MCF consensus at 
that position.  The predicted orientations of the residues in the PxD/ExxK/R motifs showed 
that, of the three salt bridge interactions observed in the crystallized ADP/ATP carrier 
(AAC) structure (Figure 2-3), only one remained intact in the MFT.  The MFT contained a 
tryptophan (CHO MFT W142) substitution in its second conserved motif and a Q (CHO 
MFT 246) in its third conserved motif, both in place of a D/E residue typically found in the 
PxD/ExxK/R motif in most MCF proteins.  These two substitutions are rarely observed in 
other MCF proteins and are fascinating considering the proposed roles of the conserved 
PxD/ExxK/R motifs in a shared mechanism of transport among MCF members.  The 
design of a second mutagenesis study benefited from the direction given by the CHO MFT 
homology model and the growing body of literature in the MCF field.  Four residues were 
selected for site-specific mutagenesis in the MFT.  These were residues that either vastly 
differed from MCF consensus residues (CHO MFT G91, W142, and Q246) or that 
appeared to have an altered function in the MFT; for instance, participation in a cation-π 
interaction (CHO MFT R249).  MFT proteins carrying these mutations were studied in a 
glyB complementation assay and a transport assay, similar to the previously presented 
MFT mutants. We then performed a molecular dynamics simulation on a modified version 
of the CHO MFT homology model to complement our mutagenesis data and to gain a 
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more comprehensive perspective on the phenomena that enable mitochondrial folate 
transport. 
 
Studying the function of the anomalous residues in the MFT 
 The MFT contains striking deviations in its conserved motifs compared to the MCF 
consensus sequence. However, these substitutions are not completely unique to the MFT.  
The MFT and four yeast MCF proteins all contain PI/LWxxK/R in their second conserved 
motif in place of the MCF consensus, PxD/ExxK/R sequence.  Because this change is 
located in a conserved motif and because these conserved motifs are proposed to be 
involved in a shared transport mechanism, the tryptophan substituted, PI/LW subfamily 
has been proposed to form a functionally distinct group (119).  The sequences of the 
PI/LW subfamily of transporters and several other MCF transporters were aligned in the 
Lasergene MegAlign program (27) using ClustalW (158) (Figure 2-14).  The PI/LW 
subfamily matches the MCF consensus residues in the first conserved motif.  The 
tryptophan substitution that distinguishes this PI/LW subfamily is evident in the second 
conserved motif.  Another interesting residue substitution that is common to all PI/LW 
proteins is the glycine residue observed at the location homologous to bAAC R79 (human 
AAC R80).  While most MCF proteins have a basic residue at this position, the PI/LW 
subfamily unanimously carries a glycine at this position. Mutation of the position 
homologous to bAAC79, typically an R, but interestingly in one case a G, has been shown 
to impair the transport function of several MCF proteins (25, 64, 97, 117).  This position 
also constitutes one of the three MCF regions previously proposed to be common  
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Figure 2-14 Alignment of MCF members. Selected regions of nine MCF proteins were 
aligned by ClustalW in the Lasergene Megalign program.  The abbreviations are: HsAAC1 
– human ATP/ADP carrier, isoform 1; HsMFT – human mitochondrial folate transporter; 
ScFlx1p – yeast FAD transporter; ScRim2p – yeast pyrimidine transporter; ScYEL006W – 
yeast NAD transporter; ScSal1p – yeast Mg-ATP/Pi transporter; HsCTP – human citrate 
transporter; HsOGC – human oxoglutarate carrier; HsORNT1 – human ornithine 
transporter.   The residue numbering for the HsAAC1 and HsMFT is shown above the 
alignment.  Key differences in the PxD/ExxK/R sequence motifs that are observed in the 
HsMFT protein are boxed at HsAAC1 positions 135 and 235, as well as a difference at 
HsAAC1 80. 
 
 
 
 
 
   
 77 
substrate-binding sites based on extensive molecular modeling and computational docking 
studies (142).  The MFT also has a less common substitution in its third conserved motif 
where the typical D/E residue has changed to a glutamine (CHO MFT Q246).  This change 
is not specific to any particular subset of MCF proteins and only two other proteins contain 
this substitution.  Interestingly, one of the two other proteins that carry this substitution, 
ScFlx1, also contains a tryptophan in its second conserved motif.  The goal of these studies 
was to understand why these residues changed in the MFT and how they impacted the 
folate-specific transport mechanism of the MFT. In addition, as most of the work in the 
MCF field has focused on the similarities between MCF proteins, by studying these 
anomalous residues in the MFT, we could learn more about aspects of the transport 
mechanism common to all MCF members by understanding the differences in this 
mechanism in the PI/LW subfamily proteins. 
 
Mutagenesis of W142 provides evidence of a cation-π interaction 
 We previously showed that CHO MFT R249 was required for the transport 
function of the CHO MFT, although the precise step in the transport process for which it 
was required was not clear.  Based on its orientation in the CHO MFT homology model, 
we proposed that R249 and W142 formed a cation-π interaction (Figure 2-15A) (39).  
Furthermore, computational docking of tetrahydrofolate within the CHO MFT homology 
model transport cavity suggested that this cation-π interaction participated in the 
coordination of the benzyl ring of tetrahydrofolate within the MFT transport cavity.  We 
proposed that this cation-π interaction was required for folate transport.  If this cation-π  
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Figure 2-15 Investigating the role of CHO MFT W142 in a proposed cation-π 
interaction. A. Orientations of CHO MFT R249 and W142 in the CHO MFT homology 
model suggested that these residues could form a cation-π interaction.  The third and fifth 
predicted transmembrane domains (TMD) of the CHO MFT are shown in transparent red 
and green ribbon tube display, respectively, with R249 and W142 shown in CPK. B. GlyB 
complementation assay with W142 MFT mutants.  GlyB cells were transfected with the 
indicated mutant mft cDNA constructs and cells were grown in 1 mg/mL G418 and in the 
presence or in the absence of glycine.  Data is expressed as a ratio of the number of 
colonies formed in the absence of glycine versus the number of colonies formed in the 
presence of glycine.  Statistical significance (p < 0.001) was determined for all data using a 
one-way ANOVA analysis followed by a Tukey/Kramer analysis and data determined to 
be statistically different are marked by “*”. 
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interaction was required for folate transport, then CHO MFT W142 would be as 
functionally important in the MFT transport mechanism as its binding partner, CHO MFT 
R249. The residue requirement at this position in the MFT was investigated in the glyB 
complementation assay and a folate uptake assay.  Three mutant MFT proteins, W142A, 
W142D, and W142F, were generated at this position.  All three mutations were designed to 
investigate the proposed cation-π interaction and to understand why the MFT changed the 
highly conserved D/E residue in its second PxD/ExxK/R motif to a tryptophan.  An alanine 
mutation (W142A) was designed to probe the requirement for the tryptophan residue in the 
MFT transport mechanism, a phenylalanine mutation (W142F) was made to investigate the 
requirement of a aromatic side chain residue at this location, and a aspartate (W142D) 
mutation would revert this position to the MCF consensus and examine the necessity of 
this deviation, which had come about during the divergence of the MFT. The W142F 
mutant protein retained MFT function, as glyB cells transfected with this mutant protein 
were able to survive in the absence of glycine (Figure 2-15B). Interestingly, glyB cells 
transfected with the W142D construct were not able to survive in the absence of glycine. 
The MFT apparently cannot function with a D/E residue at this position that is typical of 
almost all MCF proteins; a tryptophan residue is required for mitochondrial folate 
transport.  Surprisingly, glyB cells transfected with a W142A mutant mft cDNA were able 
to survive in the absence of glycine, suggesting that W142 was not required for MFT 
function.   
 The survival of glyB cells transfected with W142A mft cDNA in the absence of 
glycine was unexpected and difficult to explain given the proposed roles of the charged 
   
 81 
residues in the PxD/ExxK/R motifs in the function of MCF proteins.  It was anticipated 
that studying MFT function in a survival-based assay such as the glyB complementation 
assay, could under-report the functional effects of the transfected mutant MFT proteins.  
Specifically, cells may be able to grow and survive with significantly less mitochondrial 
folates than are normally found in mitochondria.  It is unknown exactly how much 
mitochondrial folate a cell requires for normal growth and survival. To better assess the 
effects of MFT mutations on the transport function of the MFT, glyB cells stably 
transfected with these mutant MFT constructs were studied in an assay that more directly 
reflected mitochondrial transport. In contrast to the previous mitochondrial uptake assay 
(Figure 2-8), which allowed uptake in whole cells for 20 minutes, this assay was modified 
to allow mitochondrial uptake in cells for only four minutes. We suspected that given 
enough time, MFT mutant proteins with an impaired mechanism of transport would exhibit 
wild-type mitochondrial folate accumulation.  Therefore, examining mitochondrial folate 
uptake for a shorter duration would hopefully better separate and differentiate fully 
functional MFT proteins from ones with impaired transport function.  CHO and glyB cells 
were incubated with 3H-6S-5-formyl-tetrahydrofolate (5f-thf) for varying periods of time.  
A large separation in the time-dependent uptake of 5f-thf was observed between CHO 
mitochondria and glyB mitochondria (Figure 2-16).  Mitochondrial uptake in the CHO cell 
line appeared linear at least through six minutes of incubation and there appeared to be 
sufficient separation between CHO and glyB cells at four minutes that would allow the 
interpretation of various levels of 5f-thf uptake in MFT mutant transfected cell lines.  
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Figure 2-16 Mitochondrial folate uptake in CHO and glyB cells. CHO and glyB cells 
were incubated with 1 µM 3H-6S-5-formyl-tetrahydrofolate for the indicated periods of 
time, after which mitochondria were isolated from these cells and these mitochondrial 
fractions were counted for radioactive content. 
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 Another variable that was addressed in this mitochondrial folate uptake assay was 
the level of mutant MFT protein expression. In this mitochondrial folate uptake assay, 
stable MFT mutant cell lines were established from individual colonies (ten colonies were 
picked per mutation), these colonies were separately expanded and probed for myc-MFT 
expression (see Materials and Methods).  Stably transfected, isolated clones that expressed 
myc-MFT mutant proteins at similar levels as detected by western blotting were selected 
for use in this uptake assay. MFT expression in the mutant W142 clones chosen for study 
in the folate uptake assay was nearly equivalent, although the MFT W142F protein 
appeared to be expressed at a slightly higher level than W142A or W142D MFT proteins. 
(Figure 2-17A).  Mitochondrial uptake of folate derivatives of 3H-5f-thf was then measured 
in these mutant cell lines (Figure 2-17B).  The W142F MFT protein was fully capable of 
mitochondrial folate uptake, while the W142D protein was completely incapable of any 
mitochondrial folate uptake, as suggested in the glyB complementation assay. 
Mitochondrial folate accumulation in cells transfected with MFT W142A was impaired by 
>75% when compared to uptake in CHO cells.  While the glyB complementation assay 
demonstrated that the W142A protein was capable of transporting an amount of folate that 
was sufficient for cell survival, a more direct analysis of mitochondrial folate uptake 
demonstrated that the transport function of this mutant MFT protein is limited. This 
reinforces the proposed concept of cation-π interaction and the role of the tryptophan 
substitution in the MFT.  This finding also warned us that cells could survive perfectly 
well with only a fraction of wild-type MFT transport function. We benefited from studying 
this MFT W142A mutation in two separate experimental designs as the interpretation of  
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Figure 2-17 Western blotting and mitochondrial folate uptake in W142 mutants.  
GlyB cells were transfected with N-terminally myc–tagged mutant mft cDNAs in pcDNA 
3.1(-) and grown in selective media containing 1 mg/mL G418 and glycine.  Transfectant 
colonies were selected and expanded in selective media.  A. Mitochondrial protein was 
isolated from each MFT mutant clone and 20 µg of total mitochondrial protein was loaded 
into a gel, electrophoresed and the protein contents of the gel were transferred to a PVDF 
membrane.  This membrane was probed for myc-MFT expression using an antibody raised 
against myc. B. Stably-transfected clones that expressed similar amounts of each mutant 
MFT protein (shown in A.) were incubated with 1 µM 3H-6S-5-formyl-tetrahydrofolate at 
37° C for 4 minutes.  Following whole cell uptake, mitochondria were isolated from each 
mutant cell line and counted for radioactive content. Statistical significance (p < 0.001) 
was determined for all data using a one-way ANOVA analysis followed by a 
Tukey/Kramer analysis and selected data that were not statistically different are marked by 
“0”.   
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these mutations differed depending on the assay used.  The differences between these two 
assays that led to these significantly different interpretations are analyzed in the Discussion 
section of this chapter. 
 
Informative W142R/R249W double mutant suggests folate interposition between the 
cation-π interacting residues 
 The MCF PxD/ExxK/R motifs are proposed to be essential in a MCF shared 
mechanism of opening that generates a temporary transport channel through the disruption 
of PxD/ExxK/R motif interactions that form the transport cavity floor.  Incoming substrate 
was proposed to disrupt these barrier-forming interactions at the base of the MCF protein 
transport cavity, but it was not known whether substrate disruption occurred by proximity 
or by direct positioning between the interacting residues.  Docking studies predicted the 
benzyl ring of tetrahydrofolate in the two highest scoring docking conformations to occupy 
different locations, but both were in the vicinity of a proposed cation-π interaction between 
CHO MFT W142 and R249 (Figure 2-18A).  Mutations were made in the CHO MFT to 
investigate if the incoming folate substrate interposed directly between the proposed 
cation-π interaction of W142 and R249.  A double mutation, W142R/R249W, was 
constructed that theoretically permitted the formation of a cation-π interaction, but flipped 
the location of two residues involved in this bond.  These residues were also mutated 
separately to control for any effects observed in the double mutant that were attributable to 
mutation of a single residue.  The CHO MFT W142R/R249W double mutation permitted a 
level of mitochondrial folate accumulation compatible with the survival of glyB cells in the  
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Figure 2-18 Investigating the participation of CHO MFT R249 in a proposed cation-π 
interaction. A. Tetrahydrofolate was computationally docked into the transport cavity of 
the CHO MFT homology model using the FlexX program.  The docked conformations 
were sorted by Total score and cScore and the two highest scoring conformations, THF1 
(yellow) and THF2 (gray) respectively, are shown in ball and stick representation.  CHO 
MFT W142 (licorice representation) and the third transmembrane domain (transparent 
ribbon tube display) are shown in red and CHO MFT R249 (licorice representation) and 
the fifth transmembrane span (transparent ribbon tube display) are shown in green. B. 
GlyB cells were transfected with the indicated MFT constructs in pcDNA 3.1(-) and grown 
in media containing 1 mg/mL G418 with or without glycine. Data is expressed as a ratio of 
the number of colonies formed in the absence of glycine versus the number of colonies 
formed in the presence of glycine. C. Mitochondrial protein was isolated from glyB cells 
stably transfected with the indicated mutant MFT constructs.  Twenty micrograms of 
mitochondrial protein was loaded into a gel, electrophoresed, proteins in the gel were 
transferred to PVDF membrane and the membrane was probed for myc-MFT expression 
with an antibody raised against myc. D. Stably transfected glyB cells that expressed similar 
amounts of the mutant MFT protein (shown in C.) were incubated with 1 µM 3H-6S-5-
formyl-tetrahydrofolate at 37° C for 4 minutes.  Following whole cell uptake, mitochondria 
were isolated from each mutant cell line and counted for radioactive content. Statistical 
significance (p < 0.001) was determined for all data using a one-way ANOVA analysis 
followed by a Tukey/Kramer analysis and selected data that were determined to be 
statistically different are marked by “*”.  Selected data that were not statistically different 
are marked by “0”.    
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absence of glycine (Figure 2-18B).  However, both individual mutations, CHO MFT 
W142R and R249W, were also capable of some level of mitochondrial folate transport as 
evidenced by the ability of glyB cells transfected with W142R or R249W to survive in the 
absence of glycine.  The stably transfected MFT mutant cell lines that were selected for 
uptake studies had no apparent differences in MFT expression (Figure 2-18C). In the 
mitochondrial folate uptake assay, none of the MFT mutant proteins were able to uptake 
folates into mitochondria to the same extent as CHO cells (Figure 2-18D). However, it 
does appear that the W142R/R249W mutant was able to accumulate more mitochondrial 
folates than the MFT R249W mutant alone.  There was some level of MFT function that 
was restored by reinstating this cation-π interaction, even with the residues in flipped 
orientations.  Furthermore, we believed that if the folate substrate was not directly 
interposing between CHO MFT W142 and R249, the W142R/R249W double mutation 
would not have provided this added transport advantage over the individual residue 
mutations.  Based on this data, we concluded that the folate substrate was interposing 
between a cation-π interaction formed between CHO MFT R249 and W142 at the base of 
the transport cavity.  Interestingly, the MFT R249W mutant protein provided sufficient 
mitochondrial folate accumulation to permit transfectant cell survival in the absence of 
glycine.  The apparent low level functioning of this protein could be explained by the 
aromatic side chain of the R249W mutant forming a π-π interaction with W142.  This 
could restore a vital conserved motif interaction between R249W and W142 that permits 
some level of folate transport. 
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A glycine substitution at a proposed MCF substrate-binding site is required for MFT 
function 
 CHO MFT residue G91 is located at one of the three previously proposed substrate-
binding sites that are suggested to be common to all MCF proteins based on the results of 
homology modeling and computational docking studies (142).  Interestingly, all PI/LW 
subfamily proteins contain a G at this position, while the vast majority of other MCF 
proteins have a lysine or arginine residue at this position.  Because this position was shown 
to be essential in the transport function of other MCF proteins (25, 64, 97, 117), the 
requirement of a glycine residue at this position in the MFT was investigated.  An arginine 
was inserted in silico at this position in the CHO MFT homology model, creating a G91R 
mutant MFT.  In the CHO MFT homology model containing the G91R mutation, the side 
chain of the selected arginine (G91R) rotamer was predicted to extend into the MFT 
transport cavity within close proximity to W142 (Figure 2-19A).  Based on the 
visualization of this G91R mutation in the CHO MFT, we hypothesized that the positively 
charged side chain of an arginine residue at this position could form an additional cation-π 
interaction with CHO MFT W142. By CHO MFT G91R interacting with W142 in addition 
to R249, W142 would be locked in its position in the MFT transport cavity and the proline 
residue in the second conserved motif in the MFT would not be able to induce the 
conformational change proposed to remove the transport cavity floor and permit substrate 
passage into the mitochondrial matrix.  However, based on the orientation of the second 
highest scoring docking conformation of tetrahydrofolate within the MFT transport cavity 
(Figure 2-13C), this glycine substitution could have occurred to create a substrate-binding  
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Figure 2-19 Investigating a glycine substitution at a proposed substrate-binding site 
in the CHO MFT.  A. Orientations of CHO MFT G91R, W142, and R249 within the 
CHO MFT homology model transport cavity are shown in CPK. The second (yellow), 
third (red), and fifth (green) CHO MFT transmembrane domains (TMD) are shown in 
transparent ribbon tube display. The G91R mutation was created in the MacPyMOL 
program (157) and the orientation of G91R was one of several side chain rotamers 
predicted within the program.  B. GlyB cells were transfected with the indicated MFT 
constructs in pcDNA 3.1(-) and grown in media containing 1 mg/mL G418 with or without 
glycine. Data is expressed as a ratio of the number of colonies formed in the absence of 
glycine versus the number of colonies formed in the presence of glycine. C. Mitochondrial 
protein was isolated from glyB cells stably transfected with the indicated mutant MFT 
constructs.  Twenty micrograms of mitochondrial protein was loaded into a gel, 
electrophoresed, proteins in the gel were transferred to PVDF membrane and the 
membrane was probed for myc-MFT expression with an antibody raised against myc. D. 
Stably transfected glyB cells that expressed similar amounts of the mutant MFT protein 
(shown in C.) were incubated with 1 µM 3H-6S-5-formyl-tetrahydrofolate at 37° C for 4 
minutes.  Following whole cell uptake, mitochondria were isolated from each mutant cell 
line and counted for radioactive content. Statistical significance (p < 0.001) was 
determined for all data using a one-way ANOVA analysis followed by a Tukey/Kramer 
analysis and selected data that were determined to be statistically different are marked by 
“*”.  Selected data that were not statistically different are marked by “0”.    
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pocket on the side of CHO MFT W142 that was opposite R249 and the cation-π 
interaction.  In addition, the idea of this substitution forming a substrate-binding pocket 
corroborated the homology modeling and computational docking studies of Robinson and 
Kunji that predicted this location to be a common substrate-binding site for all MCF 
proteins (142).  A mutation was made at this position (G91R) that tested whether or not the 
MCF consensus residue (K/R) was compatible with MFT transport function. In addition to 
its positive charge, arginine also has a fairly large side chain.  A G91L mutation was 
designed to control for this size as leucine also has a large chain, but without the positive 
charge (Figure 2-20).  GlyB cells transfected with the MFT G91L were able to survive in 
the absence of glycine, suggesting some level of function by this mutant MFT protein 
(Figure 2-19B).  The level of cell survival in the absence of glycine in G91L transfectants 
was about 40% of that observed with glyB cells transfected with the CHO mft cDNA.  In 
contrast, cells transfected with MFT G91R, the MCF consensus residue, were completely 
unable to survive in the absence of glycine. MFT expression levels did not appear to differ 
between MFT G91L and G91R stably transfected cell lines (Figure 2-19C).  Interestingly, 
mitochondrial folate uptake in both G91L and G91R transfected glyB cells was inefficient 
(Figure 2-19D).  While both mutations appeared to impair MFT function in the 
mitochondrial folate uptake assay, the inability of G91R mft cDNA transfectants to survive 
in the absence of glycine suggests that the G91R mutation may inhibit the MFT.  
Additionally, G91L mft cDNA transfectants were able to survive in the absence of glycine, 
suggesting that this mutant MFT protein is impaired but not inhibited.  It appears that the  
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Figure 2-20 Chemical structures of arginine, leucine and glycine. 
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MFT has inserted a glycine at this position because a basic residue, present in the majority 
of MCF transporters, will not permit mitochondrial folate transport. 
  
Another MFT conserved motif residue, Q246, does not appear to be required for MFT 
transport function 
 The MFT has substituted a glutamine residue in the D/E position of its third 
conserved motif.  Instead of the salt bridge interaction that is typical in most MCF 
members at this location, this substitution in the MFT was proposed to form a hydrogen 
bond with CHO MFT D44 based on the orientations of these two residues in the CHO 
MFT homology model (Figure 2-21A).  Thus, an interaction between the two conserved 
motifs could be maintained.  Two mutations, Q246A and Q246E, were designed to probe 
this interaction to understand the role of this glutamine substitution in MFT transport 
function and how a glutamine residue aided in the adaptation of a folate-specific transport 
mechanism.  We expected that MFT Q246E would function like the wild-type CHO MFT 
as this mutation was predicted to restore a salt bridge interaction with D44 in the MFT, and 
that the Q246A mutation would result in complete disruption of a vital interaction and 
eliminate MFT function.  However, both mutant MFT proteins appear to retain some level 
of function as both mutant MFT proteins enabled glyB transfectants to survive in the 
absence of glycine (Figure 2-21B).  Both of these mutant constructs were stably 
transfected into glyB cells and individual clones were probed for MFT expression (Figure 
2-21C).  Expression of the Q246A MFT protein appears less than the expression of the 
Q246E MFT protein in the respective cell lines.  The myc-MFT expression observed in this  
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Figure 2-21 Investigating the requirement of CHO MFT conserved motif residue 
Q246. A. Orientations of CHO MFT Q246 and K47 in the MFT homology model transport 
cavity shown in CPK. The fifth (green) and sixth (blue) CHO MFT transmembrane 
domains (TMD) are shown in transparent ribbon tube display. B. GlyB cells were 
transfected with the indicated MFT constructs in pcDNA 3.1(-) and grown in media 
containing 1 mg/mL G418 with or without glycine. Data is expressed as a ratio of the 
number of colonies formed in the absence of glycine versus the number of colonies formed 
in the presence of glycine. C. Mitochondrial protein was isolated from glyB cells stably 
transfected with the indicated mutant MFT constructs.  Twenty micrograms of 
mitochondrial protein was loaded into a gel, electrophoresed, proteins in the gel were 
transferred to PVDF membrane and the membrane was probed for myc-MFT expression 
with an antibody raised against myc. D. Stably transfected glyB cells that expressed similar 
amounts of the mutant MFT protein (shown in C.) were incubated with 1 µM 3H-6S-5-
formyl-tetrahydrofolate at 37° C for 4 minutes.  Following whole cell uptake, mitochondria 
were isolated from each mutant cell line and counted for radioactive content. Statistical 
significance (p < 0.001) was determined for all data using a one-way ANOVA analysis 
followed by a Tukey/Kramer analysis and selected data that were determined to be 
statistically different are marked by “*”.Selected data that were not statistically different 
are marked by “0”. 
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CHO MFT Q246A clone was the highest detected MFT expression level out of six Q246A 
clones that were screened (data not shown).  Nonetheless, mitochondrial folate uptake was 
observed in both stably transfected cell lines (Figure 2-21D).  Despite the discrepancy in 
apparent MFT expression levels, cells transfected with CHO MFT Q246A were able to 
accumulate ~50% more mitochondrial folate than CHO MFT Q246E transfectants.  The 
MFT demonstrated a surprising mutational tolerance at this position, suggesting that Q246 
may not be an essential residue in the transport mechanism of the MFT. 
 
Modification and generation of a new CHO MFT homology model for molecular dynamics 
simulations 
 Several MFT mutations were quite interesting, yet difficult to interpret.  The glyB 
complementation assay data suggested that the MFT retained some level of transport with 
a variety of mutations.  On the other hand, many of the mutations that were apparently 
tolerated by the MFT in the glyB complementation assay were shown to be incompatible 
with optimal folate transport in the mitochondrial folate uptake assay.  To aid in the 
interpretation of this data, we used molecular dynamics simulations to better understand 
the effects of these mutations and the roles of these residues in the MFT transport 
mechanism.  However, the structure of the MFT was unknown, which meant that these 
simulations would have to occur in a simulation system that included a MFT homology 
model. If there were errors, inaccurate structural elements, or inappropriate side chain 
orientations in the homology model, the resulting molecular dynamics simulation data and 
the interpretation of this data could be skewed.  While the initial MFT homology model 
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was useful in generating hypotheses that were testable by mutagenesis, the model needed 
to be improved before it could be used for computational experiments.    We generated a 
new MFT homology model using the ORCHESTRAR program (162), which was shown to 
produce homology models with better geometries and orientation of side chains that are 
more complete and more accurate when homology is <30% when compared to Composer 
(163), the program used to generate the initial MFT homology model (36).  The newly 
generated MFT model corrected a disruption in the α-helical structure of the predicted 
fourth transmembrane domain in the CHO MFT homology model generated in Composer 
(Figure 2-22).  In addition, the ORCHESTRAR program was able to better predict the 
structure of N- and C- terminal regions and therefore, more amino acids were modeled in 
these regions in the CHO MFT homology model generated by the ORCHESTRAR. 
 The molecular dynamics simulation was set up with the newly generated MFT 
homology model. A palmitoyl oleaylphosphatidylchloine (POPC) bilayer membrane was 
constructed in the Visual Molecular Dynamics (VMD) program (63), and water molecules 
were added on both sides of the membrane.  The newly generated MFT homology was 
inserted into the center of the membrane slab and nineteen chloride ions were added to 
obtain a neutral charge within the simulation box. The complete molecular dynamics 
system is shown in Figure 2-23. 
  
Molecular dynamics simulations of the apo-MFT 
 A molecular dynamics (MD) simulation was initially run without a tetrahydrofolate 
(THF) substrate. In this simulation, a chloride ion was almost immediately attracted to the  
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Figure 2-22 Generation of a new CHO MFT homology model for use in molecular 
dynamics simulations.  A second CHO MFT homology model was created in Sybyl 
ORCHESTRAR to more accurately model MFT loop regions. A. Cross-sectional 
membrane view of the crystallized ADP/ATP carrier (AAC ; transparent blue), initial CHO 
MFT homology model (transparent red), and the newly generated CHO MFT homology 
model (yellow) in ribbon tube display.  B. View from the inter-membrane space looking 
into the transport cavity of the crystallized AAC (transparent blue), initial CHO MFT 
homology model (transparent red), and the newly generated CHO MFT homology model 
(yellow) in ribbon tube display. 
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Figure 2-23 Visualization of the molecular dynamics system. The CHO MFT homology 
model is shown in purple ribbon tube display and was inserted in a POPC lipid bilayer 
membrane that was created in the VMD program and is shown in CPK.  An additional 30 
Å of water molecules were added to the inter-membrane space side and 20 Å of water 
molecules were added to the matrix of the MFT homology model, but are not shown.  The 
aqueous environment surrounding the lipid bilayer also included 19 chloride ions, which 
are shown in green van der Waals representation.  The presented figure represents the 
molecular dynamics system after 30 nanoseconds of equilibration. This figure was 
provided by Dr. John C. Hackett.   
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base of the transport cavity and within t = 15 ns a total of four chlorides resided and 
remained in the MFT transport cavity for the duration of the simulation.  However, no 
chloride ions appeared to be fixed in their location.  The residence of these chloride ions 
hinted at a strong electrostatic potential within the MFT transport cavity. Indeed, the 
electrostatic potential within the MFT reaches a maximum +1.9 V potential at the base of 
the transport cavity and maintains +1.5 V surface around the conserved motif basic 
residues K47, K145, and R249 (Figure 2-24).  The positive electrostatic surface potential 
and the attraction of chloride ions within the transport cavity of the MFT is similar to that 
observed in molecular dynamics simulations in the AAC (33, 86, 169).  Interestingly, the 
AAC was predicted to generate a maximum electrostatic potential of +1 V at its base (33, 
169).  Nonetheless, it is this large electropositive potential located at the transport cavity 
floor that is thought to be the driving force for substrate attraction deep within the transport 
cavity of MCF proteins.  
 We next examined the orientations of the conserved motif residues and explored 
their interaction throughout the apo-MFT simulation.  Throughout the duration of the 30 ns 
simulation, the distance between the PxD/ExxK/R motif residues that were predicted to 
interact was followed.  The residues that were predicted to interact, based on the 
orientations of homologous residues in the AAC crystal structure and the predicted 
orientations of these residues in the CHO MFT homology model, were CHO MFT D44 
and K145, W142 and R249, and Q246 and K47. The only predicted interaction in which 
the residues remained within 4 Å for a majority of the MD simulation was between CHO 
MFT Q246 and K47 (Figure 2-25).  Residues W142 and R249 maintained a distance of ~5  
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Figure 2-24 Electrostatic potential in the transport cavity of the CHO MFT homology 
model. The time-averaged electrostatic potential surface of the initial 2.5 ns of the apo-
MFT simulation was computed using the PMEPot (2) plugin of VMD.  The CHO MFT 
homology model (cross-sectional membrane view) is shown in purple ribbon tube and 
residues K47, K145 and R249 are shown in van der Waals representation.  The surface 
corresponding to a +1.0 V electrostatic potential is shown in transparent gray and is 
symmetrically located around the base of the transport cavity.  The surface corresponding 
to a +1.5 V electrostatic surface potential is shown in green at the base of the cavity 
localized around CHO MFT K47, K145 and R249.  This figure was provided by Dr. John 
C. Hackett. 
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Figure 2-25 Distance between the PxD/ExxK/R motif residues during the apo-MFT 
molecular dynamics simulation. CHO MFT conserved motif residues, D44 and K145, 
W142 and R249, and Q246 and K47 were predicted to interact based on the crystal 
structure of the AAC and the orientations of these residues in the CHO MFT homology 
model. Molecular dynamics (MD) simulations were run with the CHO MFT homology 
model without a molecule of tetrahydrofolate (THF).  During these simulations, the 
distance, in angstroms (Å), between conserved motif residues that were predicted to 
interact were measured.  The CHO MFT homology model was subjected to 30 
nanoseconds (ns) of a molecular dynamics simulation without THF.  The distances 
between CHO MFT D44 and K145 (blue), W142 and R249 (red), and Q246 and K47 
(green) are shown throughout the simulation.  
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Å throughout the entire simulation.  Of the residue pairs that were predicted to interact, the 
distance between R249 and W142 was the most stable of the three throughout the MD 
simulation; the distances between CHO MFT D44 and K145 and Q246 and K47 fluctuated 
throughout the simulation.  Whereas most MCF proteins contain three salt bridge 
interactions between the charged residues of the PxD/ExxK/R conserved motifs, the only 
salt bridge interaction predicted to be in the MFT was between CHO MFT D44 and K145.  
Surprisingly, these residues were separated by > 6 Å for the duration of the MD simulation 
and, hence, an interaction was not observed between these two residues that would 
reinforce their proposed role in the formation of a transport barrier.  
 The flexibility of the conserved sequence residues in the apo-MFT MD simulation 
was striking. We further examined CHO MFT D44 and K145 and the possibility that they 
were interacting with other residues in the MFT transport cavity. There seemed to be more 
potential for D44 to have another binding partner because the transport cavity contained 
more basic residues for D44 to interact with than acidic residues for K145 to interact with.  
The flexibility that was observed for CHO MFT D44 was quite remarkable; it appeared to 
contact three different residues during the apo-MFT simulation (Figure 2-26). Initially, 
MFT D44 interacted with K145.  However, because bAAC E29 and R137 were within 2 Å 
in the bAAC crystal structure (see Figure 2-3 for AAC conserved sequence residue 
orientations), the homologous residues in the MFT, D44 and K145, were predicted to 
assume a similar orientation in the CHO MFT homology model.  This would explain why 
an interaction between CHO MFT D44 and K145 was initially observed in the CHO MFT 
homology model.  Next, D44 briefly contacted K47 to form an intrahelical interaction,  
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Figure 2-26 Interactions of CHO MFT K47, K145 and R288 with D44 in the MFT 
transport cavity during the apo-MFT MD simulation. The CHO MFT homology model 
was subjected to 30 nanoseconds (ns) of a molecular dynamics simulation without THF.  
Throughout this simulation, the distance (in angstroms (Å)) between CHO MFT D44 and 
three basic residues within the MFT transport cavity, K47 (red), K145 (blue) and R288 
(green), was measured. 
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followed by a period of apparent freedom (Figure 2-26).  Finally, D44 settles to form a 
stable interaction with CHO MFT R288 (homologous to AAC R279), a residue that 
constitutes a substrate-binding site proposed to be common to all MCF proteins.  It is also 
interesting to note the variation in distance between MFT K47 and Q246 during this 
simulation (Figure 2-25).  Initially these residues were separated by ~6 Å and gradually 
moved towards each other.  At t = 6 ns, these residues appeared to form a stable 
interaction.  However at t = 16 ns, K47 and Q246 were momentarily separated, but this 
distance eventually re-stabilized at 4 Å after a few nanoseconds.  Nonetheless, this 
demonstrated the dynamic flexibility of these residues and interactions in the MFT that 
could not be observed in a homology model.  This flexibility of the conserved motif 
residues and the apparent distances between them have also been observed in MD 
simulations with the apo-AAC (33, 40, 68, 169).  Despite substitutions that changed 
residues involved in two of the three predicted conserved motif interactions in the MFT, 
the apo-MFT appears to behave like the apo-AAC in MD simulations.  
 
Progress of tetrahydrofolate down the MFT transport cavity 
 In addition to the simulation of the apo-MFT, we also designed a molecular 
dynamics simulation to visualize the interactions of tetrahydrofolate (THF) within the 
MFT transport cavity. A molecule of THF was manually placed in the visual center of the 
inter-membrane space opening of the CHO MFT homology model. Tetrahydrofolate was 
oriented vertically with the glutamate portion of the molecule extending down into the 
MFT transport cavity.  This orientation was chosen based on previous MD simulations that 
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demonstrated the AAC positioned the ADP substrate vertically with the phosphate groups 
of ADP pointing towards to the base of the AAC cavity, independent of the starting 
orientation of ADP (33, 169).  Computational docking studies also predicted that the THF 
molecule was vertically oriented within the MFT transport cavity with the glutamate 
portion of THF located the closest to the cavity floor (Figure 2-13).  Initially, a molecule of 
THF was placed above the MFT transport cavity in the in silico inter-membrane space.  
This placement of THF caused the THF molecule to diffuse into the aqueous space above 
the lipid bilayer and away from the transport cavity when the simulation was started.  We 
then moved the THF molecule further down towards the MFT transport cavity so that the 
glutamate tail of THF was even with the outermost loop regions of the MFT homology 
model.  As the simulation began with THF in this location, the THF molecule was 
immediately drawn to the loop regions of the MFT homology model and was not released. 
The molecule of THF was then placed in the MFT transport cavity ~20 Å above the 
transport cavity floor.  This placement of THF resulted in the successful capture of the 
substrate and its descent to the MFT transport cavity floor. 
 The descent of THF through the MFT transport cavity was simulated for 40 ns and 
THF moved through the MFT transport cavity in a step-wise fashion (MD movies 1 and 2 
– supplemental material). The distance between functional groups in the THF molecule 
and residues within the MFT transport cavity were followed over the duration of the 
simulation (Figure 2-27 ; MD movies 3 and 4 – supplemental material). The initial 
orientation of THF biased the γ-carboxyl of THF to immediately contact MFT CHO K235 
and this interaction was evident at the start of the simulation (Figure 2-27C).  The  
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Figure 2-27 Interaction of tetrahydrofolate with residues lining the CHO MFT 
homology model transport cavity as predicted in molecular dynamics simulations.  A 
molecule of tetrahydrofolate (THF) was placed in the transport cavity of the CHO MFT 
homology model and subjected to 40 nanoseconds (ns) of molecular dynamics simulations 
(MD movies 1 and 2 in supplemental material).  Distances, in angstroms (Å), between the 
indicated groups of THF and CHO MFT residues were measured throughout the 
simulation. A. The distance between the pteridine ring of THF and CHO MFT W96 (red), 
F200 (green), and Y300 (blue) is shown (MD movie 4 in supplemental material).  B. The 
distance between the α-carboxyl of the glutamate portion of THF and CHO MFT K235 
(red), R288 (green), and R249 (blue) is shown (MD movie 3 in supplemental material). C. 
The distance between the γ-carboxyl of the glutamate portion of THF and CHO MFT K235 
(red), R288 (green), and R249 (blue) is shown (MD movie 3 in supplemental material).   
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interaction between MFT K235 and the γ-carboxyl of THF was weakened (t = 2 ns) and 
THF dropped further into the transport cavity. MFT K235 released the γ-carboxyl of THF 
and later formed an interaction with the α-carboxyl of THF (t = 6 ns) (Figure 2-27B).  
During this exchange, the pteridine ring of THF formed a π stacking interaction with Y300 
(t = 3 ns) (Figure 2-27A).  This π-π interaction held the pteridine portion of THF in place 
so that the α-carboxyl of THF could rotate and contact MFT K235. These two interactions 
were maintained until t = 14 ns, when MFT R249 attracted the γ-carboxyl of THF deeper 
within the transport cavity to the cavity floor (Figure 2-27C).  Simultaneously, the α-
carboxyl of THF descended from MFT K235 to R288 (Figure 2-27B) and both carboxyl 
groups of THF were held in place for the remainder of the simulation.  As the carboxyl 
groups of THF moved deeper into the cavity, the interaction between Y300 and the 
pteridine ring of THF was broken and THF contacted MFT F200 (Figure 2-27A).  
However, the interaction of THF with MFT F200 was brief and the substrate ultimately 
interacted with W96 instead.  At t = 18 ns, the pteridine ring of THF was within 5 Å of 
W96 (Figure 2-27A).  The indole nitrogen of MFT W142 then contacted the keto group 
adjacent to the benzyl ring of THF at t = 20 ns.  This interaction caused the pteridine ring 
of THF and W96 to move closer together (t = 25 ns).  Although the simulation lasted for 
40 ns, no further interactions were observed after t = 25 ns of the simulation.  
 
Orientations of the CHO MFT conserved motif residues in the presence of THF 
 The molecular dynamics simulation predicted THF to interact with two residues, 
W142 and R249 that were located in the conserved motifs of the CHO MFT (Figure 2-28).   
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Figure 2-28 Interaction of tetrahydrofolate with CHO MFT W142 and R249 at the 
end of the MD simulation. The CHO MFT homology model is shown in transparent blue 
ribbon tube display.  The orientations of tetrahydrofolate (THF) and CHO MFT W142 and 
R249 at the end of the 40 ns THF-MFT MD simulation are shown in CPK.  The dashed 
black lines represent potential interactions with bond distances measured in angstroms (Å). 
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No interactions were observed between THF and other conserved motif residues, but these 
interactions may occur at times beyond our computational reach.  At the end of the 40 ns 
simulation, the α-carboxyl was bound to MFT R288 and was equidistant from K47 and 
K145, the basic residues in the first and second conserved motifs in the MFT (Figure 2-
29).  These residues may play a role in events that occur later in the folate transport 
process, but were not implicated in transport on the time scale used in our MD simulation.  
The distances between the conserved motif residues that were predicted to interact in the 
MFT were followed for the duration of the THF-MFT MD simulation.  Despite the THF 
substrate only interacting with CHO MFT W142 and R249, the substrate appeared to 
decrease the flexibility of all of the residues in the PxD/ExxK/R motifs of the MFT (Figure 
2-30 ; MD movie 5 – supplemental material).  As THF moved deeper within the MFT 
transport cavity and encountered the transport cavity floor (t = 20 ns), it appeared that the 
presence of substrate caused the charged residues in the conserved motifs to move closer 
together. This was in contrast to what was observed in the apo-MFT simulation, where the 
conserved motif residues had a large degree of flexibility (Figure 2-25).  The distances 
between the PxD/ExxK/R motif residues that were predicted to interact in the MFT 
fluctuated in the first half of the simulation with THF (t = 0-20 ns), as was observed in the 
apo-MFT simulation.  However, these residues converged at t = 25 ns in the presence of 
THF.  The propensity of these residues to come together and form these interactions did 
not occur until THF had completely settled within the channel.  Hence, it appeared that 
these conserved motif residues in the MFT interacted only in the presence of substrate.  
Consistent with our finding, four other molecular dynamics simulations with the AAC  
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Figure 2-29 Interaction of tetrahydrofolate with CHO MFT K47, K145 and R288 at 
the end of the MD simulation. The CHO MFT homology model is shown in transparent 
blue ribbon tube display.  The orientations of tetrahydrofolate (THF) and CHO MFT K47, 
K145, and R288 at the end of the 40 ns THF-MFT MD simulation are shown in CPK.  The 
dashed black lines represent potential interactions with bond distances measured in 
angstroms (Å). 
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Figure 2-30 Distance between PxD/ExxK/R motif residues during the THF-MFT 
molecular dynamics simulation. CHO MFT conserved motif residues, D44 and K145, 
W142 and R249, and Q246 and K47 were predicted to interact based on the crystal 
structure of the AAC and the orientations of these residues in the CHO MFT homology 
model.  Molecular dynamics (MD) simulations were run with the CHO MFT homology 
model and with a molecule of tetrahydrofolate (THF) (MD movie 5 in supplemental 
material).  During these simulations, the distance in angstroms (Å), between conserved 
motif residues that were predicted to interact was measured.  The CHO MFT homology 
model was subjected to 40 nanoseconds (ns) of a molecular dynamics simulation with a 
molecule of THF placed within the CHO MFT homology model transport cavity (THF-
MFT).  The distances between CHO MFT D44 and K145 (blue), W142 and R249 (red), 
and Q246 and K47 (green) are shown throughout the simulation. 
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showed that these conserved sequence interactions were also induced in the presence of 
substrate or inhibitor, and that these interactions were not present in the apo-AAC 
simulations (33, 40, 68, 169).  Therefore, the conserved motif interactions that are induced 
in the presence of substrate, likely reflect an event that occurs in all MCF proteins.  We 
concluded that these conserved motif interactions are not static in MCF proteins and that 
these interactions are induced by substrate as part of an intermediate step that is common 
to all MCF proteins during the transport process.  
 
DISCUSSION 
 
 Studying MFT mutants using multiple approaches provided a more holistic 
understanding of the functional effects caused by the constructed MFT mutations, in turn, 
leading to a better understanding of the transport mechanism of the MFT.  The purposes 
for the studies in this chapter were to understand the mechanism of mitochondrial folate 
uptake and the changes that occurred in the MFT that evolved a folate-specific transport 
mechanism.  An initial set of mutations was made without the guidance of a homology 
model and yet still identified two informative mutations that severely affected the transport 
function of the MFT.  However, it was the application of the homology model that was 
used post facto to understand what these mutations were doing to the MFT protein.  The 
second set of mutations was guided by the CHO MFT homology model and computational 
docking studies that focused our attention on a few residues in the MFT that had 
anomalous substitutions fixed during the evolution the folate transport mechanism.  
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Mutagenesis of these residues indicated that mitochondrial folate transport could not occur 
with the MCF consensus amino acids at most of the studied positions; these changes 
apparently evolved out of necessity for mitochondrial folate transport. We turned back to 
computational approaches to further examine the trajectory of tetrahydrofolate (THF) 
down the MFT transport cavity and the interaction of THF with residues of the transport 
cavity floor in molecular dynamics (MD) simulations.  Once again, the computational 
approach enhanced our understanding of the effects observed in the mutant MFT proteins 
and implicated several residues in the coordination of folates in early transport events.  
These residues, CHO MFT W96, K235, R288, and Y300, would be excellent new targets 
for new mutagenesis studies (See Chapter Four).  Hence, combining the glyB 
complementation and mitochondrial folate uptake assays with computational methods 
provided a more inclusive perspective than using either of these approaches alone.  The 
techniques, interpretation of the results in these assays, and their impact on our current 
understanding of MFT and MCF mechanism of transport are discussed below. 
 
Investigating MFT function in a survival-based glyB complementation assay 
 The glyB complementation assay took advantage of the glycine dependence of 
glyB cells, and MFT function was crudely measured in this assay by the disappearance of 
this glycine auxotrophy. The disappearance of the glyB phenotype is thought to correspond 
to the re-establishment of mitochondrial folate transport.  A number of mutations were 
made in the MFT that were able to complement the glyB glycine auxotrophy.  We did not 
predict that all of these mutations would provide some level of glyB complementation.  It 
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was quite possible that even a severe level of impairment of MFT function would still 
suffice for glyB survival in the absence of glycine so long as some fractional level of 
transport remained (see below).  Furthermore, complementation could also be observed in 
MFT mutants with minimal transport efficiency if they were expressed at higher levels.  
However, it should not be overlooked that many of these mutations permitted some level 
of glyB cell survival in the absence of glycine.  The fact that these proteins were still able 
to transport mitochondrial folates suggests that the proteins were still functional as 
mitochondrial folate transporters. 
 While the complementation assay did not exactly correlate with the uptake of 
folates into mitochondria at incremental levels of MFT function, this assay can be 
interpreted to indicate function versus no function in MFT mutant proteins.  There were 
four mutations, CHO MFT G192E, R249A, W142D, and G91R that did not complement 
the glycine auxotrophy of glyB cells at any level.  We believe that the inability of these 
mutant proteins to provide any complementation suggests that mitochondrial folate 
transport is completely prevented and not just impaired by these mutations.  Interestingly, 
all of the mutations involved the introduction or removal of a charged side chain.  The 
G192E, W142D and G91R mutations added charged side chain residues into the MFT.  
The W142 position was also mutated to W142A, W142F, and W142R; yet only the anionic 
nature of the aspartate side chain in the W142D mutant was unable to provide any glyB 
cell survival in the absence of glycine.  This implies that the negative charge associated 
with the aspartate residue inhibits the MFT, and interestingly, this negative charge is 
present in a majority of MCF members. Also, the G91L MFT was a mutation made to 
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control for the size of the arginine side chain of G91R, without the positive charge.  There 
was a 40% level of complementation in glyB cells transfected with MFT G91L, suggesting 
that the positive charge associated with the arginine side chain was responsible for some of 
the loss of function observed with G91R.  The only mutation that involved the removal of 
a charge and subsequent failure to transport mitochondrial folates was CHO MFT R249A.  
Since CHO MFT R249 was located in the third PxD/ExxK/R motif in the MFT, it was 
thought that this mutation abolished the residue required to participate in a cation-π 
interaction with W142.  Interestingly, when this position was mutated to R249W, this MFT 
protein complemented the glycine auxotrophy in glyB cells.  It seemed likely that this 
mutation resulted in the formation of a π-π interaction with W142 and that such an 
interaction was fulfilling the function served by the cation-π between W142 and R249.  
However, given the MFT inhibition observed with the W142D mutant, this W142:R249 
interaction appears to be more complex than originally thought. 
 
Examining mitochondrial folate uptake in cell-based transport experiments 
 There was a need to more directly study the capability of mutant MFT proteins to 
transport folates into mitochondria.  The protocol used to study mitochondrial folate uptake 
in the first set of mutants, published in Biochemistry in 2007, was slightly different than 
that used to study the second set of MFT mutants.  The first set of experiments studied 
uptake of 3H-6S-5-formyl-tetrahydrofolate in a pooled population of transfectants for 20 
minutes.  The second set of experiments examined mitochondrial folate uptake for four 
minutes in cell lines expanded from single clones in which MFT expression was similar.  
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The data produced in these experiments was subtly different.  In the first set of uptake 
experiments, only the MFT mutants that did not permit glyB cell survival in the absence of 
glycine were unable to accumulate mitochondrial folates.  In contrast, the second set of 
mutations included a number of MFT mutant proteins that were unable to efficiently 
accumulate mitochondrial folates, despite all but two mutant proteins complementing the 
glyB phenotype. When comparing the two sets of experiments, it appears that studying 
mitochondrial folate uptake for shorter intervals in stably transfected clones with known 
and relatively similar amounts of MFT protein provides a more accurate indication of MFT 
transport function.  
 Nevertheless, the mitochondrial uptake data corroborated our interpretation of data 
from the glyB complementation assay regarding the impairment of some mutated MFT 
proteins. In the second set of mutations, we observed that a majority of the mutated MFT 
proteins retained some level of MFT function.  While these stably transfected cell lines 
appeared to inefficiently transport folates in this assay, the only mutant protein that 
appeared to exhibit uptake comparable to wild-type was W142F. In contrast to the glyB 
complementation assay, this uptake assay was useful for separating functionless or 
impaired transporters from fully functional proteins.  Overall, we concluded that the glyB 
complementation assay over-predicted the transport function of mutant MFT proteins, 
presumably because cells can survive with only a fraction of the mitochondrial folate 
transport observed in wild-type cells.  Also, the mitochondrial uptake assay may tend to 
underestimate the transport function of mutant MFT proteins, as these mutated proteins 
may be able to transport folates at a slower rate.   
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Impact of experimental techniques on determining functional effects of mutant MFT and 
MCF transporters  
 In the studies presented in this chapter, we had the advantage of studying the 
function of mutations in the MFT proteins in two different assays. Using these methods, 
our data suggested that survival assays tend to underestimate functional effects, while 
direct transport studies may overestimate the impact of certain mutations.  This 
combination of assays that measure survival and direct transport are rarely combined to 
study other MCF proteins. Of the five MCF proteins that have been examined by 
mutagenesis, only two, the AAC and phosphate transport protein (PTP), have been 
examined using both survival and direct transport studies.  The study of the PTP in this 
manner has shown similar results to those that we have produced with the MFT.  Transport 
analysis over 20 seconds in reconstituted liposomes showed that mutation of some charged 
conserved motif residues in the PTP drastically impaired its transport function (132).  
However, transfection of these mutant PTP proteins into a PTP-null yeast strain showed 
that they retained some level of transport activity as evidenced by decreased colony sizes 
formed by these mutants (132). Nonetheless, the interpretation of the mutational effects 
changed depending on the assay in which the mutant proteins were studied.  Functional 
interpretations become increasingly important as the proposed mechanism of opening 
common to all MCF members and the proposed common substrate-binding sites have 
relied heavily on mutagenesis data. 
 MCF mutations are more commonly studied using methods that involve protein 
purification, typically from recombinant expression systems, and reconstitution into 
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liposomal transport systems. These systems are advantageous because they allow the direct 
analysis of transport events.  Liposomal systems are designed to contain a single protein of 
interest incubated with a single substrate.  This design eliminates the possibility of 
substrate transport by another, non-specific protein and removes other proteins that could 
modify the substrate.  Thus, the study of transport in liposomes is an ideal system to obtain 
direct kinetic data and substrate analysis.  However, there is one shortcoming with these 
systems that has been largely ignored and will be briefly addressed.  In these studies, 
purified transport protein is mixed with lipids that were subjected to sonication and passed 
over an amberlite column to facilitate the formation of intact, spherical vesicles that 
contain the purified protein embedded in a re-formed lipid membrane (123).  The major 
shortcoming with liposomal systems is that the protein appears to randomly orient itself in 
the lipid vesicle membrane.  There is some percentage of purified protein that is inserted 
with the N- and C- termini facing outside of the liposomes and some percentage is inserted 
with the terminal regions protruding into the vesicles; the protein appears to be randomly 
inserted into the membrane (54).  This would imply that even if an equal amount of protein 
were incorporated into liposomal membranes, the amount of protein available for import 
might not be equivalent when comparing different liposomal preparations because of the 
random orientation of the protein in the membrane.   
 Nonetheless, liposomal transport is the gold standard in the mitochondrial carrier 
field.  Similar to the mitochondrial folate uptake assay presented in this chapter, we believe 
that studying the transport function of MCF proteins in proteoliposomes also over 
exaggerates the effects of mutations on the transport function of these proteins.  For 
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example, the mechanism of transport was probed in the oxoglutarate transporter by 
mutating nearly every amino acid predicted to be a transmembrane domain to a cysteine 
residue (25, 26).  Recombinant mutant proteins were purified and reconstituted into 
proteoliposomes and transport was allowed for 30 seconds at 25° C.  Uptake of 14C-
oxoglutarate into proteoliposomes containing mutant oxoglutarate transporters was 
observed and numerous residues inhibited the transport rate of the oxoglutarate carrier by 
at least 75%. Residues that were found to inhibit transport function were spaced at 
intervals of 3-4 residues apart and these residues were not specifically associated with 
charged, polar, aromatic, or aliphatic side chains, suggesting that every transport cavity-
lining residue was involved in the transport process.    While we tend to believe there is a 
strict organization that occurs within the transport cavity of MCF proteins, it seems 
unlikely that each of these mutations would impact cell growth and survival in the same 
fashion.    
  
Generation and application of a CHO MFT homology model 
 The crystallization of the AAC was a monumental breakthrough in the 
mitochondrial carrier field.  It was one of the first integral membrane proteins to be 
crystallized and the X-ray crystallographic analysis that followed was performed at a 
remarkably high resolution (2.2 Å).  Since then, numerous labs have used the solved 
coordinates of this protein to predict the structures of other MCF proteins using homology 
modeling (112, 142, 166).  In fact, one group generated homology models for nine MCF 
members and computationally docked the respective substrates into each of these models 
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(142).  As a result, they analyzed the binding of substrates within the transport cavities of 
nine homology-modeled MCF proteins.  The results of this study led the authors to propose 
that all MCF proteins contain three common substrate-binding sites and the amino acids 
that were present at these proposed common binding sites dictated the substrate specificity 
of each transport protein (142).  We also generated a homology model using the solved 
coordinates of the AAC. This model aided in the interpretation of experimental results, 
predicted the molecular organization in the MFT structure, provided a basis for 
experimental design, and allowed visualization of the predicted locations of residues 
within the MFT transport cavity.  Initial application of this homology model involved the 
inspection of the residues involved in the PxD/ExxK/R motifs in the MFT. With each use, 
the homology model was able to provide insights and possible explanations for 
experimental phenomena.  Additionally, the homology model suggested additional 
experiments that evolved into an iterative process between experimental and computational 
approaches.   
 We decided to push the limits of our computational reach by using the CHO MFT 
homology model in molecular dynamics (MD) simulations.  In order to run simulations on 
our MFT model, we needed to ensure that the structure was as accurate as possible. Thus, 
we generated a second homology model in a newer module contained within the Sybyl 
program, ORCHESTRAR, that was shown to be superior in generating more complete and 
more accurate homology models when the sequence is < 30% identical, and in producing 
homology models with better geometries and side chain orientations (36).  The first 
homology model that we generated was a good model, but it had some flaws in the loop 
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regions and in the C-terminal region of the fourth transmembrane domain.  These flaws 
were largely corrected in the second generation CHO MFT homology model. We were 
initially concerned that any errors in the homology model would potentially be amplified 
and erroneous regions could produce flawed interpretations of the MD simulations. We 
now feel that MD simulations circumvent some of the limitations of homology modeling 
by equilibrating the MD system before simulations were run. 
 
Molecular dynamics simulations of the apo-MFT 
 The apo-MFT simulations were just as valuable and contained as much information 
as the THF-MFT simulations regarding the transport mechanism of the MFT. These 
simulations demonstrated a large electrostatic potential at the base of the MFT transport 
cavity and extreme flexibility of the residues in the MFT conserved motifs.  The average 
+1.5 V electrostatic charge found at the base of the MFT was greater than that (+1.0 V) 
calculated for the AAC (33, 169).  The conserved motif residues that are altered in the 
MFT are all in the D/E positions, where two typically acidic residues have been changed to 
an aromatic residue, W142, and to a polar residue, Q246.  Not only are these changes 
suspected to contribute to the substrate specificity and transport mechanism of the MFT, 
but they may also increase the electrostatic potential responsible for drawing the folate 
substrate deep into the cavity.  The electrostatic potential in the AAC may be sufficient to 
attract the highly electronegative phosphate groups of ADP, but it is possible that the less 
electronegative carboxyl groups on a folate molecule require more electrostatic pull for 
efficient capture.  
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 We observed a large degree of flexibility in the PxD/ExxK/R motif residues in the 
apo-MFT simulation.  On the basis of the X-ray crystallography of the AAC, the 
interactions between the conserved sequence pairs were thought to be sustained MCF 
transporters in the absence of substrate.  However, our apo-MFT simulation predicted that 
this was not the case.  In fact, it suggests that CHO MFT D44, W142 and Q246 may form 
a number of temporary interactions with intrahelical residues and other charged residues 
located higher within the MFT transport cavity.  We showed that D44 prefers to interact 
with CHO MFT R288 in the apo-MFT simulation and predict that K145 is stabilized by 
W142, a residue that is located on the same transmembrane domain.  The flexibility we 
observed in the MFT conserved motif residues was also observed in molecular dynamics 
simulations with the AAC and in an oxoglutarate transporter homology model (33, 40, 68, 
112, 169).  In addition, early mutagenesis on the yeast AAC suggested that conserved 
motif residues in the AAC were interacting with intrahelical residues as well as non-
conserved sequence residues (119).  In this study, second-site revertants were established 
that indicated an interaction existed between AAC residues homologous to CHO MFT D44 
and R288 (118).  Later, it was discovered that the AAC residue homologous to MFT K145 
had two second-site revertants at positions homologous to CHO MFT D44 and W142 
(119).  This data, combined with what has been demonstrated in numerous MD simulations 
of apo-MCF proteins, suggests that these conserved motif interactions are not constantly 
maintained in these proteins.  We believe that the presence of the carboxyatractyloside 
inhibitor within the transport cavity of the bAAC crystal structure induced a conformation 
where bAAC E29 and R137, D134 and R234, and D231 and K32 formed interactions and 
   
 128 
that the apparent stability of these interactions was an artifact of crystallography with a 
tight-binding inhibitor.   
 
Initial positioning of tetrahydrofolate in the MFT transport cavity for molecular dynamics 
simulations 
 The tetrahydrofolate (THF) substrate was placed ~25 Å above the MFT cavity 
floor, oriented with the carboxyl groups facing down into the MFT transport cavity for 
molecular dynamics (MD) simulations. MD simulations with the AAC demonstrated that 
despite the initial orientation of the substrate, ADP quickly adopted a position within the 
AAC transport cavity with its phosphate groups pointing down towards the cavity floor 
(33, 169).  Therefore, it was unlikely that this initial orientation of THF in the MFT 
transport cavity would bias the MD simulation. Initially, the THF substrate was placed 
higher above the MFT transport cavity.  However, if the THF was placed too high in the 
channel, it either diffused into the aqueous space above the membrane or it interacted with 
a loop from the MFT that extended into the inter-membrane space.  In a previous 
simulation with the AAC, it was shown that ADP molecules contained in the aqueous 
inter-membrane space were spontaneously attracted into the AAC transport cavity (33). 
However, the computational time required to visualize this event was significantly longer 
than that needed to simulate binding using a biased substrate placement.   Substrate 
binding to an external loop of the MFT may also be an event required to recruit the folate 
substrate into the transport cavity.  We previously showed that insertion of a myc tag into 
the first inter-membrane space loop of MFT inhibited its function as evidenced in the 
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inability of glyB cells transfected with this construct to grow in the absence of glycine 
(129).  Furthermore, studies on the homologous region in the yeast AAC demonstrated that 
four amino acids in the first inter-membrane space loop were vital for AAC transport (75).  
Therefore, it seems likely that this loop region initially attracts substrate from the aqueous 
inter-membrane space environment. 
  
Molecular dynamics simulations predict residues that contact and guide tetrahydrofolate 
down into the MFT transport cavity 
 The tetrahydrofolate substrate was passed down to the cavity floor of the MFT by 
the step-wise and sequential interaction with residues that lined MFT transport cavity. The 
step-wise nature of THF passage indicated the strict organization of residues and side 
chains that protruded into the MFT transport cavity.  MD simulations showed that a 
majority of the residues predicted to contact THF at the cavity floor were charged with one 
aromatic residue (W142) and the majority of the residues predicted to contact THF above 
the cavity floor were aromatic with one anionic residue (K235).  The arrangement of 
residues in this manner is also consistent with the THF substrate moving into the transport 
cavity with its charged carboxyl groups first.  The charged residues that were predicted to 
contact the THF substrate were CHO MFT R249, R888, and K235.  Residues R249 and 
R288 are highly conserved among proteins in the MCF, while K235 was an interesting 
discovery peculiar to the MFT.  PI/LW subfamily proteins all contain a lysine residue at 
this location.  Interestingly, the amino acid homologous to CHO MFT K235 in the vast 
majority of non-PI/LW MCF proteins is a glycine, while the AAC contains a threonine at 
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this position.  This conserved lysine residue reinforces the belief that these PI/LW 
transporters are functionally distinct from the rest of the MCF. 
 Four aromatic residues were predicted to contact THF during the MD simulations. 
CHO MFT W96, F200, Y300 all contacted the pteridine ring of THF and were located 
high up in the transport cavity near K235, while W142 is a conserved motif residue at the 
base of the transport cavity that is the hallmark of the PI/LW subfamily.  CHO MFT F200 
is homologous to AAC F191, a residue located in an “aromatic ladder” in the AAC.  This 
AAC aromatic ladder consists of four residues, AAC Y186, Y190, F191, and Y194.  Of 
these residues, Y186 and F191 were shown to be required for optimal transport in the AAC 
by mutagenesis (32). The MFT and the rest of the PI/LW subfamily only contain aromatic 
residues in locations homologous to AAC F191 and Y194. It is unclear if the MFT requires 
an aromatic ladder for folate transport. However, as the folate substrate reaches the cavity 
floor in the molecular dynamics simulations, the THF substrate samples the MFT region 
homologous to the AAC aromatic ladder, specifically CHO MFT F200.  However, this 
sampling is short-lived and the pteridine ring of THF interacts with W96 on the opposite 
side of the transport cavity instead.  This may suggest that the MFT does not require an 
aromatic ladder in the homologous position as in the AAC.  Additional mutagenesis 
studies would clarify the role of these residues in the MFT. CHO MFT W96 is also quite 
interesting.  While it is not conserved amongst the entire PI/LW subfamily, the NAD+ 
(ScYEL006W) and FAD+ (ScFlx1p) transporters also contain this amino acid.  An 
aromatic amino acid is not found at this position in any other MCF member besides these 
three; the position homologous to CHO MFT W96 is mostly polar residues throughout 
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MCF proteins. The polar residue at this position in the bAAC, Q84, was predicted to 
contact the ADP substrate in molecular dynamics simulations with the bAAC (bAAC Q84) 
(33), while mutagenesis of the homologous residue in the oxoglutarate carrier, T95C, was 
shown to impair transport by ~75% in reconstituted liposomes (T95C) (25).  Although the 
residues are different between MCF transporters, these locations appear to be important in 
other MCF proteins. 
 The most striking or, at least, most obvious changes that have occurred in the MFT 
are substitutions contained within the PxD/ExxK/R conserved motifs and the behavior of 
the residues in these motifs in the molecular dynamics simulations was of particular 
interest.  It was apparent that as the THF substrate moved through the MFT transport 
cavity and migrated closer to the cavity floor, the conserved motif residues moved closer to 
one another.  It appeared that the conserved motif interactions predicted to form and 
maintain the cavity floor were actually induced by substrate.  Interestingly, this same 
phenomenon was observed in other molecular dynamics simulations with the AAC (33, 68, 
169), but little attention was given to this in these simulations.  Recalling that the AAC 
was co-crystallized with a CATR inhibitor within the transport cavity, it was possible that 
the solved structural coordinates of the AAC were altered by in the presence of this 
inhibitor.  We believe that binding of the transport substrate deep in the transport cavity of 
MCF proteins induces these interactions; they do not contribute to a transport barrier, but 
rather represent an intermediate conformation required for transport. 
  The hypothesis that the charged residues of the PxD/ExxK/R motif do not form a 
transport barrier would explain the enigmatic effects observed with mutation of the 
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charged PxD/ExxK/R residues.  It was previously thought that the charged residues in the 
PxD/ExxK/R motifs participated in three interactions that formed a transport cavity floor, 
an apparent transport barrier.  To initiate transport, the substrate was thought to disrupt or 
rearrange these three interactions.  If the purpose of these residues were to form three 
interactions that solidified a transport barrier, then removal of one of these interactions by 
mutating an involved residue would seemingly weaken this barrier.  In addition, the 
substrate would have one less interaction to disrupt before initiating transport.  Therefore, 
removing one barrier-forming interaction by mutagenesis would theoretically facilitate 
substrate transport.  Transport of substrate by MCF proteins is not facilitated when the 
charged residues in the PxD/ExxK/R motifs are mutated; mutant proteins display impaired 
transport, at the least, and, in most cases, the transport function of the MCF proteins is 
completely eliminated ((26, 57, 58, 96, 98, 114, 117, 118, 132, 133), data presented in this 
thesis).  If we consider the interactions of the PxD/ExxK/R motifs to exist as an 
intermediate transport step, the effects by mutagenesis of the charged residues in 
PxD/ExxK/R motifs are more easily explained. We propose that the purpose of this 
intermediate step and the interaction of these charged residues is for the D/E residue of the 
interacting pair to position and maintain the location of the K/R residue.  The K/R residue 
becomes immobilized by this interaction with the D/E residue, but the location in which 
the K/R residue is held enables this cationic residue to contact the anionic groups of the 
substrate more efficiently.  Therefore, we believe that the K/R residues of the PxD/ExxK/R 
motifs are absolutely required for substrate transport because these K/R residues interact 
with substrate at locations deep within the transport cavity.  The binding of substrate to the 
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K/R residues of the PxD/ExxK/R motifs may constitute the penultimate binding step in 
substrate translocation into the matrix (see Perspectives section). 
 
Speculation and working hypothesis of the mitochondrial folate transport mechanism of 
the MFT 
 We have done considerable work on the mechanism of folate transport that, I 
believe, justifies the following speculation about this transport process.  We consider folate 
molecules to be freely permeable through the voltage dependent anion channel pores in the 
outer mitochondrial membrane.  Folates randomly diffuse throughout the mitochondrial 
inter-membrane space and are expected to be initially recruited to the first inter-membrane 
space loop of the MFT.  As all of the loop regions in the MFT are hydrophilic, this 
attraction is likely between the loop region and the carboxyl groups of the folate.  As the 
carboxyl groups interact with residues on this MFT loop in the inter-membrane space, the 
pteridine and benzyl rings of folate are free to move.  It is anticipated that these aromatic 
groups, specifically the pteridine ring, interact with residues on the opposite side of the 
MFT.  Perhaps this interaction occurs with the second inter-membrane space loop or the C-
terminal region, which were shown to complement the glycine auxotrophy of glyB cells by 
35% and 50%, respectively (129). The folate molecule would now be horizontally oriented 
above the opening to the cavity floor.  As an interaction is established with one of the 
aromatic groups of the folate substrate, the carboxyl groups are freed from interactions 
with the loop regions and move down into the channel to make contact with CHO MFT 
K235.  With the carboxyl groups held in place once again, the pteridine ring is stabilized 
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and is predicted to contact CHO MFT Y300.  As the folate molecule progresses down the 
transport channel and the molecular dynamics simulation finishes, the γ-carboxyl of the 
folate is in contact with CHO MFT R249 and the α-carboxyl is in contact with R288.  The 
benzyl ring resides in a substrate-binding pocket between W142 and G91, and the pteridine 
ring is coordinated by W96. The next step, which was not observed over the time-scale 
accessible by our molecular dynamics simulations, is proposed to be the passage of the α-
carboxyl group from CHO MFT R288 to K47 and K145, which are equidistant from R288.  
As demonstrated in the molecular dynamics simulations, when substrate is not present in 
the transport cavity, CHO MFT D44 interacts with R288.  However, the presence of the 
folate substrate induces D44 to interact with K145 and we hypothesize that this 
stabilization attracts the α-carboxyl to K145.  This would result in the rotation of the 
benzyl ring from the binding pocket between to G91 and W142 to the other face of W142, 
which was predicted to interact with R249.  This is consistent with the observed function 
of the CHO MFT W142R/R249W mutant that we examined.  Additionally, this movement 
would break the interaction between the γ-carboxyl of the folate and CHO MFT R249, 
moving this part of the folate molecule closer to the matrix.  As the folate substrate 
progresses closer to the mitochondrial matrix, the proline residues in the PxD/ExxK/R 
motifs likely provide sufficient flexibility to the 1st, 3rd, and 5th transmembrane domains so 
that the substrate is accommodated in the spatially constrained region of the MFT at and 
below the transport cavity floor.  Little is known about the events that correspond to 
translocation and passage into the mitochondrial matrix.  However, it has been suggested 
that second and third matrix-exposed loops in the AAC possess the flexibility to protrude 
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back into the membrane bound portion and play a role in gating transport in the AAC (100, 
101).  These loops may be important in accepting the γ-carboxyl of the folate and leading 
the remainder of the folate molecule into the mitochondrial matrix. However, we believe 
that the substrate-induced conserved motif interactions are prerequisites for the 
stabilization and proper orientation of the matrix-associated loop regions that eventually 
guide the folate into the mitochondrial matrix. 
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CHAPTER 3 Role of the MFT in the Compartmentalization of Folate 
Metabolism 
 
 
 
 An aspect that has been largely ignored up to this point in this thesis is that some of 
the MCF transporters function as exchangers.  For instance, the AAC is thought to 
exchange cytosolic ADP for mitochondrial ATP in a 1:1 ratio (130, 131).  Exchange has 
also been noted for the oxoglutarate carrier (malate for oxoglutarate) (122), citrate carrier 
(malate for citrate) (143), and the glutamate carrier (glutamate for aspartate) (88).  It is 
highly controversial whether this exchange occurs through a conformational change within 
a single protein, or if these proteins exist as dimers, in which one subunit transports 
substrate into the matrix and the other sequentially transports substrate out of the matrix. 
Nonetheless, these proteins are predicted to cycle through conformations known as the c-
state, where the transporter is open to the inner membrane space and accepts substrates 
from the cytosol, and the m-state, where the protein may accept and transport substrates 
from the mitochondrial matrix.  These c- and m-states have been most clearly defined in 
the AAC because of the availability of two different classes of inhibitors, bongkrekates and 
atractylates that lock the carrier in these two different conformational states  (reviewed in  
(19, 83). In the absence of inhibitors, there is thought to be equilibrium between the c- and 
the m-states of the AAC. Mechanistically, ADP is thought to bind to the c-state AAC and 
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the events that permit release of ADP into the matrix induce a conformational change that 
transitions the AAC to its m-state.  The conformational switching between these two states 
in other transporters or whether two distinguishing states even exist in other MCF 
transporters is poorly understood.  However, if this switching occurs, it is thought to enable 
substrate exchange between the cytosol and mitochondrial matrix.   
 
Folate exchange and transport of folate polyglutamate molecules across the mitochondrial 
membrane    
 The exchange function of the MFT remains to be determined. In the two published 
experiments that have examined mitochondrial folate uptake, both have studied only the 
uptake of monoglutamate folate molecules in purified mitochondria (30, 61); uptake of 
folate polyglutamate forms has not been directly examined. However, there is evidence to 
suggest that cytosolic folate polyglutamates are unable to cross into the mitochondrial 
matrix.  In a study published by others, AuxB1 cells were transfected with Escherichia coli 
(E. coli) FPGS and > 95% of the FPGS protein was localized in the cytosolic compartment 
of the transfectants (90, 91).  In these transfectants, > 95% of the total cellular folates were 
located in the cytosol and ~85% of the cytosolic folate pool was triglutamate conjugates.  
Despite the transfectants accumulating cytosolic folates at wild-type levels, mitochondria 
of cells transfected with E. coli FPGS contained 90% less folates than mitochondria of 
wild-type cells.  This suggested that the folate polyglutamate forms found in the cytosol 
were unable to enter mitochondria. Considering that the vast majority of mitochondrial 
folates are polyglutamated forms (28), these polyglutamated folates would be the most 
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likely candidates for efflux from mitochondria if folate exchange were to occur. However, 
the efflux of mitochondrial folates through the MFT is not comparable to the efflux of ATP 
through the AAC.  Where a single phosphate group is added to ADP to form ATP, 
mitochondrial folate molecules typically contain up to six additional glutamate residues 
and few folates contain ≤ 3 glutamate moieties (28, 90).  Whether or not mitochondrial 
folates efflux from mitochondria and enter the cytosolic folate pool is a fundamental 
question surrounding the function of the MFT and the design of the compartmentalization 
of folate metabolism.  
 The findings of two previous experiments suggested that mitochondrial folates 
were able to efflux into the cytosol (45, 91).  One experiment attached a sequence 
encoding a mitochondrial leader peptide to an E. coli fpgs cDNA and transfected this 
construct into FPGS-null AuxB1 cells under the control of a CMV promoter (91).  The 
transfected cells accumulated both mitochondrial and cytosolic folate polyglutamates and 
did not require any supplementation with glycine, purines, or thymidine for cell survival.  
This suggested that this mitochondrially-targeted FPGS protein was able to retain 
mitochondrial folates, as evidenced by complementation of glycine auxotrophy, and 
provide cytosolic folates within the cell, as evidenced by purine and thymidine auxotrophy 
complementation. The second study determined the sequence of the mitochondrial isoform 
of FPGS and discovered that two human mRNA transcripts were produced from a single 
fpgs gene (45, 156).   When a cDNA encoding the mitochondrial isoform of FPGS was 
transfected into AuxB1 cells under the control of a CMV promoter, the mitochondrial 
isoform of FPGS complemented purine, thymidine, and glycine auxotrophy in AuxB1 
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cells.  These studies suggested that the mitochondrial isoform of FPGS was capable of 
supplying the entire cell with sufficient folate molecules for cellular folate metabolism, 
although other explanations were possible (see below). 
 The cytosolic and mitochondrial isoforms of human FPGS are translated from two 
different RNA species that are transcribed from the same genetic locus (45, 156).  The only 
difference between the mitochondrial and cytosolic FPGS proteins is that the 
mitochondrial isoform contains an extra 42 amino acid sequence, which appears to target 
this isoform to mitochondria (45).  In addition, the transcript encoding the mitochondrial 
isoform of FPGS contains the start codon used to translate the cytosolic isoform of FPGS.  
Whereas two previous studies can be interpreted to suggest the mitochondrial isoform of 
FPGS was capable of supplying the entire cell with folate polyglutamates (45, 91), the 
cytosolic protein could be translated from the mitochondrial fpgs transcript if the 
downstream start codon was available for translation.  This could be especially possible in 
engineered cell lines that produce high amounts of full-length fpgs transcript from strong 
viral promoters (CMV).  In addition, it was also possible that a high amount of FPGS 
protein was being translated in these engineered cells and this amount of protein saturated 
one of the steps of protein import into mitochondria.  This could result in catalytically 
active FPGS protein remaining in the cytosol, awaiting import into mitochondria.  Neither 
of the published studies ruled out the presence of cytosolic FPGS protein.  In fact, one 
study showed that ~25% of the total cellular FPGS activity and ~14% of the total cellular 
FPGS protein was located in the cytosol despite being transfected with a protein that was 
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targeted to mitochondria (91).  Overall, these studies did not prove that folate 
polyglutamates were transported out of the mitochondrial matrix. 
 Mammalian cell lines were recently generated in this laboratory that were designed 
to directly answer the question of mitochondrial folate polyglutamate efflux. Fpgs cDNA 
was cloned into a mammalian expression vector in which transcription was only active in 
the presence of doxycycline (Clontech Tet-On expression system). The Tet-On expression 
system required the transfection of two vectors into FPGS-null AuxB1 cells. One vector, 
the regulatory vector, encoded a doxycycline-binding protein using a promoter that was 
constitutively active.  The other vector, the response vector, contained the fpgs cDNA, in 
which expression was controlled by a promoter that was active only when doxycycline 
bound the doxycycline-binding protein and the complex resided at the promoter.  Under 
ideal conditions, this promoter will not initiate transcription in the presence of unbound 
doxycycline or doxycycline binding protein. In this doxycycline-inducible expression 
system, varying levels of expression were achievable, in principle, by adjusting the amount 
of doxycycline that the transfected cells were exposed to. 
 Three fpgs cDNA constructs were generated, cloned into the doxycycline-inducible 
expression system, and transfected into AuxB1 cells. The first cDNA construct, cFPGS, 
allowed translation from an ATG that encoded a cytosolic FPGS protein only (Figure 3-1).  
Another construct, mFPGS, contained fpgs cDNA with both mitochondrial and cytosolic 
FPGS isoform translational start sites, and would possibly allow translation of both FPGS 
isoforms if the downstream (cytosolic) ATG was available for use by an internal ribosomal 
entry site or by ATG-skipping.  The third cDNA construct, mutFPGS, encoded a FPGS  
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Figure 3-1 Schematic representations of FPGS isoforms and transfected constructs. 
The full-length fpgs mRNA is depicted in green and yellow, and start sites are marked with 
arrows.  The mitochondrial leader peptide that distinguishes the mitochondrial isoform and 
targets this isoform to mitochondria is shown in green.  The sequences of both cytosolic 
and mitochondrial isoforms are identical in the yellow region.  The cFPGS construct does 
not contain the mitochondrial leader peptide (green region).  The mFPGS construct retains 
both cytosolic and mitochondrial start sites.  The mutFPGS construct contains the start site 
for the mitochondrial FPGS isoform, but has mutated the downstream start site for the 
cytosolic isoform to ATT. 
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protein with the mitochondrial FPGS isoform start site intact, but mutated the downstream 
ATG site to ATT.  Therefore, this mutFPGS construct would encode the mitochondrial 
FPGS isoform only. Hence, these FPGS-inducible cell lines should allow controllable and 
compartmental expression of the FPGS protein.  This controllable and compartmental 
FPGS expression, when coupled with detection of the FPGS protein, should enable the 
definitive study of folate polyglutamate flux across the mitochondrial membrane for the 
first time.   
 
Potential for antifolate inhibition of the MFT 
 Antifolates have been developed to exploit the cellular dependence on folate 
metabolism. The utility of folate analogs as therapeutic agents dates back to the late 1940’s 
where treatment with 4-aminopteroyl-glutamic acid (aminopterin) was discovered to 
induce remission in children with acute lymphocytic leukemia (41). The success of this 
compound was followed by the development of a less toxic structural analog, methotrexate 
(4-amino-N10-methyl-pteroyl-glutamic acid) (42).  Methotrexate was later found to inhibit 
dihydrofolate reductase (171), an enzyme that recycles tetrahydrofolate from dihydrofolate 
after thymidylate synthesis. After this monumental discovery, the development of 
antifolates progressed along with the increasing knowledge and understanding of cellular 
folate metabolism.  Antifolate development eventually shifted to focus on thymidylate 
synthase, where raltitrexed (D1694, N-(5-[(N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-
ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid) emerged as a potent inhibitor of 
thymidylate synthesis (67).  Later, folate dependent enzymes in de novo purine synthesis 
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were identified as targets for antifolate development and DDATHF (lometrexol, 5,10-
dideaza-5,6,7,8-tetrahydrofolate) was discovered to be an inhibitor of glycinamide 
ribonucleotide formyl transferase (GART) (12). AG2034 (4-[2-(2-amino-4-oxo-4,6,7,8-
tetrahydro-3H-pyrimidino[5,4-6] [1,4]thiazin-6-yl)-(S)-ethyl]-2,5-thienoyl-L-glutamic 
acid) and AG2037 were developed to inhibit GART as well (16).  Another antifolate, 
pemetrexed (N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl] 
benzoyl-L-glutamic acid), was part of a second series of compounds that were designed 
and targeted to inhibit GART.  Interestingly, pemetrexed was discovered to inhibit 
multiple folate-dependent targets, with thymidylate synthase being the primary target of 
this antifolate (153).  It was later shown that pemetrexed in its pentaglutamated form 
inhibited thymidylate synthase (Ki = 1.3 nM), dihydrofolate reductase (Ki = 7.2 nM), 
GART (Ki = 65 nM), and aminoimidazolecarboxamide ribonucleotide formyl transferase 
(AICARFT) (Ki = 260 nM), the other folate-dependent enzyme in de novo purine synthesis 
(149).  Recently, AICARFT has been identified as the secondary target of pemetrexed 
inhibition in intact tumor cells (139).  Of these antifolates, methotrexate and pemetrexed 
are clinically used throughout the world and raltitrexed is used only in Europe and Asia.  
Methotrexate is used in the treatment of leukemia, psoriasis and arthritis, while pemetrexed 
and raltitrexed are used in cancer chemotherapy for lung cancers and colon cancer, 
respectively. 
 The potency of antifolates not only depends on inhibition of intracellular target 
enzymes, but also depends on transport across the cell membrane and polyglutamation by 
FPGS. Like endogenous folates, most antifolates are transported into the cell by the 
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reduced folate carrier (51, 105).  Pemetrexed also appears to be a substrate for the proton-
coupled folate transporter (PCFT) at physiological pH (177). Once inside the cell, 
polyglutamation of folate analogs by FPGS is important because it results in the 
intracellular retention of antifolates and enhances the inhibitory potency of these agents (8, 
67, 149, 153).  Decreases in membrane transport and polyglutamation by FPGS are also 
implicated in antifolate resistance mechanisms (35, 109, 136, 176).  Because antifolates 
rely on many of the same proteins that facilitate and coordinate cellular folate metabolism, 
these folate analogs may be substrates for or inhibitors of the MFT, which could result in 
unknown or undesirable mitochondrial toxicities.    
 Understanding if these folate analogs are substrates for or inhibitors of the MFT is 
an important question because these agents could potentially disrupt mitochondrial folate 
metabolism. The two studies published on carrier-mediated mitochondrial folate uptake 
reported that methotrexate was a weak inhibitor of mitochondrial folate transport (30, 61).  
However, the effects of other folate analogs on mitochondrial folate transport have not 
been examined.  Inhibition of the MFT would result in decreased or abolished 
mitochondrial folate accumulation.  Disrupting mitochondrial folate metabolism has been 
shown in three other cases to result in cellular toxicity in the absence of exogenous glycine 
supplementation (45, 71, 90, 160).  In the absence of glycine, almost all glyB cells die 
within 24 hours (107), hence, dysfunctional mitochondrial folate transport initiates a rapid 
cellular response that ultimately ends in the death of the cell.  The potential effects of 
antifolates on the MFT will be examined in this chapter. 
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MATERIALS AND METHODS 
 
Culture of AuxB1 cells stably transfected with doxycycline-inducible fpgs cDNA constructs 
 Three stable cell lines were previously generated in our lab by Amy Heineman to 
express various isoforms of the FPGS protein under the control of a doxycycline-inducible 
promoter.  These AuxB1-derived cells were routinely grown in MEM-α media 
supplemented with 10% tetracycline-free fetal bovine serum (FBS), 1% Penicillin and 
Streptomycin (Pen/Strep), 500 µg/mL G418 and 200 µg/mL hygromycin at 37° C with 5% 
CO2.  MEM α media contains all of the ribo- and deoxyribonucleosides and, hence, is not 
selective for deficiencies in folate metabolism. 
 
Preparation of whole cell lysates from CEM, HCT116, H460 and transfected AuxB1 cells 
 Expression of FPGS in transfected AuxB1 cells was induced by the addition of 1 
µg/mL doxycycline 48 hours prior to cell harvesting.  During this period of exposure to 
doxycycline, cells were maintained in active growth phase.  Cells were scraped from 
dishes using ice-cold phosphate buffered saline (PBS) with protease inhibitors (PI) (Roche 
complete EDTA-free protease inhibitors, proprietary – cat. # 11873580001) as previously 
described in Chapter Two.  Cells were centrifuged at 2,000 x g for five minutes at 4° C.  
The resulting supernatant was aspirated and the pellet was washed with an additional 5 mL 
of PBS with PI, placed in a pre-weighed tube and centrifuged at 2,000 x g for five minutes 
at 4° C.  The supernatant was aspirated and a volume of lysis buffer (62.5 mM Tris, pH 
6.8; 5% glycerol; 2% SDS; 5% 2-mercaptoethanol) ten times the cell pellet weight (10 µL : 
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1 mg) was added to the cell pellet.  This solution was then repeatedly passed through a 
19G or 21G needle ~30 times to shear any DNA and centrifuged at 20,000 x g for five 
minutes at 4° C.  Because of the SDS in the lysis buffer, passing this solution through a 
needle created bubbles.  These bubbles made it difficult to get efficient shearing using a 
needle.  Therefore, centrifugation at 20,000 x g for five minutes at 4° C was used to 
collapse the bubbles and return the solution to a liquid phase versus foam phase.  The 
process of passing the solution through a needle 30 times followed by centrifugation was 
repeated for a total of four times.  Protein concentrations were determined using the 
Bradford reagent according the manufacturer’s specifications. 
 
Preparation of cytosolic and mitochondrial protein lysates from CEM, HCT116, H460 and 
transfected AuxB1 cells 
 Expression of FPGS in transfected AuxB1 cells was induced by the addition of 1 
µg/mL doxycycline 48 hours prior to cell harvesting. Active cell growth was maintained 
during this period by keeping the cultures subconfluent.  Cells were scraped from dishes 
using ice-cold PBS with PI as previously described.  Harvested cells were centrifuged at 
2,000 x g for five minutes at 4° C.  Cell pellets were resuspended in 7.5 mL of 
homogenization solution (250 mM sucrose, 1 mM EDTA, pH 6.8) with protease inhibitors. 
Following a five minute incubation in homogenization solution, cells were gently broken 
open using 15 strokes in a 7.5 mL dounce homogenizer with a “B” pestle and the 
homogenate was centrifuged at 2,000 x g at 4° C for five minutes.  The supernatant was 
kept and centrifuged at 11,000 x g at 4° C for 15 minutes. The pellet that resulted from this 
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centrifugation contained mitochondria and the supernatant contained cytosolic protein.  
Mitochondria were immediately dissolved in lysis buffer (62.5 mM Tris, pH 6.8; 5% 
glycerol; 2% SDS; 5% 2-mercaptoethanol).  To dissolve mitochondrial protein and shear 
any mitochondrial DNA, this solution was rapidly pipeted up and down for a total of 100 
times.  A manual pipet was used because the volume was typically too small to use a 
needle to shear DNA.  This solution was then centrifuged at 4,500 x g for three minutes at 
4° C.  The pipeting and centrifugation steps were repeated for a total of four times. The 
cytosolic fraction was combined with trichloroacetic acid (TCA) at a final concentration of 
6% TCA to precipitate and concentrate the cytosolic protein.  This solution was mixed by 
inversion and incubated on ice for 30 minutes.  After incubation, this solution was 
centrifuged at 7,800 x g for 15 minutes at 4° C.  The pellet was washed with 1 volume 
(initial volume of the cytosolic fraction plus TCA) of ice-cold acetone and centrifuged at 
7,800 x g for five minutes at 4° C.  This acetone wash was repeated for a total of three 
times, after which, the pellet was dried by inversion for one minute and lysis buffer was 
added to the precipitated protein. Heat, sonication, or passage through a needle were used 
to assist in dissolving the TCA precipitated protein, but the protein must be resuspended in 
a sufficient volume of lysis buffer to aid in the solubilization of the precipitated protein.  In 
this case, passage through a 19G or 21G needle was used as previously described. Protein 
concentrations were determined using the Bradford reagent according to the 
manufacturer’s specifications. 
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Detection of the FPGS protein by western blotting 
 The cytosolic isoform of human FPGS had been previously purified in this lab and 
was included (3 ng) throughout western blotting procedures as a positive control.  Tubes 
containing the samples to be loaded were placed in boiling water so that all of sample 
volume was immersed in the boiling water for five minutes and loaded into a freshly 
prepared 7.5% SDS-PAGE gel, electrophoresed in a buffer containing 192 mM glycine, 25 
mM Tris, and 0.1% SDS, pH 8.3, and the protein contents of the gel were transferred to a 
nitrocellulose membrane at 100 V for 45 minutes in a fresh portion of the buffer in which 
the gel was run.  Non-specific protein binding to this membrane was blocked using Blotto 
blocking solution containing 5% nonfat dry milk (Bio-Rad, cat. #170-6404XTU), 10 mM 
Tris pH 7.4, 0.14 M NaCl, and 0.1% Tween 20.  The membrane was incubated with Blotto 
solution for one hour at room temperature, followed by three washes of five minutes each 
in Tris buffered saline with 0.05% Tween 20 (TBS-T).  The membrane was then incubated 
in a TBS-T solution with 5% nonfat dry milk and a dilution of an antibody against the 
FPGS protein at 4° C for ~16 hours.  The membrane was washed for five minutes for a 
total of three times in TBS-T and was incubated for one hour at room temperature in a 
TBS-T solution containing 5% nonfat dry milk and a dilution of an antibody raised against 
the IgG of the organism in which the primary antibody was raised.  This incubation was 
followed by three washes of five minutes each in TBS-T. Protein complexes were detected 
using a West-Dura chemiluminescent substrate kit (Pierce SuperSignal, cat. # 34075) that 
was incubated with the membrane in the dark and the protein complexes on the membrane 
were exposed and documented on X-ray film.   
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 Two different antibodies were used in these studies; one was obtained from a group 
in Toronto (150) and the other was obtained from Lilly Research Laboratories (38).  The 
Toronto antibody was raised in rabbit against a peptide from the human FPGS protein that 
corresponded to residues 275-290 and was used at a dilution of 1:500. The secondary 
antibody used with the Toronto antibody was raised in goat against rabbit IgG (Pierce 
ImmunoPure, cat. # 31462) and diluted at 1:7,500 in a solution of TBS-T with 5% nonfat 
dry milk.  The antibody obtained from Lilly Research Laboratories is antibody 4-18 as 
referenced by Dotzlaf et al. (38).  This antibody was raised in mouse against a peptide 
from human FPGS corresponding to residues 521-550 and recognizes the FPGS amino 
acid sequence RDPIFAPPSPP (38).  The antibody obtained from Lilly Research 
Laboratories was diluted 1:600 in a TBS-T solution with 5% nonfat dry milk.  The 
secondary antibody that was used to detect the Lilly antibody was raised in goat against 
mouse IgG (Pierce ImmunoPure, cat. # 31438) and diluted at 1:15,000 in a TBS-T solution 
with 5% nonfat dry milk. 
 
Colony formation of AuxB1 cells transfected with fpgs cDNA constructs under doxycycline 
control and in the presence of various growth supplements 
 These studies were done by Ms. Guoyan Gao of this laboratory. Doxycycline was 
added to the cell culture media at the indicated concentrations 48 hours prior to the plating 
of cells.  Cells were centrifuged, pelleted and resuspended in MEM-α media without 
purines, thymidine, or glycine, and supplemented with 10% dialyzed tetracycline-free 
FBS, 1% Pen/Strep, 500 µg/mL G418, and 200 µg/mL hygromycin.  This was the basal 
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media (no additions) for this experiment. Cells were placed in 24-well plates with each 
well containing ~150 cells in the basal media as described above with the corresponding 
growth supplements and the indicated concentrations of doxycycline. Inosine was added to 
the medium of some cultures at 100 µM, thymidine at 5.6 µM, and glycine at 50 mg/L. 
Media was changed and fresh media containing identical supplementation was fed to the 
cells every other day for ~10 days.  After 10 days, cells were washed twice with PBS, fixed 
to the plates with methanol, and stained with 5% Wright-Giemsa stain for visualization and 
colony counting.  All visible colonies were manually counted and none were excluded 
based on size. 
 
Pulse treatment with 3H-6S-5-formyl-tetrahydrofolate and retention of folate 
polyglutamates in AuxB1 cells transfected with fpgs cDNA constructs under doxycycline 
control 
 This study was designed to follow the subcellular retention and distribution of 
folate polyglutamate molecules.  A diagram of the experimental setup is included in the 
Results section of this chapter in Figure 3-5. [3’, 5’, 7, 9-3H]-6S-5-formyl-tetrahydrofolate 
was obtained from Moravek Radiochemicals.   All cells were grown at 37° C and 5% CO2. 
CHO cells were included as a positive control in this experiment and were grown in a 
similar media as described below, but without G418 and hygromycin additions. Cells were 
plated 48 hours before time t = 0 hours in 100 mm dishes at 2 x 104 cells / dish in MEM-α 
media supplemented with 10% tetracycline-free FBS, 1% Pen/Strep, 500 µg/mL G418, and 
200 µg/mL hygromycin.  Also, 1 µg/mL of doxycycline was added to the indicated cells at 
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this time.  Twenty-four hours prior to time t = 0 hours, media was removed and all cells 
were fed with 3.5 mL of RPMI 1640 folate-free media that was supplemented with 10% 
tetracycline-free FBS, 1% Pen/Strep, 500 µg/mL G418, 200 µg/mL hygromycin, and 1 
µg/mL doxycycline where indicated.  This media was also supplemented with 0.5 µM of 
3H-6S-5-formyl-tetrahydrofolate at 0.25 µCi/mL. The media containing the radiolabeled 
folate was incubated with the cells for a total of 24 hours.  After 24 hours, the media 
containing the radiolabeled folate was removed, cells were washed with 10 mL of PBS, 
and the cells were fed with 10 mL of MEM-α media supplemented with 10% tetracycline-
free FBS, 1% Pen/Strep, 500 µg/mL G418, 200 µg/mL hygromycin, and 1 µg/mL 
doxycycline where indicated. After this time (t = 0 hours), the cells were not exposed to 
any further isotope for the remainder of the study.  Cells were harvested at 12 hour 
intervals after isotope exposure and the cytosolic and mitochondrial cell fractions were 
isolated as described above.  However, after the final centrifugation step at 11,000 x g for 
15 minutes a 4° C, cytosolic fractions containing cytosolic protein in homogenization 
solution were placed in pre-weighed tubes and total cytosolic volumes were estimated by 
the weight of the liquid in these tubes.  A total of 1 mL of the cytosolic fraction was added 
to 20 mL glass scintillation vials.  The mitochondrial pellet was dissolved in 500 µL of 75 
mM NaOH, after which 500 µL of 100 mM HCl was added to neutralize the solution 
containing dissolved mitochondria.  A total of 1 mL of the solution containing dissolved 
mitochondria was added to 20 mL glass scintillation vials.  Vials containing the 
mitochondrial fractions then received 1 mL of homogenization solution and the vials 
containing the cytosolic fractions received 500 µL of 75 mM NaOH and 500 µL of 100 
   
 152 
mM HCl so that all samples had exactly the same salt concentrations to simplify counting 
efficiency.  The total sample volume in each scintillation vial was 2 mL, to which 18 mL 
of SafetySolve scintillation cocktail was added.  The vials were then counted for 
radioactivity in a Beckman LS 6500 multi-purpose scintillation counter. Cells from 
replicate plates that had been identically treated, other than they were not exposed to 
radioactivity were counted for each experimental condition.  Compartmental retention of 
3H-6S-5-formyl-tetrahydrofolate metabolites throughout the experiment was normalized to 
the initial cell number at time t = 0.  Counts per minute, obtained from scintillation 
counting, were converted to fmoles of 3H-6S-5-formyl-tetrahydrofolate metabolites by 
counting duplicate aliquots of the radiolabel-containing medium and dividing by the 
concentration of 5-formyl-tetrahydrofolate in the medium. Total fmoles of 3H-6S-5-
formyl-tetrahydrofolate metabolites retained in cells was obtained by adding the 
radioactivity detected in the cytosolic and mitochondrial compartments at each time point.  
 
Supplemental rescue of antifolate toxicity in folate-depleted L1210 cells 
 L1210 cells are suspension cells that were routinely grown in RPMI 1640 media 
supplemented with 10% FBS.  For folate depletion of L1210 cells, cells were grown in 
folate-free MEM media supplemented with 10% dialyzed FBS, 1% solution A (solution A 
= 2.5 g/L L-alanine, 5 g/L L-asparagine, 3 g/L L-aspartic acid, 10 g/L L-cysteine HCl-H20, 
7.5 g/L L-glutamic acid, 4 g/L L-proline, and 2.5 g/L L-serine), 1% solution B (solution B 
= 11 g/L sodium pyruvate, 20 mg/L lipoic acid, 5 g/L L-ascorbic acid, 10 mg/L biotin, and 
0.14 g/L cyanocobalamin), 100 µM hypoxanthine, 5.6 µM thymidine, and 50 mg/L glycine 
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for at least three passages prior to experimental use.  Under these growth conditions the 
folate content of the cells diminished to < 0.1%, but the cells were still healthy.  For 
experimentation, folate-depleted cells were centrifuged and resuspended in fresh MEM 
media supplemented with 10% dialyzed FBS, 1% solution A, 1% solution B, 20 mM 
HEPES and 10 mM MOPS at a pH of 7.4, and growth supplements where indicated.  The 
concentrations of these supplements were 100 µM hypoxanthine, 5.6 µM thymidine, and 
50 mg/L glycine.  Cells were added to the wells of 24 well plates containing folic acid and 
drug for a final volume of 1.5 mL and at a final concentration of ~3 x 104 cells / mL, 2.28 
µM folic acid and the indicated antifolate concentrations.  Cells were incubated for 72 
hours at 37° C and 5% CO2, after which 1 mL of the cell suspension was counted twice 
and the average cell number recorded. Cell growth in the presence of drug is expressed as a 
percentage of the growth of untreated cells and each data point represents duplicate 
samples. 
 
Uptake of 3H-6S-5-formyl-tetrahydrofolate in isolated mitochondria 
 Mitochondria from CHO and glyB cells growing in ten 150 mm dishes were 
isolated as previously described.  However, after the final centrifugation step at 11,000 x g 
for 15 minutes at 4° C, the mitochondrial pellet was resuspended in a mitochondrial 
isolation buffer containing 300 mM trehalose, 10 mM HEPES, 10 mM KCl, 0.1 g / 100 
mL bovine serum albumin, 1 mM EGTA, 1 mM EDTA, and 2 mM ADP at a pH of 7.4; 50 
µL of this solution containing mitochondria was added to experimental tubes.  The tubes 
were placed in a shaking water bath at 37° C for 3 minutes.  Transport in isolated 
   
 154 
mitochondria was initiated by the additional of 50 µL of a solution containing 3H-6S-5-
formyl-tetrahydrofolate.  The final transport solution contained 100 µL of isolated 
mitochondria, 1.5 µM 6S-5-formyl-tetrahydrofolate at 7.5 µCi/mL, 300 mM trehalose, 10 
mM HEPES, 10 mM KCl, 0.1 g / 100 mL bovine serum albumin, 1 mM EGTA, 1 mM 
EDTA, 2 mM ADP, 2 mM ATP, 5 mM succinate, 10 mM creatine phosphate, and 100 
µg/mL creatine kinase.  Transport was stopped by the timed addition of 10 mL of ice-cold 
homogenization solution.  Samples were then loaded onto 0.45 µm HA membrane filters 
(Millipore, cat. # HAWP02500) in a vacuum manifold and a vacuum was applied to pull 
liquid through the filters. The filters were then washed three times with 10 mL of ice-cold 
homogenization solution.  The filters were removed from the vacuum manifold and placed 
in 1 mL of 75 mM NaOH in 20 mL glass scintillation vials for ~16 hours, after which 1 
mL of 100 mM HCl and 15 mL of SafetySolve scintillation fluid were added and the 
samples were counted for radioactivity in a scintillation counter.  The error bars in the 
presented experiment represent the range of two duplicate samples from a single 
experiment.    
 Uptake of 3H-5-formyl-tetrahydrofolate was also examined in isolated CHO 
mitochondria in the presence of 5 µM of various folate analogs.  Uptake in isolated 
mitochondria from glyB cells was included as a negative control in this experiment.  The 
design of this experiment was identical to the experiment in mitochondria isolated from 
CHO and glyB cells as described above.  Uptake was permitted for three minutes in all 
samples after which 10 mL of ice-cold homogenization solution was added to the 
experimental tubes to stop any further mitochondrial uptake.  Samples were processed as 
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previously described and the error bars in the presented experiment represent the range of 
two duplicate samples from a single experiment. 
 
G418 toxicity in L1210 cells 
 L1210 cells were plated in 24-well plates at densities ranging from 3.3 x 102 cells / 
mL to 1 x 106 cells / mL in RPMI 1640 media supplemented with 10% dialyzed FBS, 1% 
Pen/Strep, 20 mM HEPES, 10 mM MOPS, and 10 µM 2-mercaptoethanol.  Each density 
of L1210 cells was exposed to different concentrations of G418.  The concentrations were 
0, 250, 500, 750, 1250, and 2000 µg/mL of G418.  The growth of G418-treated L1210 
cells was followed over the course of 11 days and the media was not changed over this 
time course.  Cell growth estimates were based on subjective estimates of well confluence 
after daily visualization of the cells under a microscope.  
 
Addition of a His(6) tag to the CHO MFT and cloning into the pcDNA 3.1(-) mammalian 
expression vector 
 The CHO MFT was previously cloned into a mammalian expression vector with an 
N-terminal myc tag (129).  For purification, a His tag was added to the C-terminal end of 
the mft cDNA that encoded six tandem histidine residues immediately followed by a stop 
codon.  This was accomplished in two successive PCR reactions.  Each PCR reaction used 
the same vector-specific forward primer that was located upstream of a XhoI restriction site 
and the 5’ mft start codon.  In the first PCR, the 3’ reverse primer added six His codons 
(CAC) immediately followed by a stop codon.  This product was electrophoresed on a 1% 
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agarose gel containing ethidium bromide, extracted from the gel and purified using a 
Promega Wizard SV gel and PCR clean up system kit.  The reverse primer in the second 
reaction recognized the sequence added by the first primer and added 6 base pairs, a 
HindIII restriction site, and another 3 base pairs.  This PCR product was electrophoresed, 
visualized and purified identical to the first PCR reaction.  This final PCR product and 
pcDNA 3.1(-) were digested using XhoI and HindIII, the digested products were ligated 
together, cloned into TOP10 cells, and the vector was purified from a transformed TOP10 
clone and sequenced as described in Chapter Two. 
 
Transfection of L1210 cells with the CHO MFT in pcDNA 3.1(-) and selection of clones 
 L1210 cells were transfected using the Nucleofector II device (Amaxa) following 
the manufacturer’s specifications.  A cell line optimization nucleofector kit (Amaxa, cat. 
#VC0-1001) was obtained for nucleofection of L1210 cells.  For transfection, 3 x 106 
actively growing L1210 cells were centrifuged and the cell pellet was resuspended in 105 
µL of pre-warmed nucleofector solution V.  The cell solution then received 3 µg of 
purified plasmid, either pmaxGFP (contained in optimization kit) or pcDNA 3.1(-), which 
contained the CHO mft with an N-terminal myc tag and a C-terminal His(6) tag.  From this 
solution, 100 µL was added into an Amaxa certified cuvette that was provided in the 
optimization kit and was compatible with the Nucleofector II device.  This cuvette was 
inserted into the Nucleofector II device and nucleofection proceeded using the S-018 
program in the device.  After nucleofection, 500 µL of pre-warmed RPMI 1640 
supplemented with 10% FBS and 1% Pen/Strep was added to the cells.  The cells were 
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removed from the cuvette using a plastic pipet and transferred into a single well in a 12-
well plate in a total volume of 1.6 mL of RPMI 1640 supplemented with 10% FBS and 1% 
Pen/Strep.  The cells were incubated at 37° C and 5% CO2 for 24 hours. L1210 cells that 
were transfected with 3 µg of the pmaxGFP construct were visualized 24 hours after 
nucleofection using a fluorescent microscope and the captured images are presented with 
and without fluorescent exposure. L1210 cells that were transfected with the CHO mft in 
pcDNA 3.1(-) were collected by centrifugation 24 hours after nucleofection and 
resuspended at 28,000 cells / mL in RPMI 1640 supplemented with 10% FBS, 1% 
Pen/Strep, 20 mM HEPES, 10 mM MOPS, 10 µM 2-mercaptoethanol, and 500 µg/mL 
G418.  Media was removed and fresh media was added every other day for 18 days.   
 Some L1210 cells were able to grow and survive in the presence of 500 µg/mL of 
G418; this population became evident after 18 days of G418 selection.  These cells were 
centrifuged and resuspended in selective media (RPMI 1640 supplemented with 10% FBS, 
1% Pen/Strep, 20 mM HEPES, 10 mM MOPS, 10 µM 2-mercaptoethanol, and 500 µg/mL 
G418) at a density of 0.5 cells / mL; 200 µL of this cell suspension was plated in individual 
wells in a 96-well plate to isolate clones from this population.  After 7 days, six wells were 
observed to contain an actively growing L1210 cell population.  The cells in these wells 
were expanded and examined for MFT expression. 
 
Isolation of mitochondrial protein from transfected L1210 cells 
 Transfected L1210 cells were routinely grown in selective media (RPMI 1640 
supplemented with 10% FBS, 1% Pen/Strep, and 500 µg/mL G418). Mitochondrial protein 
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was isolated from these cells using dounce homogenization and differential centrifugation 
as described in Chapter Two, except that L1210 cells grow in suspension, so that removal 
of adherent cells from dishes by scraping was not necessary.  The concentration of isolated 
mitochondrial protein from each L1210 cell clone was determined using the Bradford 
reagent.   
 
Detection of CHO myc-MFT expression in transfected L1210 cells by western blotting 
 Tubes containing 40 µg of mitochondrial protein were immersed in boiling water 
for 5 minutes so that the volume in the tube was covered by water and then loaded into a 
freshly made 12.5% SDS-PAGE gel.  The gel was electrophoresed in a buffer containing 
192 mM glycine, 25 mM Tris, and 0.1% SDS, pH 8.3.  The protein contents in the gel 
were transferred to a PVDF membrane in a buffer containing 192 mM glycine and 25 mM 
Tris, pH 8.3 at 100 V for 45 minutes.  After the transfer of proteins to the PVDF 
membrane, non-specific protein binding to the membrane was blocked using Blotto 
blocking solution containing 5% nonfat dry milk, 10 mM Tris pH 7.4, 0.14 M NaCl, and 
0.1% Tween 20.  The membrane was incubated with Blotto for one hour at room 
temperature, followed by three washes of five minutes each in Tris buffered saline with 
0.05% Tween 20 (TBS-T).  After these washes, the membrane was incubated with a rabbit 
anti-myc antibody (Sigma, cat. #C3956) at a dilution of 1:2000 in a TBS-T solution with 
5% nonfat dry milk for 16 hours at 4°C.  The membrane was washed three times for 15 
minutes each in TBS-T and incubated with a peroxidase conjugated goat anti-rabbit IgG 
antibody (Thermo Fisher Scientific, cat. #31462) diluted to 1:10,000 in a TBS-T solution 
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with 5% nonfat dry milk, for one hour at 25° C.  Incubation with this secondary antibody 
was followed by three washes of 15 minutes in TBS-T. Protein complexes were detected 
using a West-Dura chemiluminescent substrate kit (Pierce SuperSignal, cat. # 34075) that 
was incubated with the membrane in the dark and the protein complexes on the membrane 
were exposed and documented on X-ray film.  Mitochondrial protein isolated from 
untransfected L1210 cells was included as a negative control.   
 
Purification of CHO MFT from a transfected L1210 clone 
 Clone #4 from the above transfection was selected for expansion and purification 
based on the high level of MFT expression that was detected by western blotting. Before 
expansion and purification, these cells were adapted to grow in 5% FBS instead of 10% 
FBS over the course of seven days in the selective media (RPMI 1640 supplemented with 
5% FBS, 1% Pen/Strep, and 500 µg/mL G418). These cells were routinely grown at 
densities between 1 x 105 cells / mL and 2 x 106 cells / mL in selective media.  Two 3 L 
spinner flasks were used to culture ~1.5 L of L1210 cells, equally divided between the two 
flasks.  Cells were centrifuged at 1,000 x g for 15 minutes at 4° C.  The cell pellet was 
resuspended in 7.5 mL of homogenization solution with added EDTA-free protease 
inhibitors (Roche, cat. #11873580001).  Cells were broken open with 25 strokes in a 7.5 
mL dounce homogenizer with a “B” pestle, followed by centrifugation at 1,000 x g for 5 
minutes and collection of the post-nuclear supernatant.  The pellet was resuspended in 7.5 
mL homogenization solution and received an additional 25 strokes in a 7.5 mL dounce 
homogenizer. This procedure was repeated for a total of 100 strokes of dounce 
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homogenization and a total volume of 30 mL of post-nuclear supernatant.  The pellet that 
remained after four cycles of dounce homogenization and centrifugation was collected, 
dissolved in lysis buffer and represents the nuclear fraction in the purification table and 
western blots.  The pooled post-nuclear supernatants from dounce homogenization were 
centrifuged at 1,000 x g for 5 minutes at 4° C, the supernatant was collected and 
centrifuged at 10,000 x g for 15 minutes at 4° C.  The supernatant was collected into a pre-
weighed tube and the volume was estimated based on the weight of the supernatant liquid.  
A portion of this fraction was subjected to protein precipitation with TCA as previously 
described and represents the cytosolic fraction in the purification table and western blots.  
Mitochondria were contained in the pellet, and the pellet was resuspended in a buffer 
containing 1% 3-laurylamido-N,N’-dimethylpropyl amine oxide (LAPAO) (85), 0.1 M 
NaSO4, 10 mM Tricine-KOH, 1 mM EDTA pH 7.5, and protease inhibitors (Roche, cat. 
#11873580001).  Solubilization of mitochondria in this buffer occurred for 30 minutes at 
0° C with gentle mixing by a magnetic flea.  After 30 minutes, this solution was 
centrifuged at 15,000 x g for 15 minutes at 4° C.  The pellet was collected, dissolved in 
lysis buffer and represents the LAPAO insoluble fraction in the purification table and 
western blots. The supernatant (LAPAO soluble fraction) was collected and batch purified 
by the addition of a slurry of hydroxyapatite resin with an equal amount (w/v) of a buffer 
containing 1% LAPAO, 10 mM MOPS and 100 mM NaCl, pH 7.2.  This slurry was placed 
on a rotational shaker at 4° C for 30 minutes and centrifuged at 15,000 x g for 15 minutes 
at 4° C.  The supernatant contained proteins that were not bound to hydroxyapatite 
(hydroxyapatite unbound fraction) and was collected for further purification by a talon 
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metal-affinity column (Clontech, cat. #635501).  The hydroxyapatite resin with bound 
proteins was then resuspended in an equal volume of a buffer containing 1% LAPAO, 10 
mM MOPS and 100 mM NaCl, and 1 M KHPO4, agitated and centrifuged as above, and 
the collected supernatant represents the hydroxyapatite eluate fraction in the purification 
table and western blots.  The hydroxyapatite unbound fraction was run over a talon metal-
affinity column that was prepared with 1 mL of packed resin volume in a buffer containing 
1% LAPAO, 100 mM NaCl, and 50 mM NaHPO4, pH 7.0. Once the hydroxyapatite 
unbound fraction was loaded onto the talon column, fractions were collected every 30 
seconds, each with a volume of ~1 mL.  The column was then washed three times with five 
bed volumes each of a buffer containing 1% LAPAO, 100 mM NaCl, and 50 mM 
NaHPO4, pH 7.0 and fractions were collected every 30 seconds.  After three column 
washes, five bed volumes of a buffer containing 1% LAPAO, 100 mM NaCl, 50 mM 
NaHPO4, and 5-10 mM imidazole (10 mM imidazole in the first purification and 5 mM 
imidazole in the second purification), pH 7.0 was run over the column and fractions were 
collected every 10 seconds for the first 30 seconds and then every 30 seconds thereafter.  A 
final elution buffer containing 1% LAPAO, 100 mM NaCl, 50 mM NaHPO4, and 150 mM 
imidazole, pH 7.0 was run over the column and fractions were collected every 10 seconds 
for the first 30 seconds and then every 30 seconds thereafter.  Small aliquots were 
collected from each step throughout the purification process and dissolved in lysis buffer 
for further analysis of protein concentration and western blotting.  Protein concentrations 
from representative portions that were collected throughout the purification process, but 
not fractions collected from the talon column, were determined using the Bradford reagent.  
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Protein concentrations in fractions obtained from the talon column were determined by 
absorbance at 280 nm, assuming a solution with A280 = 1.00 has 1 mg/mL protein. 
  
Detection of the CHO MFT in purification fractions 
 The CHO myc-MFT was detected by western blotting as previously described.  All 
western blots used fractions collected from the first of the two purification attempts.  Each 
lane was loaded with 40 µg of protein when available.  The protein concentrations in the 
collected fractions from the talon column were not determined. Talon column fractions 
from each wash or elution, typically 5 bed volumes (5 mL), were pooled together and TCA 
precipitated with 6% TCA as previously described and ~25% of the total fraction was 
loaded into the gel.  
 The fractions collected from the talon column in the second CHO MFT purification 
attempt were TCA precipitated and ~50% of the total fraction volume was loaded into a 
freshly prepared 12.5% SDS-PAGE gel that was electrophoresed in a buffer containing 
192 mM glycine, 25 mM Tris, and 0.1% SDS, pH 8.3.  Following electrophoresis, the gel 
was washed three times in ~200 mL of 18.2 mΩ H2O for 15 minutes each and then 
incubated with ~25 mL of Bio-Safe coomassie stain (Bio-Rad, cat. #161-0786) for one 
hour with gentle agitation.  The gel was then incubated with ~200 mL of 18.2 mΩ H2O for 
~16 hours.  Water was changed and a fresh 200 mL of 18.2 mΩ H2O was added every hour 
for the first four hours of this 16 hours incubation. 
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RESULTS 
 
I. Interplay between FPGS isoforms, folate polyglutamates and the MFT in the 
compartmentalization folate metabolism 
 
Analysis of doxycycline-inducible FPGS expression in AuxB1 transfectants 
 AuxB1 cells do not express any functional FPGS protein and therefore require 
exogenous supplies of purines, thymidine and glycine for growth and survival.  This cell 
line provides an excellent system for studying the cellular and compartmental requirements 
of the FPGS protein.  Cells were transfected with either a cDNA encoding the full-length 
fpgs with an endogenous mitochondrial leader peptide (mFPGS) or a cDNA that did not 
contain this leader peptide and encoded a protein thought to strictly localize to the 
cytosolic compartment (cFPGS).  The cDNA constructs were transfected into the AuxB1 
cells under the control of a doxycycline-inducible promoter.  It was necessary to first 
understand the process of FPGS expression induced by doxycycline.  The stably generated 
cell lines transfected with either the mitochondrial fpgs cDNA (mFPGS) or the cytosolic 
isoform of FPGS (cFPGS) were induced with 1 µg/mL of doxycycline and probed for 
FPGS expression (Figure 3-2A).  In both cell lines, it appeared that FPGS was not 
expressed in the absence of doxycycline.  In the presence of doxycycline, there was robust 
expression of FPGS in both cell lines.  This expression level appeared greater than FPGS 
expression levels in other cultured, but not transfected, cell lines: a human leukemic cell 
line (CEM), a colon carcinoma cell line (HCT116), and lung cancer cell (H460).   
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Figure 3-2 Detection of FPGS expression by western blotting. A. Detection of FPGS in  
30 µg of whole cell lysates in CEM, HCT116, and H460 human cancer cell lines and in 
AuxB1 cells transfected with cytosolic (cFPGS) and mitochondrial (mFPGS) fpgs cDNA. 
Whole cell lysates were collected from cFPGS and mFPGS cells in the presence (+dox) 
and absence (-dox) of 1 µg/mL doxycycline.  Purified human cytosolic FPGS (3 ng) is 
included as a positive control. B. Cytosolic and mitochondrial localization of the FPGS 
protein in CEM cells and in cFPGS and mFPGS cells in the presence of 1 µg/mL 
doxycycline.  Lanes were loaded with 30 µg of total cytosolic protein and 10 µg of total 
mitochondrial protein. Blots in both A. and B. were probed with the FPGS antibody from 
Sohn et al. (2004). 
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Nonetheless, it appeared that the expression of FPGS in these transfected cell lines was 
inducible with doxycycline without any detectable basal expression in the absence of 
doxycycline. 
 It was then necessary to probe the compartmental expression of these doxycycline-
inducible isoforms of FPGS. It is important to understand that the mitochondrial fpgs 
cDNA still contained an intact translational start site for the cytosolic isoform of FPGS that 
could theoretically be used to translate the cytosolic protein (Figure 3-1). We used 
doxycycline to induce FPGS expression in both constructed cell lines and examined the 
compartmental localization of the FPGS protein (Figure 3-2B).  The first few experiments 
that examined the subcellular location of FPGS in these cells suggested that the FPGS 
protein was expressed in the intended compartment when expression was induced with 
doxycycline; the cytosolic construct resulted in FPGS expression that was only detected in 
the cytosol and the full-length mitochondrial construct resulted in FPGS expression that 
was only observed in the mitochondrial fraction.  The controllable and compartmental 
expression of the FPGS protein in these cell lines appeared to make them ideal constructs 
to separate the contributions of these compartmentalized FPGS isoforms to cellular folate 
metabolism.  However, later experiments indicated that a small amount of FPGS was 
present in the cytosolic compartment of the mFPGS cells (see below). 
 The dose-responsive nature of this doxycycline-dependent expression was also 
investigated.  This system was originally selected for use based on its control over protein 
expression, a desirable feature when attempting to examine exogenous protein expression 
near endogenous levels. FPGS expression in both mFPGS and mutFPGS constructs varied 
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with doxycycline concentrations (Figure 3-3), indicating control over the amount of FPGS 
protein that was expressed. Interestingly and centrally important to this project, cytosolic 
FPGS was detected in both mFPGS and mutFPGS cell lines at increasing exposures. The 
cDNA for the mutFPGS construct contained the upstream ATG and the endogenous 
mitochondrial leader peptide, but mutated the downstream ATG to ATT.  This construct 
was designed to control for the possible translational use of the downstream start codon in 
the mFPGS construct. Therefore, this mutFPGS construct was thought to encode only a 
mitochondrial FPGS protein.  Because no cytosolic FPGS protein should be made from the 
mutFPGS cDNA construct, we believe this data suggests that import of the FPGS protein 
into mitochondria can become a limiting factor in these experiments. 
 
Both FPGS isoforms appear to be required for cell survival 
 Deficiencies in cellular folate metabolism manifest as auxotrophic phenotypes in 
cells and the complementation of these phenotypes can be used to understand the reactions 
and requirements of cellular folate metabolism.  Various concentrations of doxycycline 
were used to induce FPGS expression in AuxB1 cells stably transfected with the three fpgs 
cDNA constructs (cFPGS, mFPGS, and mutFPGS) and the growth requirements of these 
cell lines were studied  (Figure 3-4). Basal medium supplemented with inosine, as a source 
of purines, thymidine and glycine permitted the survival of AuxB1 cells transfected with 
all three constructs at all doxycycline concentrations.  This was expected as AuxB1 cells 
survive without any FPGS protein when given these supplements.  It also indicated that 
concentrations of doxycycline up to 2 µg/mL did not significantly effect AuxB1 colony  
   
 167 
 
 
 
 
Figure 3-3 Doxycycline-dependent expression of FPGS in the cytosolic and 
mitochondrial compartments of mFPGS and mutFPGS transfected AuxB1 cells. A. 
FPGS expression in the cytosol and mitochondria of mFPGS transfected AuxB1 cells as a 
function of doxycycline concentration.  Lanes were loaded with 32 µg of cytosolic protein 
and 16 µg of mitochondrial protein.  A short exposure (1X) and a longer exposure (15X) 
are shown.  The long exposure was exposed to film 15 times longer than the short 
exposure. B. FPGS expression in the cytosol and mitochondria of mutFPGS transfected 
AuxB1 cells as a function of doxycycline concentration. Lanes were loaded with 32 µg of 
cytosolic protein and 16 µg of mitochondrial protein. Blots in both A. and B. were probed 
with the FPGS antibody from Lilly Research Laboratories. 
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Figure 3-4 Growth requirements of AuxB1 cells transfected with FPGS constructs.  
Colony formation of cFPGS, mFPGS and mutFPGS cell lines in the presence of different 
growth supplements and at various doxycycline concentrations. Black lines with open 
squares represent colonies formed with inosine, thymidine, and glycine supplementation, 
green lines with open circles represent colonies formed with inosine and thymidine 
supplementation, red lines with open diamonds represent colonies formed with glycine 
supplementation, and blue lines with open triangles represent colonies formed with no 
supplementations.  This experiment was performed by Ms. Guoyan Gao. 
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formation.  None of the AuxB1 transfectants were able to survive without inosine, 
thymidine, and glycine supplementation in the absence of doxycycline, consistent with the 
western blots that indicated FPGS expression is dependent on doxycycline.  AuxB1 cells 
transfected with cFPGS were able to survive when supplemented with glycine at 
doxycycline concentrations ≥ 0.5 µg/mL.  This indicates that the cytosolic expression of 
FPGS supplies sufficient folates for the production of purines and thymidine in the cytosol, 
but these cells are deficient in folate-dependent glycine production, a function assigned to 
mitochondria.  Conversely, AuxB1 cells transfected with mFPGS required exogenous 
thymidine and purines for survival, suggesting that these cells were deficient in cytosolic 
folate metabolism.  This effect was observed in spite of the small amount of FPGS that was 
detected in the cytosol of this cell line.  The level of cytosolic FPGS expression was 
apparently insufficient to sustain optimal cytosolic folate metabolism. However, it was 
noted that small colonies formed in plates of mFPGS transfectants without any 
supplementations when treated with 1 µg/mL doxycycline, possibly related to the low level 
of FPGS protein detected in the cytosol of this cell line. AuxB1 cells transfected with the 
mutFPGS construct were able to form colonies without any supplementations when in the 
presence of doxycycline.  This can be explained by the detection of a substantial amount of 
FPGS in both cytosolic and mitochondrial compartments at low doxycycline 
concentrations in this cell line.  
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Intracellular retention and distribution of folates in doxycycline-inducible cell lines 
 The colony formation assay (above) indicated that cells expressing the 
mitochondrial isoform of FPGS contained, at the least, diminished cytosolic folate pools as 
evidenced by their requirement for exogenous supplies of purines and thymidine.  We then 
wanted to directly address the intracellular distribution of folates in these stably transfected 
cell lines.  An experiment was designed to incubate cells with 3H-6S-5-formyl-
tetrahydrofolate for 24 hours (t = -24 to 0), after which cells were not exposed to the 
isotope again (Figure 3-5).  The cytosolic and mitochondrial compartments were isolated 
from the exposed cells at various time intervals up to 48 hours after this treatment with 3H-
6S-5-formyl-tetrahydrofolate and examined for radioactive content.  It was assumed that 
only the subcellular compartments that contained the FPGS protein would be able to retain 
labeled folates and that labeled folates could not be retained in compartments that were 
devoid of FPGS activity.  The total amount of radiolabeled folates that were present in all 
experimental cell lines immediately after pulse treatment (time = 0 hours) was the same as 
the amount present 48 hours after pulse treatment (Figure 3-6), indicating a long term 
retention of intracellular folate polyglutamates. CHO cells, the parental cell line of AuxB1 
cells, contain FPGS in both compartments and retained radiolabeled folates in the cytosolic 
and mitochondrial compartments throughout the experimental time course. AuxB1 cell 
lines stably transfected with mFPGS or cFPGS were unable to accumulate any folates in 
either compartment in the absence of doxycycline.  This is consistent with the finding that 
these cell lines do not express any FPGS in the absence of doxycycline.  In the presence of 
doxycycline, differences were observed in the mitochondrial retention of folates between  
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Figure 3-5 Experimental setup of assay following the intracellular retention and 
distribution of folates in doxycycline-inducible cell lines.  Cells were plated at t = -48 
hours and 1 µg/mL doxycycline was added to the indicated cell lines to induce FPGS 
expression.  Doxycycline was present in the media for the duration of the experiment.  At t 
= -24 hours, media containing 0.5 µM 3H-6S-5-formyl-tetrahydrofolate at 0.25 µCi/mL, as 
the only folate source, was added to the cells.  Cells were exposed to 3H-6S-5-formyl-
tetrahydrofolate for 24 hours, after which the label was removed (t = 0 hours), cells were 
thoroughly washed to remove any residual media containing the radiolabel, and normal 
growth media was added was to the cells.  After t = 0 hours, cells were not exposed any 
further isotope.  Cells were harvested at t = 0 hours and every 12 hours thereafter.  The 
cytosolic and mitochondrial compartments were isolated from each cell line and the 
radioactive content in each subcellular fraction was determined. 
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Figure 3-6 Compartmental retention and distribution of folates in AuxB1 cells 
transfected with fpgs cDNA constructs. FPGS expression was induced in cFPGS and 
mFPGS cell lines with 1 µg/mL doxycycline 48 hours prior to time t = 0 hours.  Cells were 
incubated with 0.5 µM 3H-6S-5-formyl-tetrahydrofolate at 0.25 µCi/mL 24 hours prior to t 
= 0.  Radiolabeled 5-formyl-tetrahydrofolate was removed at time t = 0 hours and cells 
were not exposed any additional radioactivity after time t = 0.  Cells were collected at time 
t = 0 and every 12 hours thereafter for a total of 48 hours.  The cytosolic and mitochondrial 
cell fractions were collected at each time point and the radioactive content in these 
fractions was determined.  The radioactive content in each subcellular compartment was 
normalized to the number of cells on replicate plates at time t = 0 hours.   
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the cFPGS and mFPGS cell lines; only the mFPGS cell line was able to retain 
mitochondrial folates.  Not only were folates able to be retained in mitochondria of the 
mFPGS cell line, but these metabolites also accumulated in this organelle.  This was also 
observed in mitochondria of CHO cells and presumably reflects mitochondrial retention of 
folate polyglutamates, suggesting that mitochondrial folates do not efflux into the cytosol 
from the mitochondrial matrix.  In addition, no mitochondrial folates were observed in 
mitochondria of the cFPGS cell line, despite the establishment of a cytosolic folate pool in 
the cFPGS cell line.  We believe this cytosolic folate pool is strictly polyglutamated folate 
metabolites; this strongly suggests that polyglutamated folates are not transported into 
mitochondria by the MFT. Interestingly, in the presence of doxycycline, both cell lines 
appeared to form and retain folate polyglutamates in the cytosol to the same extent. We 
previously showed that the mFPGS cell line contained some FPGS protein in the cytosol 
(Figure 3-3) and had expected some level of cytosolic folate retention in this compartment. 
However, because the mFPGS cell line still required exogenous purines and thymidine for 
full survival in a colony formation assay (Figure 3-4), we thought the cytosolic folate pools 
would be reduced.  Both cFPGS and mFPGS cell lines appear to retain the same amount of 
cytosolic folates, yet only the mFPGS cell line remains auxotrophic for purines and 
thymidine.  This interesting combination of data is considered in the Discussion section of 
this chapter. 
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II. Effects of folate analogs on mitochondrial folate transport 
 
Secondary glycine toxicity is observed during antifolate treatment of folate-depleted L1210 
cells 
 Due to structural similarities, folate analogs may be substrates for, or inhibitors of, 
the MFT.  Given that we knew inhibition of mitochondrial folate transport would create a 
cellular dependence on glycine, the possibility of folate analogs interfering with normal 
mitochondrial folate transport was examined by cell growth and complementation of drug-
induced auxotrophic phenotypes.  Folate-depleted L1210 cells were treated with various 
concentrations of folate analogs.  At each concentration, cells received different 
supplementations to alleviate any drug-induced phenotype. Without any supplementation, 
pemetrexed rapidly killed folate-depleted L1210 cells, a mouse leukemia cell line, with an 
IC50 of ~20 nM (Figure 3-7, closed circles). The primary target of pemetrexed is 
thymidylate synthase (153).  Hence, it was expected that an exogenous supply of 
thymidine could restore growth and alleviate the inhibition of thymidylate synthase in 
pemetrexed-treated cells.  When thymidine is provided to pemetrexed-treated L1210 cells, 
it relieves the effects from thymidylate synthase inhibition and increases the IC50 of 
pemetrexed in folate depleted L1210 cells to 100 nM (Figure 3-7, open circles).  
Pemetrexed, to a lesser extent than thymidylate synthase, also inhibits aminoimidazole 
carboxamide ribonucleotide formyltransferase (AICARFT), an enzyme in de novo purine 
synthesis (139).  If both thymidine and hypoxanthine are provided to pemetrexed-treated, 
folate-depleted L1210 cells, pemetrexed should not incur any toxicity in L1210 cells as  
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Figure 3-7 Underlying glycine toxicity in folate-depleted L1210 cells treated with 
pemetrexed. L1210 cells depleted of folates were treated with various concentrations of 
pemetrexed.  Across these pemetrexed concentrations, supplements were provided to 
alleviate pemetrexed inhibition of intracellular targets.  Concentrations of these rescue 
agents were 100 µM hypoxanthine, 5.6 µM thymidine, and 50 mg/L glycine.  Data is 
expressed as a percentage of cell growth compared to untreated (control) cells.  
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supplementation with hypoxanthine and thymidine relieves the L1210 cell requirement for 
cytosolic folate metabolism.  However, the IC50 of pemetrexed in folate-depleted L1210 
cells supplemented with thymidine and hypoxanthine is ~1.8 µM (Figure 3-7, closed 
triangles).  If pemetrexed-treated cells are also supplemented with glycine, in addition to 
thymidine and hypoxanthine, no toxicity is observed in folate-depleted L1210 cells at 
pemetrexed concentrations up to 32 µM (Figure 3-7, open triangles).  It appears that 
concentrations of pemetrexed at and above 1.8 µM interfere with glycine metabolism, a 
folate-dependent process that occurs in mitochondria.  This glycine toxicity is observed 
with some, but not all, folate analogs in similar experiments (Table 3-1).  As a working 
hypothesis, we considered the possibility that some antifolates were inhibiting 
mitochondrial folate transport.   
 
Antifolates interfere with mitochondrial folate transport 
 The underlying glycine auxotrophy that was observed when folate-depleted L1210 
cells were treated with various antifolate agents suggested that some of these agents 
disrupted mitochondrial folate metabolism, which we believed to result from inhibition of 
mitochondrial folate transport.  The effects of these folate analogs on mitochondrial folate 
transport were examined in mitochondria isolated from CHO and glyB cells and incubated 
with 1 µM 3H-6S-5-formyl-tetrahydrofolate (5f-thf) for up to 15 minutes (Figure 3-8).  
Uptake was observed in both CHO and glyB mitochondria with over 60% of the total 
uptake occurring in the first three minutes. Folate transport in isolated CHO mitochondria 
was then examined in the presence of 5 µM of various antifolates for three minutes (Figure  
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Table 3-1 Toxicity of antifolate agents in folate-depleted L1210 cells. Folate depleted 
L1210 cells were treated with various concentrations of each folate analog.  IC50 values 
were recorded for antifolate growth suppression in cells with no added supplements.  The 
IC50 for mitochondrial toxicity was observed when glycine was added in addition to agents 
that would reverse the inhibitory effects of the drug and provided a growth advantage over 
the rescue agents without glycine.  Some of these experiments were done by Dr. Julie 
Bronder. 
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Figure 3-8 Uptake of 3H-6S-5-formyl-tetrahydrofolate into isolated mitochondria 
from CHO and glyB cells.  Mitochondria isolated from CHO and glyB cells were 
incubated with 1.5 µM of 3H-6S-5-formyl-tetrahydrofolate for varying amounts of time.  
Following transport, mitochondria were collected onto 0.45 µm membrane filters by 
vacuum filtration and the filters were counted for radioactivity.  Error bars represent 
variance of duplicate samples from a single experiment. 
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3-9).  All antifolates appeared to decrease the transport of 5f-thf into CHO mitochondria, 
but none of the antifolates examined appeared to decrease mitochondrial folate transport to 
the level of deficiency observed in glyB cells.  Interestingly, glyB mitochondria 
demonstrated a surprising ability to transport 5f-thf, a phenomenon not observed in 
previous whole cell transport assays (Figures 2-8A and 2-16).  This uncharacteristic 
transport of 5f-thf in glyB mitochondria raised concerns that the integrity of the 
mitochondrial membranes may have been compromised by the isolation procedure. 
 
Expression and purification of the MFT from a mammalian cell line 
 Due to the difficulties we experienced in obtaining reliable transport data for 
kinetic analysis using carefully isolated mitochondria, we decided that purification of the 
MFT and reconstitution into proteoliposomes was the best alternative to directly study 
MFT transport.  A mouse leukemic cell line, the L1210 cell, was available that grew in 
suspension and doubled rapidly (TD = 10 hours).  This cell line could be adapted to grow in 
spinner flasks and, hence, could be rapidly expanded into large mass cultures.  A C-
terminal His(6) tag was added to the CHO MFT that also contained an N-terminal myc tag 
in the mammalian expression vector pcDNA 3.1(-).  This vector also contained a gene that 
encoded G418 resistance.  The sensitivity of L1210 cells to G418 was determined in order 
to appropriately choose the conditions for selection of L1210 transfectants.  Various 
concentrations of G418 were incubated in a total volume of 1 mL containing 10,000 L1210 
cells (Figure 3-10) for 10 days.  Each well was microscopically examined every ~24 hours 
and given a rank (1-10) based on a subjective interpretation of cellular confluence.  In the  
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Figure 3-9 Uptake of 3H-6S-5-formyl-tetrahydrofolate into mitochondria isolated 
from CHO cells in the presence of folate analogs.  A. Mitochondria were isolated from 
CHO cells and incubated for 3 minutes with 1.5 µM of 3H-6S-5-formyl-tetrahydrofolate in 
the presence of various folate analogs. Uptake in isolated CHO mitochondria in the 
absence of any antifolate was included as a positive control and uptake in isolated glyB 
mitochondria was included as a negative control. Following transport, mitochondria were 
collected onto 0.45 µm membrane filters by vacuum filtration and the filters were counted 
in a scintillation counter for radioactivity.  Error bars represent variance of duplicate 
samples from a single experiment. B. The same data presented in A. with the uptake 
observed in glyB mitochondria subtracted from all experimental samples. 
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Figure 3-10 G418 toxicity in L1210 cells. Indicated concentrations of G418 were 
incubated with L1210 cells at a density of 1 x 104 cells/mL for 10 days.  Confluence of 
L1210 cells was examined under a microscope daily and given a subjective score to reflect 
the observed density, with a rank of 1 representing almost no cells visible and 10 
representing complete well confluence.   
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absence of G418, L1210 cells grew rapidly.  Nearly every concentration of G418 inhibited 
the growth of L1210 cells; 500 µg/mL of G418 was chosen to be the selection 
concentration in the transfection experiment.  
 Because they grow in suspension, transfection of L1210 cells is considered 
difficult.  Initial attempts were made to transfect L1210 cells using calcium-phosphate 
based and reagent-based (Superfect - Qiagen) methods, but did not produce any 
transfectants that survived G418 selection. Nucleofection of L1210 cells with the CHO 
MFT was to be attempted, but because of the time commitment involved in selecting for 
stable cell lines, L1210 cells were initially nucleofected with a green fluorescent protein 
(GFP) vector to examine and establish the efficiency of the nucleofection procedure.  After 
24 hours, L1210 cells transfected with a vector encoding GFP were visualized using a 
fluorescent microscope and it appeared that some L1210 cells had transiently taken up and 
were expressing GFP from the vector (Figure 3-11).   
 Based on the transient expression of GFP observed in nucleofected L1210 cells, 
L1210 cells were transfected with the pcDNA 3.1(-) vector encoding the CHO MFT with 
an N-terminal myc tag and a C-terminal His(6) tag.  Nucleofected L1210 cells were exposed 
to 500 µg/mL G418 24 hours after nucleofection.  On day 18 post-transfection, L1210 cells 
that had been growing in the presence of G418 were distributed into well plates at 0.1 
cells/well to establish stably transfected single cell clonal lines.  After 7 days of growth in 
selective media in 96-well plates, cell growth was observed in six wells out of a total of 
192 wells.  These clones were expanded and MFT expression was analyzed by western 
blotting of mitochondrial protein.  All clones that were able to grow in the presence of 500  
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Figure 3-11 Transfection of L1210 cells with pmaxGFP to establish nucleofection 
efficiency. L1210 cells were transfected with pmaxGFP using the Nucleofector II device to 
optimize the transfection procedure. Twenty-four hours after transfection, cells were 
examined for GFP expression using a fluorescent microscope.  The pictures presented are 
from the same viewing field under A. normal light conditions and B. a xenon light source 
at 495nm. 
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µg/mL G418 appeared to express a myc-tagged protein that was ~33 kDa in size, which 
corresponded to the size of the MFT (Figure 3-12).  This protein was not detected in the 
mitochondrial fraction isolated from untransfected L1210 cells.  Clone #4 was selected for 
further MFT purification based on its apparent highest level of MFT expression. 
 Two attempts were made to purify the MFT from a stably transfected L1210 clonal 
cell line. The purification procedure followed protocols established for other MCF proteins 
(85, 123, 140, 141).  These protocols isolated mitochondrial followed by solubilization of 
mitochondrial proteins using a nonionic detergent.  The soluble protein fraction was further 
purified using a hydroxyapatite resin.  We added a C-terminal His(6) tag to the MFT protein 
and used talon column chromatography as a final purification step.  Fractions were 
collected from each purification step and a purification table lists the total protein recovery 
for each purification experiment and purification steps up to the final purification using 
talon column chromatography (Table 3-2).  Less than 50% of the total starting protein was 
recovered in the cytosolic, nuclear and mitochondrial compartments after dounce 
homogenization.  This was the only step throughout the purification process in which 
significant protein loss was observed. Western blotting of these subcellular fractions 
indicated that the MFT protein was present only in the mitochondrial protein fraction 
(Figure 3-13).  Mitochondrial protein, which was less than 15% of the total cellular starting 
protein, was then incubated with 3-laurylamido-N,N’-dimethylpropyl amine oxide 
(LAPAO) to solubilize mitochondrial protein. LAPAO was chosen for use based on its use 
in purification of the AAC (85, 128).  Despite the fact that a large portion of mitochondrial 
protein remained insoluble in LAPAO (Table 3-2), western blotting indicated that the MFT  
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Figure 3-12 MFT expression in transfected L1210 cells detected by western blotting. 
The transfected CHO MFT contained a N-terminal myc tag. Forty micrograms of 
mitochondrial protein isolated from transfected L1210 cell clones was loaded into a 12% 
SDS-PAGE gel.  Proteins in the gel were transferred to a PVDF membrane and the 
membrane was incubated with an antibody against myc to probe for myc-MFT expression.  
Mitochondrial protein from untransfected L1210 cells was included as a negative control.  
The red star marks the clone that was selected for use in MFT purification experiments. 
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Table 3-2 Purification of the CHO MFT from L1210 cells. The total volume of each 
purification step of the MFT purification protocol was recorded. A fraction of the total 
volume from each purification step was collected. The protein content in each of the 
fractions was determined and multiplied by the total volume of the corresponding 
purification step.  The total protein recovered is represented in milligrams.  The 
percentages that are shown are percentages of the total protein. 
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Figure 3-13 Detection myc-MFT in purification fractions by western blotting. A 
fraction was collected from each purification step.  The protein concentration in each 
fraction was determined and 40 µg of protein from each fraction was loaded into a 12% 
SDS-PAGE gel.  The protein contents of this gel were transferred to a PVDF membrane 
and the membrane was probed for the N-terminally myc-tagged MFT with an antibody 
raised against the myc epitope. 
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was completely soluble in LAPAO (Figure 3-13).  The LAPAO-soluble protein was then 
batch purified using a hydroxyapatite resin.  Hydroxyapatite was previously reported to not 
bind MCF proteins, but to adsorb a majority of other intracellular proteins (123).  The 
exclusion of MCF proteins by hydroxyapatite is thought to be due to the hydrophobic 
nature of these proteins and the detergent that encompasses them.  Western blotting 
demonstrated that the MFT is mostly unbound in the presence of hydroxyapatite resin 
(Figure 3-13).  The protein fraction that was unbound by hydroxyapatite constituted ~2% 
of the total starting protein and was loaded onto a talon metal-affinity column.  A majority 
of the protein loaded onto the talon column, ~90%, does not bind to the column (Figure 3-
14A; fractions 1-12).  However, about 10% of the protein loaded onto the column appears 
to bind to the talon column and is specifically eluted by imidazole (Figure 3-14; fractions 
22-41).  This small percentage of protein, ~0.2% of the total starting protein, is thought to 
be the MFT protein.  The presence of the MFT in the imidazole-eluted fractions is 
demonstrated by western blotting (Figure 3-14B).  Additionally, when talon column 
fractions were loaded onto a SDS-PAGE gel and proteins were visualized with coomassie 
stain (Figure 3-15), a number of proteins were observed in the talon column flow through 
(lane 1).  After 5 bed volumes of wash buffer were run over the column three times, the 
column was washed with the same buffer, but with 5 mM imidazole added (lane 2).  No 
protein appeared to elute with 5 mM imidazole.  The column was finally washed in the 
same buffer, but with 150 mM imidazole and a dominant protein band appears in this 
fraction (lane 3) that is ~33kDa in size.  We believe that the major protein species in this  
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Figure 3-14 Protein and western blot detection of myc-MFT in talon column fractions. 
The protein that remained unbound in the presence of hydroxyapatite resin was loaded 
onto a talon metal-affinity column. Fractions 1-6 represent the total flow through volume 
that was obtained without allowing the bed resin to dry out.  Fractions 7-11, 12-16 and 17-
21 represent three separate column washes in 5 mL of a buffer containing 1% LAPAO, 
100 mM NaCl, and 50 mM NaHPO4, pH 7.0.  Fractions 22-29 and 30-41 represent elutions 
in the above wash buffer but with the indicated amount of imidazole added. A. Individual 
fractions were collected and the absorbance a 280 nm was determined for each fraction. 
Protein content of each fraction was estimated assuming A280 of 1.00 = 1 mg/mL protein.  
B. After recording the absorbance at 280 nm for each fraction, fractions were pooled 
together and the protein in these pooled fractions were precipitated in 6% TCA. 
Approximately 25% of the total protein content in each pooled fraction was loaded into a 
SDS-PAGE gel, the protein contents of the gel were transferred to a PVDF membrane, and 
the membrane probed for the N-terminally myc-tagged MFT with an antibody raised 
against the myc epitope. 
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Figure 3-15 Protein staining of talon column fractions from MFT purification.  
Fractions were collected from a talon metal-affinity column and proteins in these fractions 
were precipitated in 6% TCA.  Fifty-percent of the resolubilized, TCA precipitated protein 
from the flow through, 5 mM imidazole, and 150 mM imidazole fractions was loaded onto 
a SDS-PAGE gel.  Following electrophoresis, the gel was washed in water and incubated 
in Coomassie BioSafe stain.  The stain was removed from the gel and the gel was 
incubated in water for 16 hours.   
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fraction is the MFT.  While the procedure yields ~0.2% of the total starting protein as MFT 
purified protein, it appears that the MFT has been highly purified.   
 
DISCUSSION 
 
Limitations of studies on the doxycycline-inducible expression of FPGS isoforms 
 The goal of using an inducible expression system was to recreate the expression of 
each of the isoforms of FPGS involved in the compartmentalization of folate metabolism 
in FPGS-null AuxB1 cells at endogenous levels. We did not have an efficient or 
reproducible method to detect the FPGS protein until recently, when we obtained a highly 
specific antibody against FPGS from colleagues at Lilly Research Laboratories (38).  Prior 
to obtaining this antibody, colony formation assays similar to those in Figure 3-4 were 
used to screen and select for clones with the desired characteristics.  Clones were selected 
because they did not appear to express FPGS in the absence of doxycycline, evidenced by 
the inability of the cloned cells to form colonies in the absence of doxycycline and without 
supplementation of purines, thymidine, and glycine.  The induction dose of 1 µg/mL 
doxycycline was chosen based on the results in Figure 3-4; cells did not form more 
colonies when exposed to doxycycline concentrations above 1 µg/mL.  To more closely 
mimic endogenous levels of FPGS expression, each line may require individual 
optimization of the induction dose of doxycycline.  In particular, the mutFPGS cell line 
grossly overexpressed FPGS at every doxycycline concentration that we studied and a 
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level of doxycycline < 0.1 µg/mL would probably be required for the induction of FPGS at 
levels equivalent to endogenous FPGS expression. 
 Initially, it appeared that the cytosolic and mitochondrial fpgs cDNA constructs 
were expressing FPGS solely in their respective subcellular compartments.  However, 
when FPGS expression as a function of doxycycline concentration was probed by western 
blotting, a small amount of FPGS protein was detected in the cytosolic fraction of the 
mFPGS cell line. We considered two possibilities that would explain the detection of 
FPGS protein in the cytosol of the mFPGS cells: 1) the downstream ATG in the mFPGS 
cDNA construct was available for use or, 2) import of the FPGS protein into mitochondria 
was limiting. If the downstream ATG on the mFPGS cDNA construct was available for 
use either by an internal ribosomal entry site or by ATG-skipping, then mutation of this 
downstream ATG in the fpgs cDNA should have eliminated cytosolic expression of FPGS.  
It did not do so; the presence of cytosolic FPGS was clearly shown in the mutFPGS cell 
line, a cell line that was transfected with the mFPGS cDNA, but with the downstream ATG 
mutated to ATT (isoleucine).  It appeared that the cytosolic protein detected in the mFPGS 
cell line resulted from inefficient import of a mitochondrially-targeted protein.  Hence, 
expression of the FPGS protein in this system had intrinsic limitations and we were not 
entirely successful in creating a cell line solely expressing FPGS in mitochondria.  
 FPGS expression was induced with 1 µg/mL doxycycline in mFPGS cells and these 
cells struggled to survive, but nonetheless formed small colonies in the absence of any 
additional media supplementations.  In contrast, mFPGS cells exposed to 1 µg/mL 
doxycycline, purines, and thymidine were able to form larger colonies.  The tiny colonies 
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formed by doxycycline-induced mFPGS cells in the absence of purines and thymidine may 
be attributable to the small amount of cytosolic FPGS protein detected in these cells, but 
we cannot eliminate the possibility that folate polyglutamates made in mitochondria 
contributed to the cytosolic folate pool.  Nonetheless, we interpreted this to mean that both 
isoforms of FPGS were required for cellular folate metabolism and optimal cell growth. 
This interpretation opposes the impression lent by two previous studies, which suggested 
that the mitochondrial isoform of FPGS alone could complement the cellular requirement 
for purines and thymidine (45) and establish a pool of cytosolic folate polyglutamates (91).  
The expression of FPGS in both of these studies was driven by a strong CMV promoter, 
which undoubtedly caused overexpression of the FPGS protein in transfectants.  Therefore, 
it was likely that these transfectants contained FPGS protein in the cytosol that had not 
been imported into mitochondria, similar to that seen in highly expressing mutFPGS cells.  
In one of the previous studies, ~ 25% of the total cellular FPGS activity was, in fact, 
located in the cytosol (91).  Moreover, in several studies in which antifolate resistant 
populations were selected, there was a > 90-95% decrease in FPGS activity, and yet the 
resistant cells grew normally (89, 109, 176).  This suggests that the ~ 25% residual activity 
of FPGS in the cytosol as seen by Lin et al. was more than sufficient for cytosolic folate 
retention and normal growth phenotypes in cells.  It appears that to have an effect on 
cytosolic folate retention, FPGS activity must be substantially decreased (>90-95%). 
 The most confounding piece of data in this set of experiments related to the 
identical cytosolic retention of folate polyglutamates in doxycycline-induced cFPGS and 
mFPGS cell lines. Because FPGS can be detected in the cytosolic fraction of induced 
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mFPGS cells, one would anticipate some level of cytosolic folate retention in this cell line. 
The amount of FPGS protein that was detected in the cytosol of doxycycline-induced 
cFPGS and mFPGS cells was not the same (Figure 3-2B), and yet cFPGS and mFPGS 
cells were shown to retain equivalent amounts of folate polyglutamate metabolites in the 
cytosol (Figure 3-6).  In spite of the fact that both cFPGS and mFPGS cell lines retained 
identical amounts of folate metabolites in the cytosolic compartments, mFPGS cells 
required thymidine and purines for optimal growth and cFPGS cells did not when in the 
presence of 1 µg/mL doxycycline (Figure 3-4).  There is no reason to believe that there are 
differences between the folate polyglutamate metabolite pools in cytosolic compartments 
of the mFPGS and cFPGS cells lines. Obtaining a clear answer to the question of folate 
polyglutamate efflux from the mitochondrial matrix was seriously hindered by the small 
amount of cytosolic FPGS protein found in mFPGS cells.  While it appears that optimal 
cell growth requires both cytosolic and mitochondrial folate metabolism, it is still unclear 
if cells can sustain survival through metabolism of mitochondrial folates alone. 
 
Passage of folate polyglutamates through the mitochondrial membrane 
 We complemented the colony formation data by following the folate distribution of 
intracellular folates in the cytosol and mitochondria in these doxycycline-inducible cell 
lines as a function of time.  This assay assumed that folates would be retained in the cell 
for the duration of the experiment once polyglutamation occurred and directly examined 
the subcellular distribution of folate polyglutamates in the mFPGS and cFPGS cell lines. 
The total radioactivity counted in both subcellular compartments of all cell lines remained 
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the same for 48 hours, despite the fact that cells were not exposed to any isotope after time 
t = 0.  CHO cells grow with a doubling time of ~15 hours, so three generations elapsed 
during this experiment, yet we could not detect any loss of folates from the cells.  Two 
effects were clear in these experiments: 1) there were no folate metabolites detected in the 
mitochondrial fraction isolated from doxycycline-induced cFPGS cells. Hence, folate 
polyglutamates made in the cytosol cannot penetrate the mitochondrial membrane and be 
sequestered into the mitochondrial matrix. 2) There was a noticeable accumulation of 
folates in the mitochondria of CHO cells and in doxycycline-induced mFPGS cells that 
appeared to occur at the expense of the cytosolic folate pool. While cytosolic folate 
polyglutamates do not appear to be transported into mitochondria, cytosolic folate 
polyglutamates may be metabolized back to folate monoglutamates, in which case, some 
of these monoglutamate folate forms appeared to be shuttled into mitochondria.  The only 
intracellular enzyme capable of folate polyglutamate degradation is γ-glutamyl hydrolase, 
which is a lysosomal enzyme that removes glutamate moieties from folate polyglutamates, 
restoring them to their monoglutamate forms (47, 175). The accumulation of folates in 
mitochondria indicated that once folates enter mitochondria and are polyglutamated, they 
do not escape.  There are no enzymes capable of digesting the poly-γ-glutamyl side chain 
of folates polyglutamates known in mammalian mitochondria. Therefore, this data 
suggests that mitochondrial folate polyglutamates do not efflux from mitochondria.  
 
 
 
   
 200 
In silico predictions of folate polyglutamate acceptance by the MFT 
  As shown in the molecular dynamics (MD) simulation with the MFT in Chapter 
Two, the tetrahydrofolate (THF) molecule was vertically oriented during transit down the 
MFT transport cavity.  It appeared that the γ- and α-carboxyl groups, the benzyl ring and 
the pteridine ring of the THF were contacted at every step of THF descent to the transport 
cavity floor by residues spaced at exact distances within the transport cavity.  We predicted 
that CHO MFT K145 and W142 simultaneously positioned the α-carboxyl and the benzyl 
ring of the THF, respectively, at the transport cavity floor.  We predict that additional 
glutamate moieties on folate molecules would disrupt the recognition of the functional 
groups of folate by the residues that line the MFT transport cavity at nearly every step of 
the folate trajectory.  If the terminal glutamate on a folate polyglutamate was located at the 
base of the MFT transport cavity, the α- and γ-carboxyl groups of the terminal glutamate 
would be coordinated within the MFT transport cavity by CHO MFT R288 and R249, the 
same as was observed for the monoglutamate THF molecule in the MD simulation in 
Chapter Two.  However, the benzyl ring of the THF monoglutamate molecule, which was 
contacted by CHO MFT W142 in the MD simulation, would be replaced by another 
glutamate residue for a folate polyglutamate.  These extra glutamate residues on folate 
polyglutamates would interfere with almost every interaction that occurred with the benzyl 
and pteridine groups of the folate molecule because of the increased size of the glutamate 
tail.  It would therefore appear that a glutamate moiety alone is not sufficient to 
successfully initiate transport of folates by the MFT; the MFT must also recognize the 
other ring structures in the folate molecule and these structures must be located at exact 
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distances from the γ-carboxyl group.  This would not be the case for a folate polyglutamate 
molecule. 
 
Examining the effects of antifolates on the MFT 
 Cell culture experiments demonstrated that antifolate agents were capable of 
disrupting mitochondrial folate metabolism, as evidenced by their underlying glycine-
reversible toxicity.  An underlying glycine-related toxicity was observed in folate-depleted 
L1210 cells that were treated with DDATHF, methotrexate, pemetrexed and AG2034, but 
not with raltitrexed or AG2037.  These differences are likely indicative of the substrate 
specificity and the kinetics of substrate binding within the transport cavity of the MFT.  
Two pieces of data suggest that MFT inhibition by antifolates is competitive: 1) the 
underlying glycine-toxicity was most evident in cells exposed simultaneously to folate and 
drug and was much more muted in cells with pre-existing folate pools, and 2) uptake of 
3H-6S-5-formyl-tetrhydrofolate into CHO isolated mitochondria was impaired by AG2037, 
an antifolate agent that did not induce glycine auxotrophy in folate-depleted L1210 cells. 
Indeed, depletion of cellular folates is often observed in various pathological conditions 
and in cells exposed to antifolate agents under clinical conditions (23, 170).  Any 
conditions that induce folate depletion may exacerbate antifolate inhibition of the MFT. 
 Since it appeared that antifolate inhibition of the MFT was competitive and 
concentration dependent, a kinetic analysis of MFT inhibition by various antifolates was 
desired.  However, an isolated transport system was needed before kinetic studies could 
advance. Mitochondria isolated from CHO and glyB cells were an ideal pair of matched 
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cells and we had already shown enormous differences in the mitochondrial uptake of these 
two cell lines, albeit in a whole cell transport assay (Figures 2-8A and 2-16).  The study of 
folate transport in isolated mitochondria was guided by two studies that addressed 
mitochondrial isolation and transport (87, 174).  One of these studies demonstrated that 
mitochondria isolated using trehalose instead of mannitol or sucrose produced superior 
mitochondria that maintained outer membrane integrity even after freezing and thawing 
(174).  The second study investigated the transport of heme into mitochondria that were 
isolated in a sucrose buffer and previously frozen (87).  Following the procedures for 
mitochondrial isolation and transport outlined in these manuscripts, attempts were made to 
study 3H-6S-5-formyl-tetrahydrofolate transport in previously frozen mitochondria.  These 
attempts were unsuccessful; the uptake in CHO mitochondria was low and there was a 
much higher than expected uptake in glyB mitochondria.  We suspected that subjecting the 
isolated mitochondria to a freezing and thawing process was compromising the integrity of 
the mitochondrial membranes.  Therefore, folate uptake was analyzed in freshly isolated 
mitochondria from CHO and glyB cells.  The uptake in CHO mitochondria increased two-
fold, but the uptake in glyB mitochondria remained higher than expected.  Subsequent 
transport studies used only freshly isolated mitochondria. However, the lack of separation 
between uptake in CHO mitochondria and glyB mitochondria made interpretation of this 
transport data difficult. It was unclear if the uptake observed in glyB mitochondria was real 
or an artifact of damaged mitochondria, but we favored the hypothesis that the level of 
uptake in glyB mitochondria was due to damaged mitochondria. Because we had 
previously shown that mitochondrial folate uptake in glyB cells was nominal ((108, 160), 
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data presented in this thesis), the uptake that occurred in glyB mitochondria was subtracted 
from the other experimental samples.  With glyB uptake subtracted out, it appeared that all 
of these antifolates were impairing mitochondrial folate uptake to some extent.  However, 
the subtraction of such a large negative control value was unsatisfactory.   
 On the other hand, perhaps the conditions used in these transport studies were not 
optimal for transport to occur in CHO mitochondria. Folate transport into isolated rat liver 
mitochondria was previously shown to pH sensitive with three to five-fold more uptake 
occurring at a pH of 5-6 than at a pH of 7-8 (61). This reported pH-sensitivity of folate 
transport was not factored into the design of these transport experiments in isolated 
mitochondria from CHO and glyB cells; our studies used a transport buffer at a pH of 7.4.  
Nonetheless, transport in isolated mitochondria became a frustrating and inefficient 
method to study the kinetics of MFT transport and we opted to move on with attempts to 
purify the MFT and study transport in reconstituted proteoliposomes.   
 
Expression and purification of the CHO MFT 
 In order to study MFT transport in reconstituted systems, the purification of the 
MFT was required.  Many of the MCF proteins that have been purified and reconstituted 
into liposomal systems were expressed in bacteria (1, 25, 26, 43, 44, 58, 65, 72, 103, 123, 
132).  Previous attempts were made to express and purify the MFT from bacteria and 
insect cells in this lab, but purification of an active MFT protein was not achieved (107).  
A mammalian cell line, the L1210 cell, was selected as the host for MFT expression in my 
studies. The L1210 cell made for an ideal host cell for MFT expression and purification as 
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this cell line grew rapidly in suspension and was compatible with the production of a large 
amount of protein.  Nucleofection was chosen for DNA delivery into L1210 cells because 
of the difficulty encountered in previous attempts to transfect these cells using 
Lipofectamine (Invitrogen), Superfect (Qiagen), or a calcium phosphate-based method.  
While the characteristics of the cell largely determine their transfection efficiency, 
nucleofection appears to be a superior method for DNA delivery giving higher transfection 
efficiency with lower toxicity when compared to other transfection methodologies (104). 
 The MFT purification scheme used reagents and followed protocols that were used 
in the purification of other MCF proteins. The first step of purification from mammalian 
tissues involved the isolation of mitochondria following the solubilization of mitochondrial 
proteins.  We used LAPAO because it was also used to solubilize the AAC protein in 
previous purification experiments (85, 128).  We found that 1% LAPAO was able to 
completely solubilize the MFT.  It may be of interest to revisit MFT expression in bacteria 
and test the solubility of the recombinant protein this LAPAO detergent. Hydroxyapatite 
has been found useful in the purification of other MCF proteins because it does not bind 
the non-denatured forms of these proteins (85, 123).  Very few other purification 
procedures used further purification steps past hydroxyapatite chromatography.  However, 
most other proteins are highly expressed in bacterial inclusion bodies and therefore, 
isolation of the inclusion bodies from bacteria served as a significant purification step.  The 
purification of the MFT was not complete after hydroxyapatite chromatography and 
therefore, the hydroxyapatite unbound fraction was loaded onto a talon metal-affinity 
column for further purification.   
   
 205 
 The total amount of protein that was recovered in fractions of each step of the MFT 
purification scheme was consistent with protein recovery in the purification of other MCF 
proteins. Inexplicably yet consistently, only half of the expected total protein was 
recovered in the subcellular fractions. It is unclear why this loss of protein was observed, 
but it most likely reflected an artifact caused by interference with the Bradford assay.  In 
contrast, very little protein was unaccounted for throughout the rest of the purification 
procedure.  The protein contained in the hydroxyapatite fraction was slightly less than 2% 
of our total starting protein, and ~15% of the total mitochondrial protein.  This is consistent 
with protein recovery observed in other MCF protein purifications from mammalian cells 
(9, 85, 92, 152).  The concentrations of the fractions eluted from the talon column were too 
low to easily quantitate, but we estimated that this purification scheme yielded ~300-500 
µg of purified MFT protein, or ~0.3-0.5% of the total starting protein and ~2% of the 
starting mitochondrial protein.  This estimate is consistent with purified protein recovery in 
other purifications of MCF proteins from mammalian cells (84, 92).  If our estimates were 
accurate, this quantity would be sufficient for reconstitution into proteoliposomes (123).  
In addition, if we are able to use this purification procedure and obtain similar protein 
recovery at each step, expanding the culture of transfected L1210 cells to five liters should 
yield over 1 mg of purified MFT protein that could be use for structural analysis. 
 The distribution of the MFT protein in purification fractions was also followed 
throughout the purification procedure. All of the MFT protein was found in the 
mitochondrial subcellular fraction and was soluble in buffer containing the detergent 
LAPAO as detected by western blotting.  It appeared that the problems previously 
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encountered with MFT solubility were no longer a problem.  However, it was unclear if 
this was due to the LAPAO detergent or the mammalian expression system.  Nonetheless, 
very little MFT protein was insoluble. A majority of the MFT protein was detected in the 
protein fraction that did not bind to hydroxyapatite.  The small amount of MFT that bound 
to hydroxyapatite is reminiscent of AAC protein binding to this resin; the protein that 
binds hydroxyapatite was shown to be in denatured form (85).  Therefore, it also appears 
that the MFT protein solubilized in LAPAO was not denatured in the process.  All of the 
MFT protein that was loaded onto the talon metal-affinity column appeared to bind to the 
column and this protein eluted from the column with imidazole. The stained gel showed 
that the major protein species in the imidazole eluate was a ~33 kDa protein that appeared 
to be of high purity.  The protein is believed to be the MFT.  Future studies will focus on 
reconstituting this protein into proteoliposomes. 
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CHAPTER 4 Perspectives 
 
 
 The work presented in this thesis has built on previous efforts in this laboratory to 
understand the mitochondrial folate transport protein, its mechanism, substrates and 
inhibitors and its niche in folate metabolism. The synergistic combination of mutagenesis 
and computational technology was prominent throughout this work.  Mutagenesis 
experiments demonstrated that the investigated MFT residues diverged from the MCF 
consensus residues to evolve a folate-specific transport mechanism.  A high quality 
homology model of the CHO MFT was constructed and subjected to extensive molecular 
dynamics (MD) simulations.  These MD simulations predicted a stepwise descent for the 
tetrahydrofolate molecule into the recesses of the MFT transport cavity.  These simulations 
also suggested that residues in the PxD/ExxK/R conserved motifs were not forming 
interactions in the absence of folate transport substrate.  Hence, these simulations refuted a 
previously proposed barrier-forming role for the interactions between the residues in the 
PxD/ExxK/R motifs. Potential substrates and inhibitors of the MFT were also 
experimentally examined in cell-based assays and in isolated mitochondria.  We presented 
evidence that suggested folate polyglutamate conjugates do not cross the mitochondrial 
membrane in either direction.  This is the first evidence ever presented that implies 
mitochondrial folate polyglutamates are unable to efflux from mitochondria.  In addition, 
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folate analogs, including methotrexate and pemetrexed, were shown to impair 
mitochondrial folate transport in isolated mitochondria.  However, the desire to obtain 
direct transport data for kinetic analysis with various folate molecules was not obtained 
from experiments in isolated mitochondria.  In order to obtain data for kinetic analysis and 
to characterize the substrates and inhibitors of the MFT, we attempted to purify the MFT 
for transport studies in reconstituted liposomal systems. We stably transfected a 
mammalian cell line with CHO mft cDNA and, for the first time, we have purified at least 
~250 ng of soluble MFT protein. Purification of the MFT from this cell line now presents 
opportunities for the identification of the substrates and inhibitors of the MFT protein in 
reconstituted systems and for future structural analysis of the MFT protein.  These studies 
have also advanced our understanding of the transport mechanism of the MFT protein and 
the compartmentalization of folate metabolism, which gives rise to a new series of 
fascinating questions for future investigation.  
 
Why are cells that lack mitochondrial folate metabolism glycine auxotrophs? 
 One of the most interesting observations related to the MFT is that cells deficient in 
mitochondrial folate transport are glycine auxotrophs.  GlyB cells rapidly die within 24 
hours in media lacking glycine (107).  The same phenomenon is observed in cells 
harboring inactivating mutations in folate-dependent enzymes (FPGS and mSHMT) in 
mitochondria.  Hence, mitochondrial folate metabolism is assumed to be required for the 
synthesis of glycine, but it is not understood why cells deficient in mitochondrial folate 
metabolism are auxotrophic for glycine.  Mammalian mitochondria contain two reversible 
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reactions that are capable of synthesizing glycine, mediated by either the glycine cleavage 
system (GCS) or the mitochondrial isoform of serine hydroxymethyltransferase (mSHMT).  
The cytosolic compartment in mammalian cells also contains one reversible reaction 
capable of glycine synthesis, mediated by the cytosolic isoform of serine 
hydroxymethyltransferase (cSHMT).  It is not understood why the reversible cytosolic 
serine hydroxymethyltransferase (cSHMT) reaction is unable to compensate for decreases 
in mitochondrial glycine synthesis. In cells with (CHO) and without (glyA) mSHMT, the 
activity of cSHMT is unchanged, yet cells lacking mSHMT produce 10-fold less glycine 
than cells with mSHMT (116). Furthermore, in a computational model of hepatic folate 
metabolism the glycine concentration was predicted to remain relatively stable even when 
a large excess of serine was added to the in silico system (120).  This may suggest that 
although it is reversible, the cSHMT reaction is not capable of fully complementing 
mitochondrial glycine synthesis. Despite being isoforms, human cSHMT and mSHMT are 
encoded by separate genes and have protein sequences that are only 63% identical (49). 
Analysis of the SHMT isoforms in yeast showed that the specific activity of mSHMT 
isoform was two-fold higher than the cSHMT isoform (73). However, why cSHMT is 
unable to optimally or efficiently catalyze the synthesis of glycine from serine is still 
unknown.  
 The role of and requirement for mitochondrial glycine is largely unknown.  It is 
speculated that glycine metabolism is necessary for formate production and export to the 
cytosol.  Mitochondrial formate has been estimated to account for at least 25% of the one-
carbon units used in cytosolic purine synthesis (127).  When either mSHMT or glycine 
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were removed from a computational model of hepatic folate metabolism, the flux of 
formate to the cytosol remained “normal” (120). However, when both mSHMT and 
glycine were removed from the system, the export of formate to the cytosol was halved.  
This suggested that both reactions that produce formate must be impaired before any 
phenotypic effects or growth impairments are observed. In the absence of mitochondrial 
folate metabolism in a computational model of hepatic cellular folate metabolism, no 
formate is exported to the cytosol, yet cytosolic folate metabolism continues and only 
thymidylate synthesis and purine synthesis are predicted to be drastically impaired; the 
rates of these processes are decreased by 40% and 60%, respectively (120). This reinforces 
the hypothesis that the purpose of mitochondrial folate metabolism is to supply formate to 
the cytosol for purine and thymidylate synthesis. However, it is interesting to note that 
glycine supplementation is able to rescue cells that lack mitochondrial folates (71, 106) 
even though mitochondrial folates appear to be cofactors in reactions that metabolize 
glycine.  Thus, it is unclear how glycine supplementation relieves the requirement for 
mitochondrial folate metabolism. 
 
Does the MFT transport folate polyglutamates? 
 The data presented in this thesis suggests that the MFT does not transport folate 
polyglutamate conjugates across the mitochondrial membrane in either direction. It had 
been previously shown that folate polyglutamates are not transported from the cytosol into 
mitochondria (91), and we presented data in this thesis that supports this concept.  We also 
presented data that suggested for the first time, that folate polyglutamates do not efflux 
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from mitochondria.  In spite of the considerable effort described in Chapter Three, a cell 
line that only expresses FPGS in mitochondria has yet to be contrived.  Even at the lowest 
doxycycline induction level used in these studies, FPGS was still detected in the cytosol of 
mFPGS cells apparently because a step in the mitochondrial import of FPGS becomes a 
limiting factor.  Future studies could examine FPGS expression induced by a lower 
concentration of doxycycline.  According to the product manual, the Tet-on system is 
responsive to doxycycline concentrations as low as 10 ng/mL, a concentration that is 25-
fold lower than the lowest concentration used in these studies. In the studies presented in 
Chapter Three, cells were continuously exposed to doxycycline to induce FPGS 
expression.  However, in the Tet-on system, cells continuously exposed to doxycycline 
continue to transcribe FPGS from the doxycycline response vector. If the mitochondrial 
import of the FPGS protein was limiting, it may be possible to temporarily induce 
expression of FPGS with a pulse treatment of doxycycline so that transcription would not 
be as robust, less protein would be translated, and all of the expressed protein could be 
imported in mitochondria.  Another possibility to directly determine if folate 
polyglutamates efflux from the mitochondrial matrix would be to knock down the MFT 
using RNA interference (RNAi) in the mFPGS cells.  The mFPGS cell line expresses a 
small amount of FPGS in the cytosol and because we detect FPGS in the cytosol, we are 
unable to eliminate the possibility that this protein is responsible for the cytosolic retention 
of folate polyglutamates observed in the mFPGS cell line. By comparing the 
compartmental distribution and retention of folate polyglutamates in mFPGS cells with and 
without the MFT protein, we could study the origin of this cytosolic folate pool. A knock 
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down of the MFT protein should reduce the ability of mFPGS mitochondria to accumulate 
folates even when FPGS is induced.  If the MFT permitted folate polyglutamate efflux 
from the mitochondrial matrix, the level cytosolic folate polyglutamate retention observed 
in the RNAi MFT doxycycline-induced mFPGS cell line should decrease when compared 
to the wild-type MFT doxycycline-induced mFPGS cell line because 1) the MFT protein 
responsible for folate polyglutamate efflux had been knocked down and less protein as 
available to mediate efflux, and 2) the pool of mitochondrial folate polyglutamates was 
decreased, meaning that there would be less matrix-associated folate polyglutamates 
available for efflux.  However, if the levels of cytosolic folate polyglutamate retention 
were equivalent in doxycycline-induced mFPGS cells with and without (knocked down) 
the MFT, it would suggest that this pool of cytosolic folate polyglutamates was not 
dependent on the MFT.  Therefore, one could conclude that the cytosolic folate pool was 
established by the cytosolic FPGS protein and did not arise from the mitochondrial folate 
polyglutamate pool. 
 
How do cytosolic FPGS and the MFT coordinate the compartmentalization of folate 
metabolism? 
 If cytosolic polyglutamates are not substrates for the MFT, it would appear that the 
MFT and the cytosolic isoform of FPGS compete for cytosolic folate monoglutamates.  
However, in a single transfection experiment that was not presented in this thesis, the 
cytosolic isoform of FPGS in pcDNA 3.1(-), under a strong CMV promoter, was 
transfected in CHO cells that contain functional FPGS in both compartments.  In a setup 
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identical to the glyB complementation assay, two plates of glyB cells that were identically 
transfected were challenged to grow either in the presence or absence of glycine using 
G418 as a selection agent.  CHO cells transfected with cytosolic FPGS were able to grow 
equally as well in the absence of glycine compared to their growth in the presence of 
glycine.  In these transfectants, apparent cytosolic overexpression of FPGS was not enough 
to impair mitochondrial folate accumulation and induce glycine auxotrophy.  More 
definitive evidence could be obtained by a direct analysis of the folate levels in the 
cytosolic and mitochondrial compartments in CHO cells transfected with the cytosolic 
isoform of FPGS in pcDNA 3.1(-) compared with the levels in untransfected CHO cells. 
Other unpublished studies referenced by Lin et al. suggested that the overexpression of 
cytosolic FPGS in mammalian cells impaired the ability of mitochondria to accumulate 
folates (91).  If the MFT and cytosolic FPGS are in competition for cytosolic 
monoglutamates, the cell must coordinate the activities of each of these proteins to permit 
simultaneous folate accumulation in the cytosol and mitochondria.  
 
How to best identify the substrates and inhibitors of the MFT? 
 There is a need to directly identify the transport substrates and inhibitors of the 
MFT.  The attempts made in this thesis and in two other studies (30, 61) suggest that 
methotrexate inhibits the mitochondrial folate transport process. However, methotrexate 
does not accumulate in mitochondria (77), which would suggest that methotrexate binds in 
the MFT transport cavity, but is not transported.  In our hands, transport studies in isolated 
mitochondria were unable to provide an accurate kinetic analysis of transport events.  The 
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isolation of intact mitochondria appears to be a delicate task, but is not impossible.  
Certainly, if additional attempts were made to study transport in isolated mitochondria, the 
buffer components and pH would require more attention.  However, with a MFT 
purification protocol in place, the transport function of the MFT could be studied in 
reconstituted systems, a more ideal experimental system.  We estimated that we were able 
to produce enough pure MFT protein for liposomal reconstitution from 1.5 L of cultured 
L1210 cells.  Since the MFT does not appear to function as an exchanger, it is also unclear 
if these proteoliposomes would require the presence of folate substrate inside the liposome, 
or if the presence of substrate inside the liposome would hinder transport based on the 
disruption of a concentration gradient.  
 
What CHO MFT residues should be experimentally investigated next? 
 Questions remain about the mechanism of transport of the MFT. The studies that 
were carried out over the course of this thesis have provided a much clearer understanding 
of the events that occur within the MFT transport cavity to permit mitochondrial folate 
transport.  Characterizing the events that permit folate transport is an essential step towards 
understanding the substrate-specific transport mechanism of the MFT.  Identifying the 
residues responsible for interaction with and coordination of the folate substrate is central 
to discovering the structural requirements for MFT substrates.  MD simulations allowed 
the visualization of the THF trajectory in the MFT transport cavity and suggested that there 
was a very strict organization of amino acids and their side chains within the transport 
cavity. Three residues, CHO MFT W96, K235, and R288, which were not experimentally 
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examined in our mutagenesis studies, appeared essential in folate coordination at the top of 
the transport cavity. Mutagenesis of these residues would provide insight into their 
requirement and involvement in the positioning of folate substrates within the MFT 
transport cavity.  
 The residues investigated in this thesis were mostly residues that were charged or 
that were contained in the PxD/ExxK/R motifs in the MFT, but did not match the MCF 
consensus. Interestingly, the MFT was surprisingly tolerant to mutation of CHO MFT 
R249, W142, and Q246 in the glyB complementation assay, and yet these residues were 
thought to be indispensable to MCF protein function.  Based on the studies presented in 
this thesis, we do not believe that these residues form a transport barrier, but rather we 
believe that they attract and position the substrate deep within the transport cavity for final 
passage into the mitochondrial matrix. Of particular interest are CHO MFT K47 and K145, 
which are basic residues predicted to be located in the PxD/ExxK/R motifs of the first and 
third transmembrane domains in the MFT.  The MD simulations presented in this thesis 
were unable to capture tetrahydrofolate (THF) descent to the extent of interaction with 
either of these basic residues.  We believe that one, or both, of these residues likely 
coordinate the α-carboxyl group of the glutamate tail of the folate substrate.  It would also 
be of interest to examine the conserved motif residue, D44, on the first transmembrane 
domain.  It is the only acidic residue that remains in the three PxD/ExxK/R motifs in the 
MFT.  D44 is proposed to interact with CHO MFT R288 in the apo-MFT, and interact with 
K145 (in the second PxD/ExxK/R motif) in the tetrahydrofolate-bound MFT. The 
interaction of D44 with R288 may serve to hold R288 in place to contact the α-carboxyl of 
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THF higher up in the transport cavity.  Once THF contacts R288, D44 may be released 
from R288, at which point D44 may coordinate and position K145 to receive the α-
carboxyl group of THF from R288.  Further investigation of the interactions between D44 
and R288 and D44 and K145 is justified if it can further explain the role of these residues 
in folate transport. 
 
What are the molecular events that occur to permit folate entry into the mitochondrial 
matrix? 
 The residues responsible for the final step of substrate translocation into the 
mitochondrial matrix are largely unknown. In contrast to our knowledge of substrate 
binding within the transport cavities of MCF proteins, our understanding of this final event 
is insufficient.  The matrix-exposed loop regions of MCF proteins have been implicated in 
final substrate translocation (31, 75, 101, 102), but no amino acids have been specifically 
linked this event. The (D/E)Gxxxx(Y/F/W)(K/R)G motif of the Px(D/E)xx(K/R)x(K/R) - 
(20 to 30 amino acids) - (D/E)Gxxxx(Y/F/W)(K/R)G MCF conserved motif is contained in 
these loop regions. The MD simulations presented in this thesis predict that THF descent to 
the base of the transport cavity occurs in defined steps, where each preceding step 
appeared to be a prerequisite for further passage.  Therefore, substrate bound to the 
Px(D/E)xx(K/R)x(K/R) sequence may be a required event to induce the stabilization of the 
(D/E)Gxxxx(Y/F/W)(K/R)G sequence. It is possible that the last basic residue in the 
Px(D/E)xx(K/R)x(K/R) sequence interacts with an acidic residue in one of the 
(D/E)Gxxxx(Y/F/W)(K/R)G sequences to hold these loop regions in place.  This 
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interaction may function to hold the basic residue in the (D/E)Gxxxx(Y/F/W)(K/R)G 
sequence in place so that this K/R residue may establish contact with the substrate below 
the base of the transport carrier. The strict conservation of these residues across MCF 
proteins suggests that their conservation is likely not coincidental. The last basic residue in 
the Px(D/E)xx(K/R)x(K/R) motif and the charged residues in the 
(D/E)Gxxxx(Y/F/W)(K/R)G motif may contain some valuable information about the final 
translocation events and should be experimentally investigated.   
  
Can the MFT be a useful therapeutic target? 
 Another aspect that is particularly interesting to speculate on is the potential or 
utility of the MFT as a drug target. Scientific research is in the middle of an enormous 
translational movement, where research discoveries and laboratory findings are being 
rapidly applied in a clinical setting.  Receptors, enzymes, and transporters have all made 
for ideal pharmacological targets in disease therapy. GlyB cells grown in the absence of 
glycine do not survive longer than 24 hours (107). Hence, pharmacological inhibition of 
the MFT has the potential to induce rapid cell death.  The development of an inhibitor 
would be quite feasible. In fact, nature has developed two inhibitors of the AAC. In our 
MD simulations, it appears the glutamate portion of the folate molecule proceeds first into 
the transport cavity and this glutamate tail would seem the most likely candidate for 
modification. Our current understanding of folate recognition by the MFT would have to 
be advanced further and likely complemented by a crystal structure of the MFT.  One key 
to therapy is selectively targeting and treating malignancy, while leaving all other cells 
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untouched; a strong inhibitor of the MFT would be fairly non-specific and likely affect all 
cells, malignant and benign.  Therefore, any agent developed to target the MFT would 
have to be accompanied by a cellular delivery method that could target this hypothetical 
agent specifically to malignant cells.  Interestingly, the folate receptor is currently being 
exploited for targeted drug delivery (178). 
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